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Thesis overview 
 
During the last decade, Clostridium difficile and Klebsiella pneumoniae represented two of the most 
emblematic cause of nosocomial outbreaks, especially following the spread of epidemic variants, able to 
produce virulent factors and to present higher resistance against several antimicrobial classes.  
The rapid identification of dangerous pathogens circulating in nosocomial environment has been made 
possible by the contribution of molecular methods in support to the classical diagnostic techniques. 
The principal objective of this work is to highlight the effectiveness of different molecular typing techniques 
in the characterization of nosocomial infections, evidencing the genetic relatedness among isolates and the 
transmission routes of strains involved in epidemic events. 
 
In the first part of the work (Chapter one), the analysis of the principal molecular and phenotypic features 
of clinical isolates of KPC-producing K. pneumoniae  collected in a 27-months period at Ospedale di Circolo 
e Fondazione Macchi (Varese, Italy) is reported.  
Of the 16 isolates analyzed, 7 were involved in an outbreak occurred the Intensive Care Unit (ICU). We 
investigated the presence of genes involved in carbapenemases resistance (i.e. blaKPC, blaIMP, blaNDM, blaVIM, 
and blaOXA), the expression of genes for virulence factors (pili/fimbriae, capsular antigen, 
hypermucousviscosity protein, and siderophores), and mutations leading to colistin resistance.  
We also made a phylogenetic analysis adding all the 16 genomes to 319 genomes that represent the global 
diversity of K. pneumoniae strains. 
We found that all isolates analyzed belong to clonal complex CG258. This finding is not surprising, 
considering previous reports that showed the worldwide diffusion and high prevalence of this clonal group 
among carbapenem-resistant K. pneumoniae strains. Interestingly, three of the four previously identified 
groups of Italian isolates of CG258 were found circulating in the hospital, suggesting that several entrance 
events of the clones may occur over the study period. 
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 About resistance genes, we showed that all 16 genomes express blaKPC genes and none of them had other 
known carbapenem-resistance genes. Interestingly, 10 of the sixteen isolates, which were colistin-
resistance, presented IS5-like transposons in mgrB gene, conferring resistance to this drug.  
 
The second part of the work (Chapter two) aimed to identify and characterize all the clinical isolates of 
Clostridium difficile ribotype 027 (here, briefly CD027) collected during a 20-months period in the Hospital 
General Universitario Gregorio Marañon (Madrid, Spain).  
The main objective was to characterize the epidemiological links among the CD027 clinical isolates and to 
defining their transmission routes. To better understand the epidemiological relationships between the 
strains, all cases identified since January 2014 were added to the analyses. Besides, presence of genetic 
markers (i.e. mutation in gyrA gene) characterizing the evolution and spread of specific epidemic lineages 
of CD027 was investigated.  
During a 20-months period (January 2014-August 2015), 132 first episodes of C. difficile ribotype 027 has 
been detected, distinguishing 9 different subtypes (MLVA-types), organized in 5 different clonal complexes 
(CC) and 4 unique MLVA-patterns. Specifically, one of the five clonal groups (named MLVA-type 1) was 
responsible of an outbreak which involved 111 patients, and quickly spread in the hospital from October 
2014. MLVA typing analysis showed the close genetic relationship of all the strains, suggesting the 
evolution from a common ancestor. All CD027 isolates carried a specific mutation in gyrA genes, indicating 
the presence of high transmissible clones belonging to CD027 lineages, but  this do not provide more 
information on their dissemination course.   
Moreover, the clonal complexes showed different capacity of spread, which was evidenced by the 
dissemination of the only CC of MLVA-type 1 leading to the epidemic event.  
For this reason, the second objective of Chapter two aimed to evaluate the possible correlation between 
the transmissibility of the analyzed CD027 clinical isolates and the ability to sporulate. An in vitro protocol 
has been performed for the evaluation of sporulation rate of epidemic CD027 strain comparing them with 
those of the ribotype 001, with the objective of determining whether the increased transmissibility of 
CD027 is due to the greater ability to release endospores into the environment. Comparison between 
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strains belonging to the same ribotype was performed, to evaluate the possible association between 
sporulation rate and transmissibility. 
We found that CD027 strains possessed higher capacity (p=0.005) to produce spores respect to isolates 
belonging to CD001 but surprisingly their germination ability was significantly lower (p=0.0008) compared 
to that of CD001, leading to reflect on the adaptability of this pathogen to the environment and the 
complexity of the mechanisms regulating pathogenic capacity.  
Once characterized the rapid spread of an outbreak due to a particular CD027 clone (MLVA-type 1), a 
further aim was to highlight the possible differences between the efficiency of sporulation and germination 
of strains belonging to the same ribotype but with different transmission characteristics, underlying the 
possible association between the ability of sporulation and the strain transmissibility.  
Moreover, analysis showed non-significant strain-to-strain variability between C. difficile isolates belonging 
to the ribotype 027;  in particular, comparison was conducted between highly transmissible MLVA-type 1 
isolates and the other MLVA-types, showing that neither in sporulation rate (p value =0.72) nor in 
germination rate (p value=0.24) significant differences exist.   
Our findings suggest that further studies preferably by analysis of the transcriptome must be performed to 
clarify the features involved in CD027 pathogenicity.  
 
This work shows how is possible, by application of molecular typing, to identify pathogens responsible for 
epidemic situations and to determine the presence of virulence factors o drug resistance genes associated 
with pathogenicity of strains. Besides it is possible to obtain useful and additional information as the 
genetic relationships between analyzed strains and their transmission route.  
In conclusion, it is showed that active surveillance and characterization of circulating strains at local and 
national level is crucial to prevent the spread of more virulent variants, with benefits for the patient and 
the health system. 
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1.1 Introduction 
 
1.1.1. General features of Enterobacteriaceae  
Enterobacteriaceae are members of a family of Gram-negative rod-shaped bacteria of which the most 
known members are Escherichia coli, Klebsiella spp, Proteus spp, Enterobacter spp, Serratia spp, Citrobacter 
spp, Morganella spp, Providencia spp and Edwardsiella spp, which are widespread in the environment and 
largely disseminated in the long-term care facilities and hospitals, where they may cause a broad range of 
infections.  Principal risk factors for the acquisition of infections due to Enterobacteria are the extended use 
of antibiotics, the underlying diseases presented by the patients, the old age and long hospital stay. 
For these reasons, the ability to trace the circulating nosocomial pathogens which spread rapidly causing 
large outbreaks has become a major responsibility of the Clinical Microbiology Laboratory, giving the 
necessity to avoid consequences as largest hospitalization of the patient; poorest clinical outcome and 
necessity of additional or specific treatment for eradicate the infection, leading to increase in sanitary 
costs. 
 
Enterobacteria are Gram-negative bacilli, asporigenous, mobile for the presence of peritrichous flagella, or 
non-mobile, and present, almost constantly, pili; variants of non-mobile species normally are to be 
considered in normally mobile strains.  
Gram negative bacteria structure is constituted by an inner cytoplasmic membrane, the cell wall and the 
outer membrane. This latter is critical in the pathogenesis and selection of mechanism of resistance to 
antimicrobial drugs, interacting directly with the external environment (fig 1). 
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Figure 1. Structure of Gram negative cell wall 
 
 
The outer membrane is characterized by the presence of numerous molecules of lipopolysaccharide (LPS 
know as bacterial endotoxin).  
LPS consist of three main regions: 
? lipid A, that is the bacterial endotoxin which plays the toxic action on the organism; 
? oligosaccharide core, also called common portion; 
? O antigen, which is a polysaccharide chain consisting of 20 to 50 repeat units. Generally can contain 
up to eight sugars, some commune (as galactose, glucose, and mannose) and other specific of 
bacterial species (colitose, abequose or paratose). It represents the outer portion and so the one 
exposed to the immune system (fig 2). 
 
 
Figure 2. Lipopolysaccharide structure 
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Another important antigen in Gram negative bacteria is the K antigen, which is situated more superficially 
than O-antigen. It is mainly constituted by acidic polysaccharides or present as mucous layer; sometimes it 
assumes the dimensions of a capsule well developed (for example, in Klebsiella-Enterobacter-Serratia 
group, KES). 
The K antigen prevents agglutination of bacteria when tested with sera containing anti-O, because acts 
masking the O-antigen and preventing a sufficient approach of bacterial cells required for the binding of 
bivalent antibody molecule. 
Finally, the flagellar proteins, denominated H antigens, allow bacterial motility and exist in a large variety of 
antigenic types; possess proteic nature and are sensible to high temperature.  
It is necessary to evaluate this antigen characteristic in the serological identification of several 
Enterobacteria. 
 
 
1.1.2 Klebsiella pneumoniae infection 
Klebsiella pneumoniae (KP) isolates are ubiquitous in the natural environment. They are found in surface 
water, sewage and soil and on plants, furthermore they colonize the mucosal surfaces of mammals such as 
humans, horses or swine. 
In healthy people, the predominance of colonization by K. pneumoniae reaches mostly in the colon, and in 
the pharynx, while the skin is colonized only transiently. Therefore, Klebsiella spp. is frequent in human 
fecal material. 
Recent data showed that K. pneumoniae bloodstream infection isolation rates are 1.5 times greater during 
the warmest months of the year. These rates most likely reflect increased fecal carriage in humans, which 
in turn is a reflection of increased organisms in the environment during warm months. This has important 
implications since colonized patients have a fourfold-increased risk of infection over non-carriers. 
Classical studies show that there subspecies of K. pneumoniae involved in severe disease: Klebsiella 
rhinoscleromatis and Klebsiella ozaenae are involved in specific chronic infectious diseases, respectively 
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rhinoscleroma and atrophic rhinitis (ozena). These diseases occur most frequently in the tropical areas of 
the world. 
Another subspecies of K.pneumoniae involved in sever diseases is Klebsiella granulomatis, which is the 
causal agent of inguinal granuloma (chronic genital ulcers). 
K. oxytoca strains carrying a chromosomally encoded heat-labile cytotoxin have been increasingly 
recognized as a cause of antibiotic–associated hemorrhagic colitis [1].  
 
The most frequent infectious processes caused by Klebsiella pneumoniae are represented by: 
i. Community-acquired pneumonia: Klebsiella pneumoniae it is involved in a small percentage of 
cases of community-acquired pneumonia. This type of pneumonia is more common in Africa and Asia than 
in Europe and the United States, and occurs mostly in patients with co-morbidities such as alcoholism, 
diabetes and respiratory disease. The lung infection is common in hospitalized patients or admitted to long-
term care facilities, due to the increased rate of colonization of the pharynx, considering the mechanical 
ventilation as prevalent risk factor [2]. From a clinical point of view, there are the typical production of 
purulent sputum, and evidence of a disease in the airways. Initially, the pulmonary involvement is very 
extensive and very frequently reflects the classic infiltrated involvement of fissures. Necrosis lung and 
pleural effusion may occur with the progression of the disease (fig 3). 
 
 
Figure 3. The image represents a cytological section of lung infection due to Klebsiella pneumoniae. In detail, a K. 
pneumoniae cell, presenting an evident capsule 
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ii. Urinary tract infection (UTI): Klebsiella pneumoniae is responsible for 1-2% of the episodes of UTI in 
healthy adults, while it is involved in the 5-17% of complicated UTI, including those associated with the 
presence of bladder catheter [3]  
iii. Intra-abdominal infections: the spectrum of intra-abdominal infections caused by K. pneumoniae is 
comparable to that supported by E. coli, even if it is isolates with lesser frequency in these clinical 
manifestations. 
The new variant “hypervirulent” Klebsiella pneumoniae (hvKP) have emerged in the past decade as a most 
dangerous pathogen, and was first reported in the Pacific areas [4] and, later, also in the USA [5], Canada 
[6], and Europe [7-10], leading to increased rate of intra-abdominal infection due to this pathogen, mainly 
in patients presenting liver abscesses caused by community-acquired infections or those who have no 
history of hepatobiliary disease traced to other organisms 
iv. other infectious diseases: patients with devitalized tissue, such as diabetic ulcers, pressure ulcers 
and burns, as well as immune-compromised patients are predisposed to cellulite and soft tissue infections. 
Klebsiella spp also causes: surgical site infections, osteomyelitis and occasional contiguity with soft tissue 
infected, hematogenous endophthalmitis (particularly in combination with the presence of liver abscess), 
nosocomial sinusitis, neonatal and post-neurosurgical meningitis [11-13]. 
 
1.1.3 Treatment of infection due to Enterobacteria 
The early initiation of appropriate antibiotic therapy, especially in severe infections, is associated with 
improved outcomes. When antibiogram profile is available, considering that the previous empirical 
treatment includes broad-spectrum drugs, it is important to continue the specific treatment with the most 
appropriate short-spectrum agent. This management avoids the selection of resistant bacteria and the 
potential super-infection by these, reduces costs and maximizes the usage duration of the antimicrobial 
agents currently available. 
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Generally, the most reliable drugs in the treatment Enterobacteria infections are amikacin, cefepime 
(resistant to β-lactamase AmpC), piperacillin-tazobactam, tigecycline and polymyxins (showing in vitro 
activity against the carbapenemases-producing strains) and carbapenems (molecules more effective, 
particularly against ESBL-producing strains). 
 
The emergence of Klebsiella pneumoniae strains which present resistance to third generation 
cephalosporins is a growing phenomenon. This increasing incidence of multidrug resistant bacteria is 
mediated by acquisition of plasmids containing genes coding for ESBLs enzymes (resistance to beta-
lactamic antibiotics) and leading to resistance against others drugs as aminoglycosides, tetracyclines and 
trimethoprim-sulfamethoxazole, resulting in the difficulty or the inability to treat the patients. 
Consequently, in severe infections due to ESBL-producing K.pneumoniae, it is reasonable to set empiric 
therapy including amikacin or carbapenems. However, the use of these drugs has led to the selection of 
strains producing carbapenemases enzymes, able to confer resistance to those drugs. 
The treatment is therefore very challenging, since carbapenemases-producing strains are often pan-
resistant. In these cases, the optimal choice of therapy is uncertain, including tigecycline, polymyxin B and 
polymyxin E (colistin), which seems to be the most active agents in vitro, although in recent years an 
increase of colistin-resistant strains is registered. 
 
 
1.1.4 Antibacterial drugs  
Enterobacteria are particularly prone to present resistance against many antibacterial drugs, which may be 
natural or be resulting from the selection of particular variants. 
Therapeutic choices must necessarily be guided by the determination of drug susceptibility through in vitro 
tests. 
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Drugs activity and mechanisms of resistance 
Antibacterial drugs act through different pathways, with highly selective toxicity: 
a) Inhibition of protein synthesis: the antibiotics that act on protein synthesis are mainly aminoglycosides, 
macrolides, tetracyclines, chloramphenicol and lincomycin. The mechanisms of action by which these 
perform their function act primarily by inhibiting the activity of bacterial ribosomes (different from those of 
the eukaryotic cells) and of all the initial complex necessary for the synthesis of the peptide chain, leading 
to a stop or a misreading or bacterial mRNA and the inability to produce proteins 
b) Inhibition of nucleic acid synthesis. In this case, depending on the compound used, synthesis of DNA or 
RNA will be inhibited. Drugs inhibiting DNA synthesis are quinolones, fluoroquinolones and trimethoprim 
(TMP), which act on nucleic acid precursors or on DNA gyrase. Rifampicin stops mRNA synthesis, as it acts 
on the DNA-dependent RNA polymerase as showed 
c) Inhibition of bacterial cell wall synthesis and function. All β-lactam antibiotics selectively inhibit bacterial 
cell wall synthesis. Initially, the drug interacts with the PBPs (Penicillin-Binding Proteins), involved in the 
transpeptidation reaction, so that peptidoglycan synthesis is blocked and the bacterial cell undergoes lyses 
or fragmentation (fig 4) [14].  
Acquired resistance to drugs results from biochemical processes encoded by bacterial genes. Antimicrobial 
resistance arises by alteration of the binding sites of the antimicrobial agent and/or alteration of the 
membrane permeability or porin channels, via activation of efflux pumps, which extrude the drug from the 
cell before it can bind to its target (fig 4). 
Drug-susceptible bacteria become resistant to antibiotics after mutation and selection (so-called "vertical 
evolution") or obtaining genetic information from other bacteria (for example plasmids; in this case we 
speak of "horizontal evolution") [15]. 
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Figure 4. Schematic representation of action site of antibiotic (left) and drugs mechanism of resistance in bacteria 
(right); source [14] 
 
 
Beta-lactamic drugs and beta-lactamases 
Until the late 90s, efforts were focused on the study of microorganisms expressing mechanisms of 
resistance against different drugs but especially to beta-lactam antibiotics, representing about 50% of 
antimicrobial drugs used in humans.  
The β-lactam antibiotics date back to the 1940-50s when only two β-lactam agents were known: penicillin 
G and penicillin V, that were the first β-lactam antibiotics introduced into clinical practice. It was not until 
the 1960s that semi synthetic penicillin was developed followed by semi synthetic cephalosporins and 
other β-lactam antibiotics. Today, class of β-lactam antibiotics include penicillins, cephalosporins, 
carbapenems, and monobactam, which act blocking the bacterial membrane formation, through inhibition 
of transpeptidase, the enzyme responsible for the formation of peptidoglycan. It constitutes the outer layer  
of the cells and it is composed by a polymer of N-acetyl-glucosamine (NAG) and N-acetyl-muramic acid 
(NAM) are cross-linked via the peptide chain.  
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Penicillin-binding proteins (PBPs) are transpeptidases (TP) that catalyze the formation of a cross-linked 
polymer of NAM-NAG, using D-ala dimers [16, 17]. 
The β-lactam antibiotics act miming the D-ala-D-ala component of the cell wall, which is the normal TP 
enzymatic substrate. The PBPs mistakenly attacks the carbonyl group of the β-lactam ring creating a 
covalent interaction in which PBPs remain bound and cell wall synthesis is blocked (fig 5).  
In general, β-lactams account for greater than 60% of all antimicrobial consumption, but heavy usage has 
selected strongly for resistance [18, 19] . 
 
 
Figure 5. Mechanism of action of beta-lactam antibiotic: the PBP binds the peptide side chains and forms the cross-
link with the expulsion of one D-Alanine; then it dissociates from the wall once the cross-link has been formed. 
Beta-lactam is added to the system and enters in the active site of the PBP. Drug reacts (covalently and 
permanently ) with the active site and inhibits interaction between PBPs and chain, blocking wall synthesis (source, 
https://en.wikipedia.org/wiki/Penicillin) 
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Resistance to this type of antimicrobial agents is due to the expression of β-lactamase and extended 
spectrum β-lactamase (ESBL). These enzymes act by hydrolyzing the β-lactam ring of penicillins and 
cephalosporins, and may be mediated by plasmids or chromosomal genes.  
Over 400 different β-lactamase produced by many bacterial species have been described in the literature. 
The classification of these enzymes is complex, but can be divided into two main schemes: 
a) functional classification of Bush, Jacoby and Medeiros: divides β-lactamase in 4 functional groups and in 
different subgroups (indicated by letters of the alphabet) based on enzyme activity against different 
substrates and their susceptibility to inhibitors (clavulanic acid, sulbactam, tazobactam) [20]; 
b) molecular classification of Ambler: groups the β-lactamase in four molecular classes (A, B, C and D) based 
on their primary structure [21, 22]. 
 
Extended-Spectrum β-lactamases (ESBL) 
Enzymes belonging to the ESBL class confer resistance to penicillins, cephalosporins, to the third 
generation, to aztreonam and sometimes fourth-generation cephalosporins. They are inhibited in vitro by 
clavulanic acid and other inhibitors of the β-lactamase (sulbactam, tazobactam) and do not hydrolyze 
carbapenems or the cephamycins, such as cefoxitin and cefotetan.  
With the exception of OXA-type enzymes, which are class D enzymes, the ESBLs are mainly of the Ambler 
class A and can be divided into three groups: TEM, SHV, and CTX-M types. Most are located on plasmids 
which allow an efficient and rapid transmission of resistance [23-26]. 
The production of ESBL not always determines MIC values above the clinical resistance breakpoints, as in 
relation to the different hydrolytic activity of the enzymatic variants, as for the amount of enzyme 
produced, and as the variable ability of β-lactam antibiotics to cross the outer membrane of bacteria.  
In these cases, despite the apparent susceptibility in vitro, the extended-spectrum cephalosporins may fail 
in the treatment of infections caused by ESBL-positive. Based on these considerations, there is an 
international consensus to interpret carefully all ESBL-producing strains, introducing a two-steps laboratory 
assay, constituted by a first screening and a subsequent confirmatory test.  
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AmpC β-lactamase 
The first bacterial enzyme reported to hydrolyze penicillin was the AmpC β-lactamase of E. coli, although it 
was not given this name since the 1940s.  
AmpC enzymes are grouped into Ambler class C and shows its activity against penicillins, expanded 
spectrum cephalosporins of third generation (such as cefotaxime, ceftriaxone, ceftazidime), cephamycins 
(cefoxitin and cefotetan), and aztreonam. The full spectrum of activity occurs when there is overexpression 
of the enzyme. 
Unlike ESBLs, AmpC β-lactamases are not inhibited by the commonly used inhibitors as clavulanic acid, 
sulbactam, and tazobactam, but may be inhibited by cloxacillin or boronic acid. 
Some strains of Escherichia coli, Klebsiella spp., Salmonella spp., Enterobacter aerogenes, and Proteus 
mirabilis have acquired plasmids containing genes of the β-lactamase AmpC, of which the most common 
enzymes belong to the families of CMY, FOX, and DHA. 
The action of AmpC enzymes is given by its overproduction but may exist concurrently with other 
mechanisms such as the alteration of the membrane permeability or of the porins functionality, for which, 
as for ESBLs, the assessment of the sensitivity tests is to be carefully evaluated. 
 
Carbapenem drugs and carbapenemases 
The increase of resistance to penicillins and cephalosporins led some pharmaceutical companies to screen 
soil actinomycetes for searching new antibiotics. After several years, in 1980s, industries made available the 
first carbapenem: imipenem [27]. 
Carbapenems are a class of β-lactam antibiotics with an exceptionally broad spectrum of activity and, like 
beta-lactams. These drugs has been the main treatment choice, especially for severe infections caused by 
ESBL- and AmpC-producing Enterobacteriaceae [28]. 
Resistance to carbapenem is due mainly to the production of carbapenemases, which are enzymes able to 
make ineffective treatment with penicillins, cephalosporins, aztreonam, cephamycins and carbapenem, 
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although occasionally it may be due to the presence of a β-lactamase associated with a reduction of the 
permeability of the bacterial membrane. 
Carbapenemases are divided into two principal molecular groups: metallo-carbapenemases and serine-
carbapenemases (distinguished by hydrolytic mechanism at the active site) [20].  
The first are inhibited by EDTA and contain at least one zinc atom at the active site; the second contain 
serine at the active site and are sensible to clavulanic acid and tazobactam, but not to EDTA [29-31] (table 
1). 
 
 
Molecular Class A B D 
Functional group 2f 3 2d 
Active site Serine Zn++ Serine 
Aztreonam hydrolysis + - - 
EDTA inhibition - + - 
APBA inhibition + - - 
 
Table 1. Representation of principal characteristic of the carbapenemases, grouped according to Ambler 
classification 
  
 
The major family of class A serine carbapenemases include KPC enzymes, while the most diffused and 
studied acquired metallo beta-lactamases include IMPs, VIMs, SPM-1, GIM-1, AIM-1, SIM-1, NDM-1 and 
DIM-1 families [32-36]. 
The emergence of carbapenems resistance constitutes a major clinical problem, since these antibiotics 
represent the reference drugs for the therapy of invasive infections due to multiresistant (MDR) gram-
negative enterobacteria [35, 37, 38].  
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The carbapenem-resistant Enterobacteria represent a significant danger to public health, because they are 
frequent cause of hospital-acquired infections; it was observed an increased rate of mortality; resistance to 
carbapenems may be transmitted to other microorganisms through plasmids [39, 40]. 
For these reasons, it is essential to improve the preventive measures and implement specific guidelines as 
the most effective in the diagnosis of these microorganisms. 
Automated systems for the determination of drug susceptibility can be unreliable in the detection of 
carbapenemases, in particular those which confer resistance to imipenem and meropenem. So, the 
presence of a high MIC for carbapenems should provide for the execution of additional tests: can be 
applied molecular methods, such as PCR for the identification of resistance genes, or phenotypic assays, as 
the modified Hodge tests [41, 42]. 
 
Focus on most diffused carbapenemases 
KPC-type  
This denomination refers to Klebsiella pneumoniae carbapenemases (KPC), because are most commonly 
expressed by this bacterium. KPC-type carbapenemases are included in molecular class A and functional 
group 2f (Ambler class); can hydrolyze different antimicrobial agents such as aminoglycosides, 
fluoroquinolones, and β- lactams including penicillins, carbapenems, cephalosporins, and aztreonam [43] 
[44] and are inhibited by clavulanic acid and tazobactam [45]. 
To date, several KPC gene variants have been reported and classified from KPC-2 to novel KPC-16 and KPC-
17, grouped into blaKPC-2-like (including alleles 2, 4, 5, 6, 11, and 12) and blaKPC-3-like (including alleles 7, 8, 9, 
10, and 13) [46, 47]. Interestingly original KPC-1 was found identical to KPC-2 [48, 49], while the KPC-2 to 
KPC-11 genes are characterized by non-synonymous single nucleotide substitutions within four codons [47]. 
The KPCs are predominantly found in K. pneumoniae; however, they have also been found in many other 
Enterobacteriaceae including Salmonella species [34], Escherichia coli [50-53] and others, such as in many 
non-Enterobacteriaceae including Pseudomonas aeruginosa and Acinetobacter baumannii strains [54-56]. 
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Although the first case of isolation of KPCs was in America, these enzymes are now widely distributed 
worldwide [57] (fig 6). 
 
 
Figure 6. Global spread of KPC enzyme: a) worldwide distribution; b) spread in USA; c) European dissemination; d) 
distribution in China. In blue, single KPC-producing isolates; in green, detection of outbreaks due to KPC-producing 
isolates; in purple, endemic KPC-producing strains (source [57]) 
 
 
 
Infections produced by KPCs have frequently nosocomial spread and are associated with treatment failure 
and high mortality; for this reason, combination therapy is recommended for the treatment of KPC 
infections [58]. 
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VIM-type 
Verona Integron-encoded (VIM), called in this way because was first isolated in Verona, Italy, in 1997 is a 
metallo-β-lactamase belongs to the Ambler Molecular class B (metallo carbapenemases) [59].  
These enzymes hydrolyze carbapenems and extended-spectrum beta-lactams, but are not inhibited by beta 
lactamase inhibitors such as clavulanic acid, sulbactam, and tazobactam [60]. 
 VIM-dependent resistance production is considered a serious problem because of the rapid spread of this 
enzyme; moreover treatment options of VIM-producing organisms are considered limited, although 
combination therapy seems to be the best treatment [61-63] (fig 7).  
 
IMP-type 
IMP is a metallo beta-lactamase widespread globally and transmitted by transposons or plasmids. The first 
issues of IMP-1, the most popular IMP variant, date back to 1999, when it was isolated from P. aeruginosa, 
K. pneumoniae and S. marcescens and was associated with resistance to carbapenems [64]. Always during 
those years, there was a great spread of strains of K. pneumoniae IMP-producing that had the ability to 
induce strong resistance to carbapenems [65, 66]. 
Today the spread of this variant is expressed globally, similarly to VIM (fig 7), and to date most than 50 IMP-
like variant are known (Lahey Clinic.: http://www.lahey.org/studies/ ) [67] 
 
 
 30 
 
Figure 7. Geographical distribution of VIM and IMP enzymes (a) worldwide and (b) in Europe. About VIM-producing 
strains distribution: in yellow, VIM-producing nosocomial outbreaks; in red, VIM interhospital spread, and in 
purple, high prevalence of VIM-producing isolates. About IMP-producing isolates, in light blue, presence of 
nosocomial infection due to IMP-producers spread, and in blue prevalence of IMP enzyme diffusion [57] 
 
OXA-type 
Oxacillin-hydrolyzing enzymes (OXA) are part of the class D of the serine beta-lactamase. They were 
identified for the first time in Scotland, in a patient colonized by Acinetobacter baumannii presenting 
resistance to cephalosporins [23, 45]. The enzyme involved was named OXA-23 and, to date, more than 
two hundred variants of OXA-like enzymes are known, capable of hydrolyzing extended-spectrum 
cephalosporins and, in some cases, also confer low levels of resistance to carbapenems [68-70]. 
Among oxacillinases, OXA-48 is a plasmidic resistance gene widespread in the family of Enterobacteriaceae 
and confers resistance to different classes of drugs (cephalosporins, penicillins, β-lactam and even 
carbapenems) [68, 71, 72]. Moreover, K. pneumoniae OXA-48-producing is widespread worldwide [73-75]. 
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NDM-type 
The New Delhi Metallo-β-lactamase (NDM-1) is one of the β-lactam enzymes more recently identified and 
more quickly spreading worldwide: was isolated from a patient of Indian origin in Sweden and to date exist 
16 NDM variant (NDM 1-16; Lahey Clinic.: http://www.lahey.org/studies/)[32]. 
In accordance to all beta-lactamases, also NDM is commonly expressed by K. pneumoniae and even by 
Enterobacteriaceae family at global level [76-78]. Curiously, the peculiarity of this enzyme is that has been 
recently shown to be associated with the highly successful, E.coli virulent clone, ST131 [79, 80].  
 
1.1.5 Drug resistance in Klebsiella pneumoniae  
K. pneumoniae carbapenemases 
K. pneumoniae is major nosocomial pathogens, capable of rapidly spreading in hospitals [81], considering 
that infections caused by this bacterium are difficult to eradicate, especially due to the frequent carriage of 
drug resistance determinants: β-lactams and extended-spectrum cephalosporins (ESC), other classes of 
drugs such as aminoglycosides and occasionally also polymyxin B and colistin. 
In 1996, a new strain of K. pneumoniae resistant to carbapenems was identified in New Carolina and was 
designed as carbapenemase-producing K. pneumoniae (KPC) [48]. 
Although the first hospital outbreak was described in a centre in New York, reports are now showing that 
KPC producing bacteria are disseminated worldwide [44, 82-88]. 
Genetic determinant of resistance to beta-lactam, moreover, have now been detected in several other 
members of the Enterobacteriaceae family and Pseudomonas aeruginosa [45, 89, 90]. Spread of 
carbapenemase-resistance genes among different bacterial species is possible thanks to the localization of 
them on plasmids and their association with transposons and insertional elements. 
Different genes encoding for carbapenemases are blaKPC, followed by blaNDM (New Delhi metallo- β -
lactamases), blaVIM [91-96], and blaOXA-48 [61, 97]. 
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Since the first isolation of a clone of KPC in the United States, 13 genetic determinants of these enzymes 
have been identified. Determinants KPC-2 and KPC-3 were described for the first time in the USA [98] and 
seem  to be the most frequent in Europe, with wide dissemination in Italy [99-101]. 
 
Colistin resistance 
Colistin is considered as the last resort for treatment of severe infections caused by MDR Gram-negative 
bacteria because of its toxicity. However, in recent years the spread of genetic variants resistant to colistin 
is increasing [102, 103]. In K. pneumoniae, resistance to polymyxins and other cationic antimicrobial 
peptides is mediated by alterations of the lipopolysaccharide (LPS), with subsequent decrement of the 
affinity of polymyxins to the target. At the base of the mechanism regulating colistin resistance, relevant 
genetic factors include the mgrB gene, the pmrC gene (aminotransferase acting for the LPS synthesis) and 
the pmrHFIJKLM operon [104, 105]. Recent evidences suggest that insertional inactivation of the mgrB gene 
in K. pneumoniae represents the presumptive mechanism responsible for the emergence of colistin 
resistance via alteration of specific signaling pathway.  
Normally the upregulation of the pmrHFIJKLM operon via the PhoQ/PhoP signaling pathway leads to 
modulation of the bacterial survival mechanism and to the LPS synthesis via activation of the pmC gene 
[108] (fig 8). During stress condition, MgrB mediates the negative feedback of the PhoQ/PhoP pathway, but 
if this protein results altered, PhoQ/PhoP signaling pathway cannot be inhibited and possible alteration on 
the LPS structure may occur. This means that the drug cannot recognize the LPS target, causing bacterial 
resistance [106, 107]. 
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Figure 8. Schematic representation of MrgB function mediating negative feedback in the PhoP/PhoQ system. PhoQ 
stimulation (low extracellular magnesium, low pH or cationic antimicrobial peptides, CAMPs) leads to higher 
production of phosphorylated PhoP, which lead to increasing transcription of mgrB gene. MgrB inserts in the inner 
membrane and represses PhoQ, resulting in decreased PhoP phosphorylation [107]  
 
 
1.1.6 K. pneumoniae virulence factors 
 
The expression of virulence factor is a prerequisite for pathogenic bacteria, because it makes them capable 
of infecting effectively the host. 
Innate and humoral immunity are the main mechanisms of defense against infections mediated by 
Enterobacteria. If these mechanisms are congenitally absent or temporarily compromised, susceptibility to 
infection and severity increase. 
The mechanism of action of pathogenic Enterobacteria is complex and includes several co-factors involved 
in the development and evolution of infectious process: capsular antigens, siderophores and superficial 
adhesion molecules (fig 9). 
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Figure 9. Representation of main virulence factors in K. pneumoniae; source, [81] 
 
 
Capsular antigens 
The extra cellular pathogens are able to resist to the bactericidal activities immune cells through surface 
elements as the lipopolysaccharide (LPS) and other elements present in the bacterial capsule. 
The molecular mechanism at the basis of this activity would seem to consist in inhibiting or in the 
absorption of several immune system components.  
In Klebsiella spp. are known more than a hundred different serotypes of the capsule; just think that already 
in 1998 were 77 known antigens [81]. 
 It seems that great differences in virulence exist between strains that express specific capsular types and 
those that do not express them. For example, it was shown that strains of K. pneumoniae expressing 
capsular antigens K1 and K2 are particularly virulent in liver murine models, while isolates with the same 
mutant serotype showed lower virulence [109-113]. 
Maybe, the ability to resist to external environment is due to the production of a massive polysaccharide 
capsule. Studies have shown that overexpression of genes (rpmA and magA) encoding for this mucous 
viscous phenotype is associated with enhanced virulence [114-116].  
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Adhesion molecules 
The initial and fundamental stage of infection is represented by the adhesion process, by which 
microorganisms adhere to the guest mucosa. The adhesive properties of Enterobacteria are mediated by 
several types of pili. These, also known as fimbriae, are filamentous and non-flagellar projections of 
bacterial surface. 
These structures reach up to 1-2 micrometers in length and 2-8 nm in diameter and are composed of 
polymeric globular protein subunits (pilin) with a molecular mass of 15-26 kDa.  
The direct link between the bacteria and host cell is mediated by molecules called adhesins or fimbriae that 
are differentiated primarily on the basis of their ability to agglutinate erythrocytes of different animal 
species. In fact, depending on whether the agglutination reaction can be inhibited by D-mannose, the 
adhesins are categorized as mannose-sensitive hemagglutinin (MSHA o type-1) or mannose-resistant 
(MRHA o type-3). 
Klebsiella pneumoniae presents on the cell surface both type of adhesins [117-119]: 
 
a) Type 1 fimbriae 
Type 1 fimbriae are expressed by the majority of enterobacterial cells and are mannose-sensitive 
molecules. Several studies, aimed to characterize these molecules in E. coli and in K. pneumoniae, showed 
an high similarity in composition and gene cluster regulation  [118]. Their main role is allow bacteria to 
adhere to the epithelium of the host leading, mainly,  to urinary tract infections (UTI). Moreover, the type 1 
fimbriae are also able to bind soluble glycoproteins rich in mannose, such as the Tamm-Horsfall protein, 
which allow them to mediate bacterial colonization of both the respiratory and urogenital tract [120, 121].  
Type 1 fimbriae are archetypal and are encoded by a gene cluster fimACDEFH, where adhesive components 
are rapresented by fimA and fimH [121] 
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b) Type 3 fimbriae 
The adhesin of type 3 are able only to agglutinate erythrocytes treated with tannin, for this reason defined 
as resistant to mannose. Moreover, although the commonly definition is "mannose-resistant Klebsiella-like 
hemagglutination" (MR/K-HA), this type of fimbriae is synthesized from many strains of Enterobacteria. 
The main function of type 3 fimbriae seems associated with the formation of biofilm. Type 3 fimbriae are 
able to bind to different human cells: the endothelial cells, the epithelium of the respiratory and urinary 
tract. In the kidney, this type of pili allows the bacterial adhesion to the membrane of renal tubules, of the 
capsules of Bowman and of renal vessels [122, 123].  
Genes involved in the synthesis of type 3 fimbriae are included in a cluster (mrkABCDF) containing protein 
subunits (mrkA gene), minor subunits (mrkF gene), genes coding for chaperone (mrKB gene), usher-protein 
(mrkC gene), and adhesins (mrkD gene) [123]. 
Phylogenetic analysis has shown that genes may be located at the chromosomal level, but also transferred 
between bacteria through plasmids and transposons [124, 125]. 
 
Transport of iron 
The capacity to capture and metabolize iron is crucial for pathogen surviving. The growth of bacteria in the 
tissues of the human organism is limited not only by the host defense mechanisms but also by the low 
availability of iron, since it is linked to host proteins that may have deposit activity (i.e. hemoglobin, ferritin, 
hemosiderin and myoglobin) or transport activity (i.e. lactoferrin and transferrin). The effect of an iron 
supply on the pathogenesis has been demonstrated for K. pneumoniae using a animal model: after 
parenteral administration of iron, the susceptibility to infection with K. pneumoniae increases dramatically, 
so it is suggested that only microorganisms that are able to ensure the presence of intracellular iron can 
survive and replicate in the host tissues [126, 127] (fig 10).  
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Figure 10. Mechanism of action of bacterial siderophores. Iron is usually bound to chelant protein (hemoglobin, 
myoglobin) expressed by the host cell. For its survival, bacteria have developed strategies concerning the release 
molecules called siderophores (1), which bind the ion with high affinity (2) and allow its subsequent entry into the 
bacterial cell (3) http://intranet.tdmu.edu.te.ua/data/cd/disk2/ch007.htm 
 
Bacteria have developed strategies to sequester iron from infected tissues producing siderophores that are 
molecules able to capture host iron [128]. Different siderophores are proper of the Enterobacteriaceae 
family, of which the encoding genes are located in "pathogenicity islands" [128].   
Under conditions of iron deficiency the Enterobacteria are able to synthesize siderophores belonging to 
two different chemical groups: "phenolate-type siderophores" and "hydroxamate-type-siderophores" (PTS 
and HTS, respectively). 
The PTS are the most common group of siderophores, of which the best known representative of this group 
is the enterobactin or enterochelin, which has, compared to other siderophores, higher affinity to iron. 
In the HTS class, ferrochromes (synthesized only by fungi), ferrioxamins and aerobactin are included; in 
particular, the aerobactin, unlike from enterobactin, is known to be necessary for bacterial virulence and 
surviving having different metabolic advantages. For example, it seems to have greater stability and 
solubility and, while enterobactin is hydrolyzed by an esterase after transferring the iron, the aerobactin 
can be reused at every metabolic cycle [127]. 
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Data on the incidence of the aerobactin production in Klebsiella spp suggest that this siderophore could 
play a central role in its pathogenesis, but isolates of Klebsiella pneumoniae not capable of synthesizing 
aerobactin, are absolutely able to use exogenous aerobactin as the unic source of iron. This is a great 
advantage mainly in mixed infections, because these aerobactin-producers strains can gain an advantage 
over other bacteria [129, 130]. 
Although aerobactin play an important role in bacterial surviving, however K. pneumoniae is mainly known 
for the high production of the siderophore enterobactin (Ent). This siderophores is encoded by genes  
carried on the transposon EntABCDEF and possesses higher affinity for the iron respect other siderophores 
[131]  
Unlike the aerobactin, the enterobactin functionality is compromised by the lipocalin2 (lcn2), a molecule 
produced by the host tissues that competes with the iron for the siderophore binding site causing, once 
bound, its inhibition [132]. To obviate this problem, it seems that the bacteria are capable of producing 
several "alternative siderophores", as salmochelin (glycosylated enterobactin) or yersiniabactin, which is 
structurally different from enterobactin. 
Yersiniabactin (Ybt) initially was reported in the genus Yersinia. Subsequent studies have shown that this 
siderophore, as well as others commonly produced by various species of Enterobacteriaceae, is codified by 
genes carried on HPI (high-pathogenicity islands) [133]. In particular, in K. pneumoniae, yersiniabactin is 
encoded by YbtAS genes and regulated by iron-repressible genes irp1 and irp2 [134]. The yersiniabactin 
could have a key role in the survival of virulent strains of K. pneumoniae, but to date little is known with 
respect to the precise role played by the siderophores in the host organism, although a recent study 
affirmed that that the expression of these molecules is specific and tightly regulated in the various host 
tissues. In fact, different siderophores may coexist in the same host tissue and a specific combination of 
siderophores may exist in different host tissues, suggesting that the siderophores may have an important 
role in modulating host cellular pathways and determining the bacterial survival during infection (fig 11) 
[135]. 
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Figure 11. Bacteria can express a number of molecules with high affinity to the iron (siderophores). These may act 
specifically in different tissue, allowing bacteria to survive and infection to progress. In particular, it is showed a) in 
the lung lcn2 may capture enterobactin, but in absence of lcn2, enterobactin bind the iron allowing bacterial 
replication, while ybt may bind iron; b) in the liver, presence of aerobactin is prevalent; c) in the kidney, there is the 
presence of aerobactin and yersiniabactin. Ybt, yersiniabactin; ent, enterobactin; aer, aerobactin; Fe, iron; lcn2, 
lipocalin. Source [135] 
 
 
1.1.7 Laboratory diagnosis of infection due to Enterobacteriaceae 
In biological materials taken from a site of extra-intestinal infection, the identification of 
Enterobacteriaceae is less specific than that from anatomic sites considered sterile (such as blood), because 
the clinical suspicion of infection is intended to characterize any bacterium is present. For the bacterial 
growth the use of nonselective and enriched (blood, serum, etc) culture media is suitable for the 
development of the largest possible number of bacterial species. Each colony, consisting of Gram-negative 
bacteria that are negative to test of the indo-phenol oxidase and positive to catalase reaction (a part of 
Shigella dysenteriae), it must be considered as potentially generated by Enterobacteria. 
Enterobacteria grow well in the common culture media, showing generally similar morphology, which may 
not be a critical method for the correct identification.  
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Figure 12. Imagine representing a hypermucousviscous K. pneumoniae strain, which appears sticky and forms 
mucous extensions of capsular component 
 
The colonies of bacteria of the Klebsiella-Enterobacter-Serratia (KES) group, as with evident capsule, have 
mucosal appearance. In particular, the hypervirulent variant of Klebsiella pneumoniae may presents a 
typical viscosity of the colonies (fig 12).  
 
The medium on which normally can be observed the growth of Klebsiella spp is the MacConkey agar (BD, 
Heilderberg, Germany), differential for Gram negative bacteria, in which colonies of discrete size, of color 
pink or whitish with mucous appearance and weakly lactose fermenting are observed. The preparation of 
MacConkey is based on the knowledge that bile salts are precipitated by acids and certain enteric bacteria 
can ferment lactose whereas others do not possess this ability, while bile salts and crystal violet inhibit the 
growth of Gram positive organisms. It is ideal for the analysis of clinical specimens containing mixed 
microflora, for example samples from urine, respiratory apparatus, wounds, etc., as it allows making an 
initial identification of Enterobacteriaceae and other Gram-negative fermenting and non-fermenting 
lactose. 
 
Following the recent spread of bacteria showing high resistance to beta-lactamases and carbapenemases, it 
is necessary to improve the efficiency of screening methods used, also considering that, for both ESBLs that 
for carbapenemases, not always the identification of a certain value of MIC discriminates certainly for the 
presence of a resistant or sensitive strain. For example, the susceptibility assay, especially in the case of 
ESBLs, not always determines MIC values above the clinical breakpoints for resistance, as there is a lot of 
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variability due to the hydrolytic activity of the different variants, the amount of enzyme product and the 
variable ability of β-lactam antibiotics to cross the outer membrane of the bacteria. In these cases, despite 
the apparent sensitivity in vitro, the treatment may fail. 
The protocol for the identification of ESBL and carbapenemases production in microorganisms isolated 
from clinical samples is strongly adjusted both by Clinical Laboratory Standard Institute (CLSI) that by 
European Committee on Antimicrobial Susceptibility Testing (EUCAST), for epidemiological purposes and 
control of infections, even if to date there is not still a phenotypic screening method for resolving all cases.  
 
The detection of ESBL is performed in two steps, with an initial screening test to identify isolates potentially 
ESBL productors and a subsequent confirmation test, targeted to distinguish ESBL-producing isolates from 
those resistant to cephalosporins or presenting others mechanisms of resistance. 
CLSI guidelines suggested testing as indicators of ESBL production drugs belonging to the cephalosporins 
class (i.e. cefotaxime, ceftazidime, ceftriaxone, cefpodoxime and aztreonam), considering that reduced 
susceptibility to one or more drugs indicates resistance against antibiotics. But because of different ESBL 
enzymes may have a different hydrolytic activity against the various drugs; there is no single indicator drug 
capable of detecting the totality of the ESBL-producing isolates. 
The confirmation test of ESBL production can be done by phenotypic test based on demonstration of the 
synergy between clavulanate and cephalosporins (ESBL are inhibited by clavulanate acid, tazobactam and 
monobactam), with possible different methods: the test of “double discs” consists in a classic agar diffusion 
assay where discs of a cephalosporin alone are positioned around a disc of amoxicillin-clavulanate placed in 
the middle of the plate, to assess the recovery of the activity of β-lactam in the presence of the inhibitor. 
The test is positive when it appears a distortion of the halo surrounding the β-lactam ring in the proximity 
of the disc of amoxicillin-clavulanate (fig 13) [136]. The combination test, another confirmatory test, is 
performed positioning on the plate discs containing the cephalosporin alone and a combination of 
cephalosporins and clavulanate acid. The halos of the discs related to the drug alone or the drug with 
clavulanic acid are compared and the sample is considered positive for ESBL if the diameter of inhibition is 
≥5mm. Finally, the method of combination with E-test provides at the same time the MIC of a 
 42 
cephalosporin (ceftazidime or cefotaxime) alone and in combination with clavulanic acid. Even in this case, 
ESBL production is confirmed if the clavulanic acid reduces the MIC of cephalosporin at least 3 fold dilutions 
(fig 13). 
 
a) Confirmation of ESBL production by testing 
the double disc in Klebsiella pneumoniae 
producing SHV-12. Top, ATM, aztreonam (30 
mg/mL); bottom, CRO, ceftriaxone (30 mg/mL) 
left, CTX, cefotaxime (30 pg/mL) right, CAZ, 
ceftazidime (30 pg/mL); at the center, AMC, 
amoxicillin + clavulanate (20+10 g/mL).
a
b
b) Confirmation of ESBL production by test 
combination (E test) in Klebsiella pneumoniae 
producing SHV-12. Left E test: top, TZ, 
ceftazidime (MIC> 2 mg/mL); bottom, TZL, 
ceftazidime + clavulanic acid (MIC 0.5 mg/mL); 
right E test: top, CT, cefotaxime (MIC 2 mg/mL); 
bottom , CTL, cefotaxime + clavulanic acid (MIC 
0.094 mg/mL)
 
Figure 13. Two examples of confirmatory sensibility test performed to detect the presence of β-lactamases in K. 
pneumoniae strains.  a) “double discs” method; b) combination E-test assay  
 
 
In some cases, due to the difficulties in the interpretation of the test, for final confirmation of the presence 
of a gene coding for a ESBLs and characterization of the type and the variant enzyme produced, it has 
suggested the application of methods of molecular biology. 
 
Also in the identification of carbapenemases-producing strains, it is recommended to apply both screening 
and confirmatory tests. The clinical significance in the diagnosis and treatment of carbapenemases is due to 
the fact that, virtually, a producer strain carbapenemase presents resistance to all beta-lactams, and 
possibly other medications. Furthermore, treatment of the patient can be difficult and the infection is 
generally associated with high mortality.  
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Furthermore, as previously mentioned, these mechanisms may be combined with others (alteration in 
efflux and/or membrane permeability, presence of beta-lactamases etc), leading to the presence of a great 
number of phenotypic variants. Besides, some strains may present decreased susceptibility to carbapenems 
due to the combination of production of ESBLs enzymes or AmpC enzymes combined with porins and 
membranes alterations. 
The presence of carbapenemases for reduced susceptibility in respect of meropenem (MIC ≥0.25 ug/mL; 
diameter of the inhibition halo ≤25 mm) is an indicator of possible carbapenem resistance strains and it is 
preferable to use it than imipenem and ertapenem whereas the MIC values of producing strains 
carbapenemases may be in the cut-off and meropenem has good sensitivity and specificity in detection of 
them. If this drug is not available to testing, it is possible to use imipenem, while the use of ertapenem 
increases susceptibility but reduces the specificity and therefore further tests to confirm the result are 
required. 
Confirmatory tests commonly in use in Clinical Microbiological Laboratory are the synergy test and the 
Hodge test. The first is performed by combination of carbapenem and specific inhibitors of 
carbapenemases, in order to assess the recovery of the activity of the drug in the presence of the inhibitor. 
The confirmatory test is based on the knowledge that carbapenemases of class B are inhibited by dipicolinic 
acid, as the class A by the boronic acid and that cloxacillin inhibits the AmpC enzymes helping to 
differentiate between the overproduction of AmpC with loss of porins or the production carbapenemases. 
The table below showed the algorithm used to characterize presence of carbapenems in 
Enterobacteriaceae (fig 14). 
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Figure 14. Schematic representation of diagnostic algorithm to carbapenemases detection, EUCAST guidelines ( 
http://www.eucast.org/resistance_mechanisms ). 1 combination of MBL and KPC may present high resistant 
isolates in absence of synergy. They are easiest to be detected by molecular methods; 2 presence of high temocillin 
resistance strains may indicate presence of OXA-48 production, it is suggest to consider it in absence of synergy 
with inhibitor of A and B classes of carbapenemases. APBA, aminophenyl boronic acid; PBA, phenyl boronic acid; 
DPA, dipicolinic acid; EDTA, ethylenediaminetetraacetic acid. 
 
 
 The Hodge test or MHT (Modified Hodge Test) is based on the reduction of activity of the carbapenem 
tested against a sensitive strain that serves as an indicator [137]. 
Of this test we have been proposed numerous methodological variations, but the most common protocol 
provides for: the preparation of a suspension of 0.5 McFarland in saline water of E. coli ATCC 25922 
(indicator strain) and its confluence spread on plate of Mueller-Hinton agar; positioning in the middle of the 
plate a meropenem disc; deposition of 1-2 colonies of the strain to be tested in the proximity of the 
antibiotic and spread on a straight line in the direction of the edge of the plate (or inoculated by cutting in 
the surface of the agar) [137]. The test is considered negative if the zone of inhibition of the control strain is 
not a clear indentation at the inoculum of the strain tested. The test is considered positive whether the 
zone of inhibition of the control strain present a clear indentation at the inoculum of the strain tested. 
The test is to define doubt in the presence of faded or minor alterations of the halo. The test Hodge does 
not allow the distinction between the different classes to which belong the carbapenemases, but shows 
only the presence of hydrolytic activities.  
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1.1.8 Molecular typing 
To date, with the relentless spread of more virulent bacteria and with the increase of antibiotic resistance, 
the ability to trace the origin of pathogen isolates, to describe the genetic relatedness among them or to 
highlight the virulence factors and resistance genes, is imperative [138].  
The use of molecular methods plays a crucial role in the identification, characterization and control of 
infections, with an integrated approach together with clinical methods [139, 140]. In recent years,  
molecular typing allow to implement an effective control of infectious diseases, resulting in the rapid 
detection and characterization the etiologic agent and the activation of specific surveillance programs 
[139]. 
Typing methods, a part of being accessible, rapid, easy to apply and as possible economic, may present so 
called “performance” criteria, such as  discriminatory power, reproducibility, and typeability [141]. In 
particular, typeability refers to the ability of the method to assign a type to all isolates tested with that 
method in an elevated percentage of success; discriminatory power is the ability of a method to assign 
different types to two unrelated strains analyzed "randomly" within a population of a given species. For 
example, typing methods investigating polymorphisms in multiple sites of the whole genome have more 
probability to have a greater discriminatory power than the methods that investigate a single locus. Finally, 
reproducibility is refers to the ability of a typing method to often assign the type of one strain tested in 
independent occasions, separated in time and/or space. The reproducibility may be affected by various 
elements in a process, such as because of changes in microbial growth condition, the methods used in the 
extraction DNA, in the reagents used, different types of equipment, diversity in the observation and 
interpretation of results [141].  
For this reason, sometimes it is not possible to compare results obtained from different laboratory. A 
molecular technique aimed to typing isolates cannot be separated from the adequate knowledge of its 
interpretation criteria, which vary depending on the methods. Guidelines have been proposed, for 
example, for the interpretation of patterns obtained by molecular techniques as Pulsed Field Gel 
Electrophoresis (PFGE), PCR-ribotyping and amplification with arbitrary primers (RAPD). 
 46 
Numerous are the molecular techniques used to date, and it is very important to make a correct choose of 
the methods [142]. Although numerous molecular techniques exist, the most widely used are: 
? Restriction Fragment Length Polymorphism (RFLP): based on analysis of fingerprinting obtained 
starting from the digestion of the DNA with restriction enzymes with rare cutting sites and a 
subsequent electrophoretic run on agarose gel. It was used for the first time in years 80s for the 
typing of viruses, fungi and bacteria. Its usefulness lies in the detection of changes (insertions, 
deletions, etc.) in the bacterial genome [143-146]; 
? PFGE is one of the most diffused and well characterized molecular typing techniques [147]. It is 
used for molecular characterization of many pathogens transmitted with food or pathogen causing 
nosocomial outbreak [148-151]. This method is considered for many laboratories as the “gold 
standard” for its good discriminatory power and easiness in application. It is based on the 
enzymatic digestion of the whole genomic DNA with restriction enzymes that perform a few cuts 
(i.e. HindIII), so it is possible to generate a number of fragments very small but with large dimension 
between 40kb and 600kb that are separated by the use of an electrophoretic system with pulsed 
electric field, in which the orientation of the field electricity is periodically changed to order to 
obtain a better separation of fragments. The fragments generated can be analyzed and compared 
through the use of dedicated software (such as BioNumerics and GelCompare, Applied Maths) that 
identify the locations of the bands, and so calculate the molecular weight of the DNA fragments 
using a mathematical matrix that analyzes similarities of the profiles [145, 152]; 
? certainly by its discovery, the Polymerase Chain Reaction (PCR) has been and is the technique most 
widely used in molecular biology laboratories. Thanks to the PCR and to the newer method based 
on this approach can be amplified many genes, including the most relevant to the study of 
pathogenic virulence factors related to pathogenicity and transmissibility of the bacteria and the 
genes of antibiotic resistance [153, 154]. For several years it has been introduced as an alternative 
to common PCR, called Real-time PCR, which allows to increase the susceptibility and reliability of 
the results obtained with the PCR and is based on measurement of the fluorescence signal that is 
generated at each cycle of amplification, by which method it was possible to reduce the processing 
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time and increase the efficiency and specificity of the final result. Various are PC-based techniques 
[155, 156], but the frequently used are Randomly Amplified Polymorphic DNA-PCR (RAPD-PCR) and 
Arbitrarily Primed PCR (AP-PCR) are part: the gene fragments are amplified using primers that 
recognize accidentally complementary sequences, leading to the final production of fragments of 
different length and specific to each strain. The fragments are often very variable and polymorphic, 
allowing, therefore, carrying out an effective investigation of the intraspecific variability of 
pathogens [157-159] 
? among the methods based on sequencing of bacterial DNA, one of relief is the Multi-Locus 
Sequence Typing (MLST) [147]. It is one of the most used molecular methods for epidemiological 
investigations and studies on molecular evolution of many pathogenic and non-pathogenic 
bacteria, especially when there is necessary the typing of a microbial species with a high rate of 
genetic recombination. It is based on the detection of the polymorphisms present in the 
"housekeeping" genes, which code for enzymes that catalyze important metabolic functions [160, 
161]. A variant of classical MLST is the Multilocus Ribosomal Sequence Typing (rMLST) that allows 
to evaluate the molecular change of the genes that encode bacterial proteins of the ribosomal 
subunits and, compared to MLST, had higher discriminatory power [162]. Thanks to the good 
reproducibility and transferability of data MLST was possible develop databases accessible to all 
which allow the identification of the strains in question [163, 164]. The disadvantage of this 
technique is the necessity of a genetic analyzer to sequence all the products obtained with relative 
high cost; 
? Single-Nucleotide Polymorphisms (SNPs) analysis has the advantage of lead to the identification of 
polymorphisms in specific DNA sequences present, in according to the change of a single base 
nucleotide (SNPs). Initially used for the study of the genetics of eukaryotic cells, it is now largely 
worked to the characterization and differentiation of bacterial strains.  
The necessity to investigate more thoroughly and to eliminate possible limitations due to the 
variability of the methods and to the difficulty of interpretation, allowed to go up to the ideation of 
a methodology of massive sequencing. Is the case of the Whole Genome Sequencing, which detects 
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precise genetic changes, occurred in bacterial genomes also analyzing mutations at single 
polymorphic locus and presents more vantages as the highest discriminatory power respect to 
other methods [122, 165].  
 
After the success of the Human Genome Project, it has been evidenced the necessity to study extensively 
the single alteration of whole genome [166-169], to better understand genomic rearrangements involved in 
diseases process. Since that moment there was an exponential development of new sequencing 
technologies aimed to meet the requirements of speed, optimum relationship cost/efficiency and broad 
applicability [170-172].  
Certainly, most of the applications of massive sequencing were about the study of human diseases, such as 
rare diseases or cancer [165, 173-175], but subsequently the benefits of this innovative technology have 
been applied to other areas, as the study of pathogens involved in hospital-acquired infections or zoonotic 
transmission or related to food [165, 176, 177]. 
The ability to sequence numerous bacterial genomes and interpret the resultant sequence information in 
near "real-time" is the basis of whole genome sequencing (WGS) technologies, mostly because it is possible 
to support clinical information and make more rapid diagnosis and prevention [178-180]. 
 
There were different platforms engaged the use of next generation sequencing. The most known from 
earlier years of 2000s were (454) GS FLX sequencer (Roche, Branford, USA), Illumina Genome Analyzer™ 
(Illumina Inc., San Diego, CA, USA) and Solid Sequencer™ (Thermo Fisher Scientific Inc., USA) [181-183] 
(table 2).  
All platforms used the same basic workflow with small variations; this workflow consists in producing a 
library of DNA fragments (originated from a variety of front-end processes), in the preparation of a reaction 
amplification via PCR and in the sequencing of the products obtained. The big change compared to the 
classical methodology (Sanger sequencing) it is that, for all platforms, the products (clonally amplified or 
separated in flow cells) can be sequenced in parallel and massively, whereas previously it was necessary to 
analyze the fragments of different length by electrophoresis with individual reactions.   
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With the technology of next generation sequencing it is possible to carry out repeated cycles of 
amplification (through the action of a DNA polymerase or iterative cycles of ligation of oligonucleotides) 
that allow to obtain hundreds of Mb (millions of base pairs) or Gb (billion pairs of bases), which are 
sequenced in parallel. 
 
Platform 
 Roche 454 Illumina SOLiD 
Sequencing chemistry 
Pyrosequencing Polymerase-based 
sequencing-by-synthesis 
Ligation-based 
sequencing 
Amplification approach Emulsion PCR Bridge amplification Emulsion PCR 
Paired ends/separation Yes/3kb Yes/200bp Yes/3kb 
Mb/run 100 Mb 1300 Mb 3000 Mb 
Time/run (paired ends) 7h 4 days 5 days 
Read length 250 bp 32-40 bp 35 bp 
 
Table 2. Comparation of metrics and performance of the three most diffused platforms to perform next Generation 
Sequencing Analysis; adapted by [184] 
 
In particular, in the Roche 454 system, specific adaptors are bound to the extremities of DNA fragments 
and the PCR reaction is performed by emulsion PCR where the beads in the solution bind one of the 
adaptors linked in the extremities of the DNA fragments allowing extension of the single strands of DNA. 
When amplification cycle ends, products are analyzed by pyrosequencing method 
(https://www.youtube.com/watch?v=rsJoG-AulNE). This platform has the disadvantage to be highly 
expensive and to present high error rate during sequencing reaction (table 2). 
 
In SOLiD system (Sequencing by Oligo Ligation and Detection), the amplification reaction takes place with 
emulsion chemistry as in 454 platform, but the sequencing protocol is different and it is known as 
sequencing by ligation. The process starts with binding of beads on the amplification products and with the 
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preparation of a solution containing a ligase enzymes and “di-bases probes”, fluorescently labeled with 4 
different dyes, where each dye represents the 16 combinations of di-nucleotides sequences. The ligase 
adds to each single DNA strand the complementary di-bases probes with emit a fluorescence signal based 
on the sequences bound (educational video at https://www.youtube.com/watch?v=nlvyF8bFDwM). 
Respect to 454 platform, SOLiD system is more accurate and allows to analyzed a higher quantity of data 
[181, 185] (table 2).  
  
Finally, Illumina platform is based on sequencing by synthesis scheme (SBS, 
https://www.youtube.com/watch?v=womKfikWlxM).  
The solid substrate, on which amplification is performed, takes the name of "flow-cell" and it is constituted 
by eight lanes where two types of synthetic oligonucleotides, complementary to the specific adapters of 
DNA fragments, are attached. 
The sample DNA is fragmented and at each extremity a specific amplification primer and a adaptor 
sequence (complementary to the synthetic oligonucleotides of the flow cells) are added. 
DNA fragments bind with one extremity the flow cell, so that complementary strand is synthesized and 
denatured, and the remaining single strand binds the other synthetic oligonucleotide, forming a bridge (fig 
15). Amplification reaction synthesizes the complementary strand, leading to the formation of a double-
stranding bridge that is subsequently denatured, resulting in two complementary single strands. This 
process is repeated a number of times, resulting in millions of amplified product bound to the flow cells. 
In this phase, the reverse strands are washing up and the forward strands are used for sequencing; 
fluorescent nucleotides are added to form the complementary strand and signal emitted are read as 
fluorescence with a process called “synthesis by sequencing” (SBS). When sequencing of the forward strand 
ends, a new bridge is formed and amplification cycles are performed, at the end of which the sequencing of 
the reverse strand is carried out in the same way mentioned above (fig 15). 
For the analysis of fragments, forward and reverse sequences obtained are coupled and linked to similarity  
clusters, forming contigs which are aligned to reference genomes [186] or assembled together using 
advanced computational techniques if no reference genome is available (de novo sequencing). 
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 The reassembling phase requires a comparison with the genomes deposited on the database, as well as a 
high level of preparation especially to assemble properly similar fragment of genome and repetitive 
sequences [186, 187].  
The advantage of this platform is the innumerable amount of information obtained with a new sequencing 
chemistry, but presents the disadvantage to shows increased errors rate with the greater reads length. 
 
In the last years, platforms based on ion semiconductor sequencing are used, which have a sequencing 
chemistry similar to pyrosequencing, however with the detection of the release of ion (H+) instead of 
pyrophosphate. This new system seems to be more cost-effective and time-efficient [188].  
 
 
 
Figure 15. Schematic representation of amplification and sequencing reactions by “polymerase-based sequencing-
by-synthesis” performed by Illumina platform (MiSeq System) 
 52 
1.2 Shortcoming of the literature and aim of the study 
 
Following the global spread of Multi-Drug Resistant Carbapenemases-producing K. pneumoniae (KPC-Kp) it 
is essential that the sanitary structures may act on prevention and control of infections. 
Worldwide dissemination of K. pneumoniae carbapenemase-producing is due mainly to clonal group 258 
(CG258), which divided into four subclades [189]. Several studies focused on the characterization of this 
pathogen [190], but many points have been not totally clarified. In our study, we addressed some of them. 
 
a) In Italy, the dissemination of the GC258 and its transmission route has been elucidated only recently [99, 
191]. Because of the lack of literature, the description of genetic relatedness of these KPC-Kp lineages at 
the local/regional level is poor. 
 
b) During the last years, typing methods made possible the development of an integrated approach 
between phenotypical and molecular characterization [192, 193]. It is supposed that this progress is 
reflected in a more rapid and efficient identification of hospital infections. Different techniques are 
available but effectiveness in clinical practice must be depth and reinforced [194, 195]. 
c) K. pneumoniae may produce a number of pathogenicity features (virulence factors or genes implicated in 
antibiotic resistance) which are involved in the rapid dissemination and increased disease severity [196]. In 
the presence of epidemic events, these factors may promote the dissemination of more virulent variants. 
To date, only a few notions had been published evaluating the effect of convergence of virulence factors 
and resistance genes leading to the selection of epidemic isolates [196, 197]. 
 
The emergence of carbapenems- and colistin- resistant K. pneumoniae, for which there are even less 
treatment options, has been described recently. Following the increased incidence of this pathogen in our 
institution, the aim of the work was to assess a phylogenomic study of the collected clinical isolates to trace 
the origins and transmission routes of them.  
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Moreover, we aimed to compare genomes all of the strains collected with 319 publicly available genomes, 
representing the global diversity of K. pneumoniae to tracing phylogenic features of local isolates and to 
verify if increased rate of KPC K. pneumoniae in a single center was due to a single clone spread, 
characterizing the expression of high risks factor (virulence factors and genes of antimicrobial resistance). 
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1.3 Materials and methods 
 
 
1.3.1 Infections due to K. pneumoniae and bacterial isolates 
During a 27-months period (January 2011-March 2013), all the cases of infection due to carbapenem-
resistant K. pneumoniae identify at the Ospedale di Circolo and Fondazione Macchi (Varese, Italy) were 
subjected to the study. During this time, a total of 16 non-duplicated isolates of K. pneumoniae were 
investigated. Seven of the clinical cases occurred in the intensive care unit (ICU) and were suspected to be 
part of a single epidemic event started in February 2013.   
Specifically, the first isolate obtained from each patient was included in the study. Different K. pneumoniae 
isolates were obtained subsequently from each patient both for clinical reasons (e.g., spread of infection to 
other bodily sites), or in the course of surveillance studies.  
Anatomical sites, from which the samples were taken, were multiple, as indicated in table 3: urine, blood, 
bronchoalveolar lavage, sputum, tracheal aspirate, and wound specimens. During the outbreak period, ICU 
patients were screened every three days for surveillance using swabs (direct to nasal, inguinal, armpit, and 
rectal sites).  
Species identification and antibiotic susceptibility tests were performed with the FDA approved Phoenix® 
Automated Microbiology System (Becton Dickinson, Sparks, MD). Additional phenotypic assays were 
performed using the Etest (BioMerieux, Marcy l’Etoile, France) on Mueller Hinton Agar II (BD) plates 
according to clinical breakpoints from the European Committee for Antimicrobial Susceptibility Testing 
(EUCAST).  
 
1.3.2 Molecular assays for drug resistance genes and virulence factors 
Pure cultures of K. pneumoniae were isolated on MacConkey agar and subsequently bacterial DNA was 
extracted following a lysozyme pretreatment (Sigma-Aldrich, Milan, Italy) by extraction with the QiAmp 
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DNA Blood Mini Kit (Qiagen, Milan, Italy). Confirmatory species identification was performed via 
amplification by PCR and direct sequencing of the 16s rRNA gene. PCR was performed using AmpliTaq 
Gold® with Buffer I (Applied Biosystems, Life Technologies, Monza, Italy) using master mixes with a final 
volume of 50µL, prepared according to manufacturer’s directions. PCR primers were synthesized by Sigma-
Genosys (Haverhill, UK). Published primers and thermal protocols were used as previously described [198].  
Analysis of DNA fragments was performed by electrophoresis in 1.5% gel made of standard agarose 
(Standard Low-mr Agarose, Bio-Rad Laboratories, USA) in TBE buffer (89 mM Tris-borate and 2 mM EDTA, 
pH 8.3) containing GelRed™ (10,000x in water; Biotium, DBA Italy, Segrate, Italy). Subsequently, PCR 
products were purified and sequenced on an ABI Prism 310 genetic analyzer (Life Technologies). 
Comparison of sequences was made with those of reference in GenBank (www.ncbi.nlm.nih.gov/blast/). 
PCR assays for detecting antimicrobial resistance genes [199] and virulence factors were performed 
according to published protocols. Genes coding for adhesion fimbriae, enterobactin and yersiniabactin 
siderophores were searched for; in detail: fimH gene coding for type-1 fimbriae [118]; mrkA gene coding for 
the major subunit protein and mrkD gene coding for the adhesin of type-3 fimbriae [122, 200]; entE gene 
coding for synthase subunit E and entB gene coding for isochorismatase of enterobactin siderophore 
synthesis [201, 202]; ybtS gene coding for salicylate synthase of yersiniabactin siderophore synthesis; genes 
related to siderophore yersiniabactin, irp-1 and irp-2 [134]. Direct sequencing was performed as reported 
above.  
 
1.3.3 Whole genome sequencing analysis 
Whole genome DNA was sequenced using an Illumina MiSeq platform (Illumina Inc., San Diego, CA), with a 
2x250 paired end run, after Nextera XT paired-end library preparation. Sequencing reads were assembled 
using the MIRA 4.0 (Mimicking Intelligent Read Assembly) software [203] with accurate de novo settings. 
MIRA is a multi-pass DNA sequence data assembler for whole genomes and allow manipulating contigs 
obtained from the different next generalization sequencing platforms. Genome assemblies were deposited 
to the EMBL database under accession number PRJEB7661. 
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1.3.4 Core SNP detection and phylogeny 
Whole genome sequences of the 16 isolates were added to a previously characterized database of 319 
genomes of K. pneumoniae isolated worldwide [204]. Single nucleotide polymorphisms (SNPs) were 
detected using an in-house pipeline based on the Mauve software [205], using the genomic sequence of 
the published NJST258_1 as reference [204]. Mauve software allows performing genome-wide 
phylogenetic analysis, constructing multiple genomes alignment in the occurrence of large-scale 
evolutionary events, recognizing recombination events and genomic rearrangements. Each genome was 
individually aligned to the reference one and alignments were merged with Perl scripts (Practical Extraction 
and Reporting Language) to obtain a global alignment. Core SNPs are variations in the single nucleotide 
flanked by at least one identical nucleotide on both sides present in all analyzed genomes [206], were 
detected. To obtain a  Maximum likelihood phylogeny, all core SNPs were merged in a multialignment file 
using the RAxML software [207] with specific parameters, i.e. generalized time reversible (GTR) model and 
100 bootstraps (computer-based method for assessing the precision of almost any statistical estimate). 
Besides, mining of the genes, coding for antibiotic resistance and virulence factors, of which the preliminary 
screening was previously performed using classical PCR assays, was determined using BLAST-based 
alignment on a specifically designed database, i.e. BIGSdb-Kp [208]. 
All hits were manually checked and genes requiring specificity for a particular variant (e.g., blaKPC vs. 
blaOXA-48) were required to present 100% identity with the database sequences. BLAST searches and 
filters were also used to test the presence of yersiniabactin genes (ybtS, ybtA, irp1, and irp2) in all genomes 
used for the global phylogeny analysis. Analysis of the presence of deletions within the mgrB gene (a 
supposed determinant of colistin resistance) was performed by manually corrected BLAST search [108]. 
 
1.3.5 Core genome and in silico MLST 
MLST profile was obtained in-silico by analyzing appropriate gene variants on each genome using an in-
house Python script (another specific programming language used to analyze data on genomic sequences).  
MLST profiles of analyzed samples are compared with those of reference deposited in a specific database: 
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(http://bigsdb.web.pasteur.fr/perl/bigsdb/bigsdb.pl?db_pubmlst_klebsiella_seqdef_public&page_downloa
dAlleles). 
Core genome MLST (cgMLST) analysis was performed using the BIGSdb software and database [209], which 
allow to compare genomic sequences of the 16 strains analyzed with those of other deposited strains. 
In this work, cgMLST profiles made of allelic variants at 694 loci were obtained for 219 genomic sequences 
of the clonal group 258 (CG258), comprising the 16 investigated genomes. Core genome MLST profiles were 
used to produce a similarity tree of all 219 genomes using the Unweighted Pair Group Method with 
Arithmetic Mean (UPGMA) method. 
 
1.3.6 Outbreak reconstruction 
The transmission route of the clinical isolates involved in the ICU outbreak was reconstructed by combining 
core SNPs and the dates of samples collection, applying the SeqTrack implemented in the Adegenet R 
library [210]. Unlike the software used in phylogenetic analysis where the relatedness among samples is 
obtained reconstructing hypothetical ancestors, the SeqTrack system considers sampled in the same group 
ancestor and descendants strains, analyzing the relationships between all the existing samples. SeqTrack 
reveals as a more efficient algorithm respect the phylogenetic approaches, especially for the reconstruction 
of transmission routes of outbreaks. 
The chain of transmission of the epidemic strain was then obtained using the R library Outbreaker [211]. 
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1.4 Results 
 
 
1.4.1 Species identification and antimicrobial susceptibility 
In this work, the first isolate obtained from each single patient has been investigated. Biochemical 
approach and molecular assays allow identifying the species. The seven cases recognized in February 2013 
were suspected to belong to a single outbreak, started when a 69 years old man recognized as the  patient 
zero (indicated as KpVA-8 in figure 16) has been transferred to the ICU from a nearby hospital with an 
already diagnosis of infection due to KPC-producing K. pneumoniae. During his stay in the ICU, infection 
extends to other six patients, with a total of seven clinical isolates collected and defined as epidemic. In the 
figure 16, it is possible to observe the time-frame of ICU permanence of each patient involved in the 
outbreak and the date of first isolation of K. pneumoniae strains. 
 
 
Figure 16. Time-frames of ICU permanence of the seven patients involved in the outbreak. Horizontal bars 
represent the length of stay of each patient; black squares indicate date of first isolation of K. pneumoniae for each 
patient 
 
The other isolates are defined as sporadic, being identified as punctual and unrelated infections. Five out of 
the 16 isolates were obtained from blood cultures (3 of 7 among patients involved in the ICU outbreak) 
(table 3) while the others from different bodily sites.  
Phenotypic assays detected resistance to imipenem, meropenem and ertapenem in all 16 clinical isolates, 
so that were thus classified as carbapenem-resistant. The seven epidemic isolates were also resistant to 
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colistin, but susceptible to aminoglycosides (gentamicin, amikacin, tobramicin). Only three out of 9 sporadic 
isolates presented resistant to colistin (table 4). A short description of the investigated isolates is reported 
in table 3 while results of minimal inhibitory concentration (MIC) values related to E-test assays for each 
isolate are reported in table 4. 
 
Patient Clinical status Date of isolation Source Sequence Type 
KpVA-4 Sporadic 01/11/11 B ST-258 
KpVA-5 Sporadic 01/28/11 B ST-258 
KpVA-6 Sporadic 03/14/11 B ST-258 
KpVA-7 Sporadic 05/03/11 B ST-258 
KpVA-1 Sporadic 10/31/12 SP ST-512 
KpVA-2 Sporadic 01/30/13 BAL ST-258 
KpVA-8 Epidemic 02/01/13 BAL ST-512 
KpVA-10 Epidemic 02/08/13 BAL ST-512 
KpVA-9 Epidemic 02/12/13 BAL ST-512 
KpVA-11 Epidemic 02/13/13 B ST-512 
KpVA-12 Epidemic 02/15/13 TA ST-512 
KpVA-13 Epidemic 02/16/13 WS ST-512 
KpVA-14 Epidemic 02/19/13 BAL ST-512 
KpVA-3 Sporadic 03/14/13 B ST-258 
KpVA-15 Sporadic 03/24/13 U ST-512 
KpVA-16 Sporadic 03/24/13 U ST-512 
  
Table 3.Clinical isolates involved in the outbreak. Description of clinical status, date of isolation of the sample 
analyzed, sequence type (ST), and source. B, blood; SP, sputum; BAL, bronchoalveolar lavage; TA, tracheal aspirate; 
WS, wound swab; U, urine 
  
 
KpVA
-1 
KpVA
-2 
KpVA-
3 
KpVA-4 KpVA-5 KpVA-6 KpVA-7 KpVA-
8 
KpVA-
9 
KpVA-10 KpVA-
11 
KpVA-
12 
KpVA-
13 
KpVA-
14 
KpVA-
15 
KpVA-
16 
Antimicrobial 
agents  MIC (mg/L) 
Ampicillin R>8 R>8 R>8 R>16 R>16 R>16 R>16 R>8 R>8 R>8 R>8 R>8 R>8 R>8 R>8 R>8 
                 
Amoxicillin-
clavulanate R>8/2 R>8/2  R>8/2 R>16/8 R>16/8 R>16/8 R>16/8 R>8/2 R>8/2 R>8/2 R>8/2 R>8/2 R>8/2 R>8/2 R>8/2 R>8/2 
Ceftazidime R>8 R>8 R>8 R>16 R>16 R>16 R>16 R>8 R>8 R>8 R>8 R>8 R>8 R>8 R>8 R>8 
Cefotaxime R>4 R>4 R>4 R>32 R>32 R>32 R>32 R>4 R>4 R>4 R>4 R>4 R>4 R>4 R>4 R>4 
Aztreonam R>16 R>16 R>16 R>16 R>16 R>16 R>16 R>16 R>16 R>16 R>16 R>16 R>16 R>16 R>16 R>16 
Ertapenem R>1 R>1 R>1 R>1 R>32 R>1 R>1 R>32 R>32 R>32 R>32 R>32 R>32 R>32 R>1 R>1 
Imipenem R>8 R>8 R=8 R>32 R=8 R=32 R=8 R>32 R>32 R>32 R>32 R>32 R>32 R>32 R>8 R>8 
Meropenem R>8 R>8 R=12 R>32 R=32 R>32 I=6 R>32 R>32 R>32 R>32 R>32 R>32 R>32 R>8 R>8 
Ciprofloxacin R>1 R>1 R>1 R>2 R>2 R>2 R>2 R>1 R>1 R>1 R>1 R>1 R>1 R>1 R>1 R>1 
Levofloxacin R>2 R>2 R>2 R>4 R>4 R>4 R>4 R>2 R>2 R>2 R>2 R>2 R>2 R>2 R>2 R>2 
Amikacin R>16 R>16 R=48 R=48 R=64 R=48 R=64 S=1 S=1 S=1 S=1 S=1 S=1 S=1 R>16 R>16 
Gentamicin S=2 S=2 S=1.5 S=0.5 S=1.5 S=1 S=2 S=0.25 S=0.25 S=0.25 S=0.25 S=0.25 S=0.25 S=0.25 S=4 S=2 
Tobramicin R>4 R>4 R=12 S=0.5 R=16 R=16 R=24 S=0.38 S=0.38 S=0.38 S=0.38 S=0.38 S=0.38 S=0.38 R>4 R>4 
Colistin R>4 S≤1 S=0.19 S=0.125 S=0.19 S=0.38 S=0.19 R=8 R=8 R=8 R=8 R=8 R=8 R=8 R>4 R>4 
 
Table 4. Antimicrobial susceptibility values (MIC) profiles of the 16 investigated clinical isolates. S, susceptible; I, intermediate; R, resistant
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1.4.2 Drug resistance determinants and virulence factors 
Isolates were subjected to PCR assays to detect drug-resistance and virulence factors genes. The blaKPC 
gene was detected in all isolates (fig 17), while other carbapenem resistance genes (blaNDM, blaIMP-1, blaOXA-
48, blaVIM) were not detected.  
 
Figure 17. PCR assay for detection of blaKPC gene (798 bp). Sample 1-7, ICU epidemic KPC-Kp isolates. Samples 8-
10, sporadic KPC-Kp isolates; +, positive control K.pneumoniae ATCC®BAA-1705; -, negative control “reference 
strain” K.pneumoniae ATCC®-700603 
 
All isolates were positive for the presence of genes coding for type-1 and type-3 fimbriae (fim and mrk 
operons, respectively) as well as for the enterobactin siderophore that is harbored in the ent operon 
(table 5). Three of the nine sporadic isolates carried ybtS and the iron-repressible irp1 and irp2 genes for 
yersiniabactin [130, 201, 212].  
 
 
1.4.3 Whole genome sequencing and characterization 
Whole genome sequences were obtained for all 16 K. pneumoniae isolates and genes coding for drug 
resistance determinants and virulence factors were investigated on assembled genomes; moreover 
strains were characterized by in silico for MLST (table 3). MLST analysis enabled to identify two groups of 
isolate: six isolates, in particular, KpVA-2, KpVA-3, KpVA-4, KpVA-5, KpVA-6, and KpVA-7, were of ST258 
and 10 isolates, together with the epidemic ones, belonged to ST512. The two Sequence Types differ for a 
single nucleotide, thus are considered belonging to the same clonal group, the CG258 [190, 191].  
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cgMLST analysis was performed on the same genomic dataset used for SNPs phylogeny (219 genomes of 
K. pneumoniae belonging to CG258) (fig 19). The resulting UPGMA tree is largely coherent with that 
resulting from the SNP-based phylogenomic analysis. Specifically, in both analyses, the main subdivisions 
of CG258 [213] are clearly detectable, while the 16 genomes presented in this work are clustered in four 
monophyletic groups, one of which corresponding to the seven strains involved in the epidemic. 
Confirming the results obtained by molecular analysis, all strains encoded the blaKPC gene. In three of six 
isolates belonging to ST258 the blaKPC variant 2 (KPC2) was found, while the remaining 13 isolates coded 
for the blaKPC variant 3 (KPC3). Samples were also investigated for the presence of any beta-lactamase 
gene  and it was found that all 16 isolates presented blaSHV genes,  while blaTEM genes were detected in 13 
of the 16 genomes, being absent only in KpVa-2, KpVA-3 and KpVA-4 (table 5) [190]. 
The three sporadic isolates belonging to ST258 and possessing the blaKPC2 variant also presented unique 
virulence profile. In fact, these strains, the so called KpVA-2, KpVA-3 and KpVA-4, harbored the irp1, irp2, 
ybtA and ybtS genes, that were not detected in the other strains. These four genes encode yersiniabactin, 
a virulence factor expressed by Yersinia and other Enterobacteria, including K. pneumoniae [133, 190]. All 
16 strains analyzed were positive for the presence of the mrk and fim operons, coding for fimbrial genes 
[117, 214], and the Ent operon coding for enterobactin [201], consistent with previous results showing 
that these genes are highly conserved in K. pneumoniae [122, 190]. None of the isolates coded for rmpA 
and wzy-K1 (magA) genes, which are hypermucoviscosity associated genes [190, 215, 216]. 
Genes related with colistin resistance were also investigated. The entire operon of pmr genes was highly 
conserved among the 16 strains, including locus pmrB, which has been indicated as a colistin resistance 
determinant [217]. All colistin-resistant strains presented a deleted variant of the mgrB gene interrupted 
by IS5-like transposons, as indicated in figure 18 and table 5.  
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Sample ID Type mgrB Colistin susceptibility
KPCVA1 Sporadic Del R
KPCVA2 Sporadic Wt S
KPCVA3 Sporadic Wt S
KPCVA4 Sporadic Wt S
KPCVA5 Sporadic Wt S
KPCVA6 Sporadic Wt S
KPCVA7 Sporadic Wt S
KPCVA8 Epidemic Del R
KPCVA9 Epidemic Del R
KPCVA10 Epidemic Del R
KPCVA11 Epidemic Del R
KPCVA12 Epidemic Del R
KPCVA13 Epidemic Del R
KPCVA14 Epidemic Del R
KPCVA15 Sporadic Del R
KPCVA16 Sporadic Del R
a
b
 
Figure 18.  a)  colistin-resistant strains carried the deletion in the mgrB gene via insertion of a IS5-like element;  b) 
graphic representation of the genetic interruption of mgrB gene by IS5-like element 
  KpVA-1 KpVA-2 KpVA-3 KpVA-4 KpVA-5 KpVA-6 KpVA-7 KpVA-8 KpVA-9 KpVA-
10 
KpVA-
11 
KpVA-
12 
KpVA-
13 
KpVA-
14 
KpVA-
15 
KpVA-16   
 Antibiotic Resistance Determinants 
blaKPC allele 2 3 3 3 3 3 2 3 3 3 3 3 3 2 3 3 
blaVIM No No No No No No No No No No No No No No No No 
blaNDM1 No No No No No No No No No No No No No No No No 
blaIMP No No No No No No No No No No No No No No No No 
blaOXA48 No No No No No No No No No No No No No No No No 
blaSHV 12 11 11 11 11 11 12 11 11 11 11 11 11 11 11 11 
blaTEM No 1 1 1 1 1 No 1 1 1 1 1 1 No 1 1 
mgrB insertion No No No No Yes No Yes Yes Yes Yes Yes Yes Yes No Yes Yes 
 Virulence determinants 
fimACDEFH 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
mrkABCDF 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
rpmA 
No No No No No No No No No No No No No No No No 
magA 
No No No No No No No No No No No No No No No No 
EntABCDEF 
Yes No No No No Yes No No No No No No No Yes No No 
ybtA/S Yes No No No No Yes No No No No No No No Yes No No 
Irp1/2 Yes No No No No Yes No No No No No No No Yes No No 
Table 5. Table indicating the virulence factors and resistance determinants detected in the 16 clinical isolates of Klebsiella pneumoniae analyzed in this study
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 1.4.4 Global core SNP phylogeny 
A global genome phylogeny of K. pneumoniae, including the 16 isolates investigated in this study, was 
obtained by adding the de novo assembled genomes to a previously constructed database of 319 isolates 
[204]. Phylogeny was obtained in order to contextualize these strains within the previously sequenced K. 
pneumoniae isolates. The 16 novel genomes clustered in 5 monophyletic groups on the global tree (fig 19) 
and were fitting within CG258. 
Interestingly, these 16 isolates belong to three of the four previously identified groups of Italian isolates of 
CG258 [204]. The relatedness among the investigated clinical strains was evaluated through the inclusion of 
them in the global phylogeny.  
KpVA-2, KpVA-3, and KpVA-4, the three yersiniabactin-positive sporadic isolates, clustered together in a 
clade comprising 9 additional Italian strains and two American strains, all presenting the yersiniabactin 
genes [211]. Thirty-nine additional isolates, belonging to different sequence types and scattered on the 
global K. pneumoniae phylogeny, were also coding for yersiniabactin. 
The genomes of the seven isolates collected in the ICU and hypothesized to belong to a single epidemic 
event, clustered together in a single, well supported, phylogenetic clade (fig 19). This result confirmed the 
starting hypothesis of a single clone being responsible for the seven infections that occurred in the ICU. 
When analyzing the number of SNPs differentiating the isolates, the seven strains belonging to the 
investigated outbreak presented an average of 20 SNPs per genome, if compared among them. 
Interestingly, a similar average number (27 SNPs per genome) differentiates strains KpVA-1, KpVA-15 and 
KpVA-16 that are also grouped in a single clade, but have been sampled over a longer time span (about five 
months). This could indicate a difference in the measured pace of the molecular clock between the two 
clusters. Multiple hypotheses could explain the observed situation, such as the presence of different 
environmental conditions, or a conservative pressure by purifying selection. 
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Figure 19. Schematic representation of phylogenetic relationships between isolates of Klebsiella pneumoniae. The 
16 novel isolates investigated in this study are highlighted in bold. In the blue boxes, the four clades encompassing 
Italian isolates are evidenced. Triangles represent coherent monophyletic clades of isolates from other countries. 
Orange dots indicate the presence of yersiniabactin (ybtA-S) genes 
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1.4.5 Outbreak reconstruction 
Core genome SNPs and isolation date of the epidemic strains were used to build a genomic network aimed 
to define genomic relatedness among them in the epidemic context. 
The analysis showed a star-like topology centered on the isolate obtained from patient zero (KpVA-8), 
suggesting that infection do not spread linearly but multiple events of contagion probably took place, all 
starting from patient zero and infecting six ICU patients (fig 20).  
This fits with the fact that the patient zero (KpVA-8) was hospitalized for over two months in the ICU and 
that the stay of the remaining infected patients was concomitant with his presence (fig 16). 
Besides, the position of the beds in the ward is not related to transmission route (i.e., patients in beds 
closer to the bed of patient zero where not infected prior to patients in beds that were more distant from 
patient zero’s bed). Anyway, the result thus confirms that isolate KpVA-8 was at the origin of the outbreak. 
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Figure 20. Representation of star-like diffusion pattern of the KPC-Kp outbreak. A) isolates belonging to a single 
outbreak event that occurred in February 2013. The star-like topology was obtained using the software Outbreaker. 
Numbers in bold indicate the temporal order of contagion. B) Graphic representation of the bed-to-bed spread of 
infection on ICU ward 
 
69 
1.5 Discussion 
This work aimed to characterizing, with the use of molecular techniques, the genomic characteristics of 16 
multidrug resistant K. pneumoniae clinical isolates, collected in the Ospedale di Circolo e Fondazione 
Macchi (Varese) during a period of 27-months. 
 The objective was to identify the possible presence of an outbreak; to elucidate the epidemiological 
relationships among the clinical isolates, and to place them in the context of the global phylogeny of K. 
pneumoniae.  
Whole genome analysis allow defining that all 16 isolates belong to clonal complex CG258, the most 
prevalent KPC-producing K. pneumoniae lineage.  About presence of resistance genes, all 16 genomes 
express blaKPC genes and none of them had other known carbapenem resistance genes.  
Prevalent presence of clonal complex 258 is not surprising, considering that previous studies showed the 
worldwide diffusion and high prevalence of KPC isolates of this clonal group among the carbapenem-
resistant K. pneumoniae strains [189, 204, 218]. 
Sensitivity assays against different classes of antibiotics have been performed on all the samples, which 
unsurprisingly result being carbapenem resistant, but the most significant difference observed was 
presence of resistance to colistin in some of these. In fact, 10 of the analyzed samples showed MIC of 4 
mg/L or higher, thus above the EUCAST MIC breakpoint. Molecular analysis showed the presence of the 
IS5-like transposons in the mgrB gene. Deletion of this gene leads to alteration in the lipopolysaccharide 
biosynthesis and subsequently to resistance to colistin, which target it [107, 108]. 
The obtained results appear to support this causative link, considering that none of the six colistin-sensitive 
strains presented the aforementioned insertion. 
The global phylogeny of K. pneumoniae reveals that all the 16 isolates belong to three of the four previously 
characterized Italian clades of the CG258, which are probably representative of four different events of KPC 
dissemination in Italy, between 2008 and 2010 [204]. 
It is suggested that currently three of this four clades are circulating in Italy, because we were able to 
detect them in a single center hospital during a period of 27-months. 
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About virulence genes, all analyzed isolates possessed fim, ent, and mrk operons but lacked of genes coding 
for hypermucousviscosity proteins (rpmA and magA genes). 
The only virulence factor that seems to be otherwise present in the samples is the yersiniabactin. In fact, in 
only three sporadic strains, the four genes responsible for yersiniabactin synthesis (ybtA, ybtS, irp1, and 
irp2) were present. Yersiniabactin has been known to provide advantages in bacterial metabolism and 
multiplication, particularly in mixed infections and under iron-deprived conditions and especially in 
pulmonary infections, according to recent studies [130, 201, 212]. Interestingly, through the global analysis 
of the CG258, it appeared that, apart from these three novel strains, other Italian isolates of the same 
subclade and two Americans strains constituted a monophyletic group and were positive for the presence 
of yersiniabactin genes. Moreover, the results suggest that these genes, once acquired before 
diversification in specific subclades, have been maintained since. 
Moreover, we aimed to identify the presence of a nosocomial outbreak, occurred in the ICU in February 
2013. According to the whole genomes analysis, seven of the total analyzed strains appeared to be 
genetically related in a monophyletic cluster and were confirmed to belong to a single outbreak. When 
analyzing the number of SNPs differentiating the isolates, the seven strains belonging to the investigated 
outbreak presented an average of 20 SNPs per genome, if compared among them. 
We were also able to obtain the transmission route of the epidemic event, which was represented by a 
star-like diagram, originating from patient zero.  
The seven epidemic isolates could not be discriminated from sporadic strains based on a specific pattern of 
the presence/absence of specific virulence factors and also the drug resistance profiles were highly similar. 
This shows that the dissemination of the outbreak was not related to genes conferring a specific advantage 
to the epidemic clone. 
In conclusion, the availability of classical molecular methods and whole-genome sequencing analysis allow 
to easily and accurately characterizing multiresistant pathogens circulating in the hospital, which represent 
the major cause of outbreaks spread. The prosperity of data from genome sequencing allows 
reconstruction of the relatedness among clinical isolates collected in a single hospital and allows identifying 
the presence of an outbreak; moreover analyzed isolates were placed in overall global phylogenies, 
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highlighting, through comparison with deposited genomes, the presence of common characteristics that 
might give specific selective advantages. The possibility to introduce the bacterial genomics into clinical 
settings will allow the reconstruction of the routes of transmission and of the causes of nosocomial 
infections, with estimation of the relative roles of human- and microbe-related factors. 
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CHAPTER TWO 
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2.1 Introduction 
 
2.1.1 General features of C. difficile 
Clostridium difficile is the leading cause of nosocomial diarrhea, mainly associated with the use of 
antibiotic, and increasing cause of community-acquired diarrhea.  
C. difficile owes its name to the Greek "kloster" (κλωστήρ, spindle) and to the Latin "difficile" and belongs to 
the phylum Firmicutes comprising the Bacillus and Clostridia classes. Clostridiaceae family belongs to the 
latter class, and contains the Clostridium genus (sensu strictu) and others (for example, Anaerobacter, 
Oxobaxter etc). 
Clostridium genus includes gram-positive and anaerobic bacteria, many of which are capable of producing 
endospores, (dormant cell forms able to survive in extreme environmental conditions) [219] (fig 21). 
Clostridium spp are ubiquitous microorganisms, which can be isolated from the soil, water, sewage system, 
and made part of the normal flora of the gastrointestinal tract of animals and humans. 
 
 
 
Figure 21. A differential stain of C. difficile spores. Malachite green staining methods allows identifying endospores 
(spherical shaped, in green) and vegetative cells (elongated cells, in red).  
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C. difficile was first reported in 1935, when the species was isolated from fecal samples of asymptomatic  
infants and, due to the difficulty of growing in conventional media, was named Bacillus difficilis [220]. 
Subsequently, studies demonstrated the ability of this microorganism to produce toxins, which caused 
respiratory arrest and occasionally death in the animal models used [221] while other studies were showing 
evidences of a correlation between antibiotic-associated diarrhea [222].  
In the same years, Bacillus subtilis were renamed Clostridium difficile and the cytopathic effect of the toxins 
produced was increasingly associated with the onset of colitis, of which one of the most severe 
manifestations was the formation of pseudomembranes, leading to pseudomembranous colitis (PMC). 
Interestingly, the first cases of this disease were erroneously attributed to Staphylococcus aureus and 
Candida albicans [223] and only in 1978 PMC was definitively related to toxigenic C. difficile infections 
[222]. 
 
 
2.1.2 Clostridium difficile clinical disease 
CDI is frequently associated with long hospital stay and antibiotic treatment; even if cases of community-
acquired or community-associated diarrhea are increasingly reported (25%), and in these cases the patients 
do not normally show “traditional” risk factors for the CDI onset. For this reason, to distinguish between 
different types of CDI onset, a health-care onset case is associated with the health institution when 
symptoms start at least 48 hours after the admission in the healthcare setting, while it is considered as 
community-onset even the symptoms occurs within 4 weeks after discharge. If patient presents symptoms 
within 48 hours of admission and without previous hospitalization in the last 12 weeks, CDI is considered 
community-acquired (figure 22). 
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Figure 22. Graphical representation of the classification of community-onset, healthcare-onset and community-
acquired C. difficile infection, source [224] 
 
A patient is to be considered symptomatic when presenting ≥3 depositions of diarrhea during the 24 hours, 
with the presence of unformed stools appearing liquid (value 5 and 7 of Bristol scale), greenish and smelly. 
The severity of the CDI episode can be classified according to the clinical manifestations into mild, severe 
and severe-complicated CDI and may range from uncomplicated colitis to toxic megacolon, sepsis and 
death [225]. 
 
In the case of mild to moderate CDI, diarrhea is the principal feature and normally it is not accompanied by 
systemic manifestations, whereas severity is defined as a CDI episode with severe systemic symptoms as   
fever, abdominal pain, leukocytosis ≥15.000 cells/uL and other symptoms. In cases in which the patient 
shows symptoms not directly deducible as vomiting without diarrhea, fever of unknown origin, 
accompanied by diagnostic tests proving alterations of the intestinal wall (i.e. colon distension) and 
antibiotic treatment, it is any way possible to suspect Clostridium difficile infection. 
One severe but infrequent (about 3% of all cases) clinical manifestation of CDI is toxic megacolon, which 
has a mortality of 50% and in which common symptoms are absence of diarrhea, leukocytosis (in severe 
cases, may arrive to >50000cells/uL), abdominal pain, fever, severe inflammatory response with nausea, 
dehydration, tachycardia, lethargy, and shock [226]. 
 Doubtless, PMC is one infrequent but well known clinical manifestation of CDI: it was described for the first 
time in 1893 [223] and was commonly associated to the excessive use of antibiotic [227], while, although 
rare, cases of extra-intestinal CDI are described which are due in particular to surgical procedures, 
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manipulation of the intestinal tract or combination of other states of illness, which can lead to leakage or 
intestinal perforation [228]. 
One of the distinguishing characteristics of CDI is the frequency of relapses, which is around 15-30%, 
especially in patients with severe disease, subjected or less to antibiotic treatment. 
The recurrences may be due to relapse or reinfection, distinguished by molecular typing of the causative 
strain: relapses usually occur in the first 10-14 days from the term of treatment and are due to the activity 
of the strain causing the first episode, while reinfection are caused by another strain and may occur in 
larger time periods as it depends on the time of exposure and on the contact between contaminated 
environment and patient [229] (table 6).  
 
 
CDI disease category 
 
Laboratory and clinical signs 
 
Risk factors 
Mild to moderate 
Diarrhea; no systemic signs; 
leukocyte count <15.000cell/µL; 
serum creatinine <1.5 times 
baseline 
Antimicrobial treatment; proton pumps 
inhibitors; long stay in hospital; 
chemotherapy; chronic kidney disease 
Severe 
Systemic symptoms and/or 
leukocyte count ≥15.000 cells/ µL 
and/or serum creatinine ≥1.5 
times baseline 
Infection due to more virulent strain (i.e. 
C. difficile ribotype 027); advanced age 
Severe-complicated Systemic symptoms and hypotension, paralytic ileum or 
toxic megacolon 
Recent surgery; inflammatory bowel 
diseases (IBD); intravenous treatment 
with immunoglobulin; and all the above 
Recurrence New episode in <8 weeks from successful completing CDI 
treatment 
Patients ≥65 years; underlying diseases; 
comorbidity; increased initial severe 
disease; concomitant use of proton 
pumps inhibitors and/or antibiotic 
treatment 
 
Table 6. CDI classification based on disease severity, adapted by [226]. For each degree of disease severity, the main 
clinical manifestation and risk factors are described 
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Infection due to Clostridium difficile has, therefore, great clinical importance in several respects: it is the 
most known leading cause of nosocomial diarrhea, its incidence and relapses rates are increasing with the 
dissemination of epidemic strains (i.e. CD027); patients are forced to prolonged hospital stays. This may be 
translated in a high sanitary cost apart from a decline in the quality of life of the patient [230], for this 
reason a rapid, sensitive and efficient diagnosis is imperative with the main objective to identify presence 
of outbreaks and/or polyclonal spread of higher transmitted pathogen, aiming to limit their transmission 
between patients. 
 
 
2.1.3 Risk factors for CDI acquisition  
The main risk factors associated to the development of C. difficile infection are the antibiotic treatment, the 
use of proton pumps inhibitors because they lead to dysbiosis and weakened of the microbiota of the gut, 
favoring colonization and proliferation of C. difficile cells. Also other factor, as well as the underlying 
diseases and long stay in hospital, may affect immune response and so favoring the disease progression. 
 
Probably, the principal risk factor for CDI progression is the large use of broad- spectrum antibiotics 
prescribed to the patient, leading to debilitation of the normal intestinal flora with the subsequent 
proliferation of opportunistic bacteria such as C. difficile. This bacterium presents resistance against a large 
number of drugs and so may survive and generate the production of toxins responsible for the onset of the 
disease. 
 Third generation cephalosporins, fluoroquinolones and clindamycin, used to treat a large number of 
diseases, had been ever considered the antibiotic giving the greatest risk factors for the onset of CDI [231] 
for their broad activity against many commensal bacteria. 
The use of proton pumps inhibitors, which reduce gastric acid secretion and are prescribed for a wide range 
of diseases including acid reflux and peptic ulcers, probably it related to the higher ability of the C. difficile 
spores to cross the stomach, once ingested, despite the gastric acids produced here. The hypothesis is that, 
 
78 
because of the increased gastric pH, the spores pass more easily from the stomach into the gut, when they 
can germinate and lead to inflammation and disease [232].  
Other risk factor related to the patient are the older age, the long stay in hospital, the hospitalization in the 
intensive care unit or in contact with symptomatic patients, and the underlying diseases which make the 
immune system weaker against possible infections. In particular, several studies show an increase of CDI 
rate in patients >65 years, although incidences are also increasing in youngest population. The combination 
of the old age with other factors, such as antibiotic treatment and hospital admission, is crucial to confer 
high risk to the patient in developing CDI [233]. 
For these reasons, it proves crucial the introduction of control measures as environmental hygiene 
(decrease transmission) as patients care (a greater awareness in the use of antibiotics). 
Prevention starts with the introduction of good hygiene habits that the medical stuff must follow such as 
hand washing with soap and water when going to visit another patient and the other and the use of gloves 
to prevent the spread of spores. Furthermore, it would be appropriate to reduce the use of broad spectrum 
antibiotics, as far as possible, to avoid making sensitive the patient. 
In the case of symptomatic patients, it is necessary to proceed to the isolation of this or, in case of low 
availability of rooms and/or in case of outbreak, it is appropriate to create specific cohorts. 
The rooms of symptomatic patients must undergo further cleaning with sodium hypochlorite or sporicidal 
products, knowing that the common detergents do not eliminate the spores of C. difficile. Medical staff 
(and family members of patients if allowed entry) should use gloves and disposable gowns to enter in the 
rooms in isolation in order to avoid the greater spread of spores in the environment. 
Finally, each new case should be promptly notified to the group for hospital infection control to ensure 
rapid infection survey and management [234]. 
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2.1.4 Treatment of CDI 
First line antimicrobials used in CDI treatment are metronidazole and oral vancomycin, although nowadays 
a good range of treatment is available for the patient, as biotherapy (fecal microbiota transplantation or 
probiotics) or new treatment options, such as monoclonal antibodies or vaccines (several awaiting approval 
by the FDA) (table 7).  
 
Metronidazol is the drug most widely used for the treatment of mild episodes of infection due to C. difficile. 
It is a nitroimidazole that displays bactericidal activity towards both protozoa and many anaerobic bacteria 
with a unique metabolic pathway. When administered orally, metronidazole is absorbed rapidly and almost 
completely, with only 6%–15% of the drug excreted in stool [235].  
On the other hand, its disadvantages are the higher failure and recurrences rates compared to vancomycin 
in severe cases, so that therapy must be targeted towards eligible patient with a good probability to be 
cured.  
 
FDA-approved Off-Label Options New Drugs in development Biotherapeutics 
Metronidazole Rifaximin (Xifaxan, 
Salix) 
LFF571 (Novartis) 
Fecal microbiota 
transplantation 
Vancomycin Nitazoxanide Surotomycin (CB-183, 315, Cubist) VP20621 (ViroPharma) 
Fidaxomicin (Dificid, 
Cubist) 
Tigecycline (Tygacil, 
Pfizer) 
SMT 19969 (Summit) Probiotics 
  Cadazolid (ACT-179811, Actelion)  
  
Oritavancin (LY333328, The 
Medicines Company) 
 
  Cholate meta-benzene sulfonic 
derivative 
 
Table 7. Treatment options for C. difficile infections; adapted by[236] 
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Vancomycin, unlike the metronidazole, appears to be more effective in the treatment of the first episode of 
moderate to severe CDI or in cases of metronidazole therapy failure. It is a drug of choice for the treatment 
of CDI cases in pregnant women because lack of systemic absorption. Given to its hydrophilic nature, 
vancomycin it is not able to cross the intestinal wall, so that it is necessary to administer it orally [235].  
Both vancomycin that the metronidazole are believed highly effective drugs in the treatment of mild CDI, 
also if studies demonstrate that the rate of failures associated to metronidazole in treatment of severe CDI 
is significantly higher than in vancomycin [237]. 
A detailed prospective study done by Zar et al showed that treatment of mild C. difficile associated disease 
(CDAD) with metronidazole or vancomycin resulted in clinical safety of the patients (90% versus 98%, 
respectively ), while among the patients with severe CDAD, treatment with vancomycin was more effective 
than those with metronidazole (97% versus 76%, respectively) [238].  
 
Rifaximin (Xifaxan, Salix) is a semi synthetic derivative of rifamycin approved for the treatment of travelers’ 
diarrhea also used off-label for irritable bowel syndrome and hepatic encephalopathy. It shows its 
effectiveness mainly in the treatment of CDI recurrences. It is a drug particularly indicated for the 
treatment of bowel microbial infections, given to its low systemic absorption, estimated at a maximum of 
about 1%. These important pharmacokinetic properties allow to the antibiotic to reach the intestinal tract 
at high concentrations and to exert the therapeutic action directly in situ [239]. 
Although is a promising treatment option, difficulties in using rifaximin are the increased  number of high 
resistant isolates (however infrequent)and the lack of guidelines on interpretation of in vitro susceptibility 
tests [240]. 
 
Fidaxomycin (FDX; Dificid, Cubist), a member of a new class antibiotics targeting bacterial RNA polymerase, 
shows high activity against C. difficile and a short activity spectrum against other intestinal microorganisms.  
In 2011, pivotal trials demonstrate that fidaxomycin respect to vancomycin was not inferior showing similar 
high cure (92.1% and 89.8%, respectively) and recurrence (13.3% versus 24%) rates, associated with its 
ability to preserve the normal gut microbiome and completely resolve the underlying CDI status [241, 242]. 
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Other possible therapeutic options are: nitazoxanide, with acts interfering with the anaerobic metabolism 
of some bacteria, similarly than metronidazole [243]; intravenous tigecycline, possible adjunctive treatment 
for patients who had failed to respond to metronidazole and vancomycin [244]; ramoplanin which acts 
against vancomycin-resistant enterococci as well as C. difficile [245]; cadazolid, a antimicrobial used for 
treatment of multidrug resistant gram positive bacteria, showed a high activity against C. difficile and lower 
ability to induce resistance and toxicity [246, 247]; and surotomycin (CB-183,315, Cubist) that seems to 
have good potency against several strains of C. difficile being also able to minimize intestinal microbiota 
alteration and leading to a rapid recovery of the normal flora [248]. 
 
In recent years, patient showing treatment failure or recurrent CDI have been treated with fecal microbiota 
transplantation (FMT). 
The first published cases of FMT use were about veterinarians who performed fecal transplantation to treat 
horses with diarrhea, infusing stool from healthy donors into the rectum of the sick animals. In fact, 
treatment was based on the ability of the donor’s microflora to reintroducing a healthy intestinal 
microbiota in the host, reestablishing colonization resistance against C. difficile and other pathogenic 
bacteria [249]. 
The application of bio-therapy is useful in the treatment of CDI, especially in recurrent cases, leading the 
intestine to a state of equilibrium, considering that the administration of antibiotics is effective but still acts 
by destabilizing the gut environment.   
The FMT may be administered by nasoduodenal/gastric tube, colonoscopy, enema or capsules; following 
different protocol which includes vancomycin pre-treatment or bowel lavage (fig 23) [250, 251]. 
Despite the proven scientifically benefits, the FMT is located in the middle of a strong scientific debate 
about possible adverse effects (AE) against the receiving patient. However, it appears that the adverse 
effects are less than the benefits received and that the biggest problem remains, however, the higher cost 
of therapy respect antibiotic treatment [252].  
 
 
82 
 
Figure 23. Infection process of C. difficile and utility of Fecal Microbiome Transplantation (FMT) to restore normal 
bacterial flora of patient [253] 
 
 
2.1.5 Clostridium difficile virulence factors  
Toxigenic Clostridium difficile strains are known to express different virulence factors, of which the mainly 
characterized are A, B and binary toxins (causative of disease progression) and spores (involved in the 
transmission), in addition to other less described factors of pathogenicity such as fimbriae, a polysaccharide 
layer and hydrolytic enzymes. 
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C. difficile sporulation and germination 
Clostridium difficile isolates are capable of producing spores, whose casual ingestion by the patient, for 
contact with the contaminated surfaces, represents the first step for the transmission of the disease. 
The spores are able to survive in extreme environmental conditions and are resistant to different chemical 
and physical agents, so that when they are released in the environment by a symptomatic patient, may 
contaminate the surfaces of the healthcare environment (bed linen and stainless steel, for example) and 
also the hands of the medical staff [255]. 
 
Sporulation is the adaptive process by which a bacterial species forms metabolically dormant, highly stress-
resistant endospores and is divided into different phases: asymmetrically division of the cell into prespore 
and mother cell compartments; double-membrane prespore formation; synthesis of peptidoglycan cortex; 
spore coat assembly and release of mature spore in the surrounding environment.  
Structurally, spores of C. difficile seem to be composed similarly to those of B. Subtilis, although many 
differences are showed to exist. Spore structure consists of a number of concentric layers, which are, from 
the inner to the outer: the inner core, which contains bacterial DNA, RNA and several enzymes and 
provides for DNA [256]; the inner membrane; the cortex, which differs in composition from that of 
vegetative cells, to ensure to the spores a strong resistance to environmental stimuli [257]; the protein 
coat, that seems may have an important role in generate inflammatory processes, being able to resist to 
different chemical agents and to play a key role in recognizing germination stimuli [258] (fig 24). 
 
 
84 
 
Figure 24. C. difficile spores staining and structure. a) endospores staining; sp: spores, veg: vegetative cells; 
ex:extracellular matrix; b) malachite green spores staining; c) imagine of a the ultrastructure of a spore by electron 
transmission microscopy; d) magnified section of outer surface of the spore [258] 
 
In the last years, it was suggested that higher transmission of epidemic strains (i.e. C. difficile ribotype 027) 
may depend on the ability of these strains to produce a higher amount of spores. 
In 2008, a study by Akerlund et al, performed to evaluate the sporulation rate of several isolates of C. 
difficile 027, showed that CD027 strains sporulated more than other ribotypes and that, in particular, C. 
difficile 027 strains collected from USA outbreaks presented higher sporulation and toxin production rates  
than all the others [259]. Therefore with the years, other studies have attempted to make a contribution on 
the higher virulence of C. difficile ribotype 027 [260, 261], but the results are contradictory [262]. 
However, the real conclusion of these studies is unclear, considering that to date there is not an in vitro 
method that may be considered standard. In fact, although several studies have used the same reference 
strains, conflicting results had been obtained. This could be due to growth variability of the bacteria, to the 
use of different culture media or to the restricted number of samples [263]. 
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It is also necessary to consider that also at the molecular level, the sporulation signaling pathway of 
Clostridium difficile has not been yet understood, so that it is necessary to use Bacillus subtilis as model 
[264]. 
A recent review claimed that, although the model of B. subtilis is universally accepted, it is not possible to 
hide the presence of substantial differences in C. difficile signal transduction, mainly about the regulatory 
mechanisms relative to factors (called sigma factors) involved in synthesis of asymmetrical septum from 
mother cell and spore coat assembly [265].  
In conclusion, although the discrepancy of studies published, the hypothesis that epidemic strains (i.e., 
CD027) have a greater capacity to sporulate is generally accepted. 
 
While sporulation mechanism allows cell to produce spores under prohibitive conditions, the germination is 
the event in which the spore can mature in a metabolically active cell, able to release toxins, leading to the 
onset of the disease. 
As for sporulation, also B. subtilis germination pathway is used as model of C. difficile, although it was 
demonstrated that the latter lacks of the germinant receptors expressed by B. subtilis and other species of 
Clostridia, suggesting that other unknown regulation mechanisms are involved. 
Germination process is characterized first by the interaction of the germinant receptors with specific 
effectors molecules called germinants. At this point, a signaling cascade is activated that leads to metabolic 
activation of the spore: the water content of the spore increases, the core expands and enzymatic activity, 
metabolism and spore outgrowth occur [256]. 
In particular, for the germination begins, spore has to recognize specific germinants, which in human gut 
are represented by the bile salts. These are produced by the liver and then transported to the intestine, 
when they have different functions, including that of regulating bacterial colonization. The primary bile 
salts produced by the liver consist mainly of cholate and chenodeoxycholate conjugated with either taurine 
or glycine, leading to synthesis of glycochenodeoxycholate, taurochenodeoxycholate, glycocolate and 
taurocholate. Along the digestive tract they are metabolized, reabsorbed and recycled in a high percentage 
(95%). Unconjugated primary bile salts are taken up by a small percentage of bacterial species present in 
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the colon, which transform cholate and chenodeoxycholate in the secondary bile salts deoxycholate and 
lithocholate, respectively [266] (fig 25).  
This knowledge lead to identify the possible mechanism by which starts the infection process mediated by 
C. difficile: ingested spores resist to the gastric acids of the host stomach and arrive to the jejunum, where a 
high concentration of nutrients and primary biliar salts (such as taurocholate) is present. Primary bile salts 
stimulate the germination of spores in vegetative cells, which go into the anaerobic environment of the 
cecum: here, they can survive together with other bacteria species which are metabolizing the cholate 
derivatives into secondary bile salts (i.e. deoxycholate) preventing outgrowth of C. difficile cells.  
In the case of imbalance of intestinal microflora (for example, following administration of antibiotics), the 
protection of the gut is compromised and high amounts of primary bile salts are produced, causing the 
proliferation of vegetative C. difficile cells which acts releasing toxins and starting the inflammatory process 
[267, 268] (fig 25).  
 
 
Figure 25. Germination in C. difficile may be enhanced or inhibited by production of primary and secondary bile 
salts, respectively. (a) bile salts synthesis and effect on C. difficile cells in (b) normal or perturbed gut [269] 
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Aside from play a fundamental role in starting the germination of C. difficile cells, the taurocholate has 
been used, since 1982, for the production enriched culture medium for the recovery of C. difficile [270, 
271].  
In fact, the culture media previously formulated, for example, the CCFA (with cefoxitin, cycloserine and 
fructose) were not adequate to C. difficile growth because they presented inhibitory effects against the 
bacterium. Consequently, modifications of these media were performed as the preparation based on horse 
serum, the addition of mannose instead of fructose and, especially, that of sodium taurocholate to 
promote germination of the C. difficile spores [272]. 
The possibility of using selective media containing taurocholate (i.e. ChromID™ C. difficile agar, BioMérieux,   
Marcy l'Etoile, France) for C. difficile growth can have several applications, such as to favor the 
identification of the pathogen in diagnostic laboratory, but also for studies of collected samples in the 
evaluation of the environmental contamination, due to the release of spores [273]. 
 
Toxin A (tcdA) and toxin B (tcdB) of Clostridium difficile 
C. difficile infection (CDI) is caused by the toxigenic variants, whereas the non-toxigenic strains are not 
involved in pathogenicity. Infection cycle begins with the ingestion of C. difficile spores excreted from 
symptomatic patients, which may contaminate the environment for large periods. Spores are able to resist 
many physical and chemical stresses and, once ingested, can arrive in the anaerobic environment of gut, 
passing through the stomach without being affected from gastric acidity. In the gut of the patient, the 
spores can germinate in response to specific stimuli (i.e. primary bile salts), and mature into vegetative 
cells.  
Mature cells adhere to the intestinal epithelium, through specific surface proteins (SlpA complexes), 
colonizing this environment. Subsequently, these can proliferate and can produce several types of toxins 
that alter the integrity and permeability of the intestinal epithelial cells, triggering various inflammatory 
processes responsible for the different clinical manifestations of the CDI (fig 26). Normally, the invasion of 
the intestinal mucosa by C. difficile occurs when competition of other microorganisms is not balanced and 
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when the intestinal microbiota is altered, for example after administration of broad spectrum antibiotics. C. 
difficile may also remain part of the intestinal flora for long time, exercising its pathogenic action later, 
when the alteration of the intestinal microbiota occurs. All these processes are very complex and factors 
related to both host and the microorganism may be involved. 
Toxigenic strains are causative of the disease and produce two types of toxins called toxin A and toxin B, 
which are encoded respectively by tcdB and tcdA genes, located along with several regulatory genes in the 
Pathogenicity Locus (PaLoc) (fig 27). 
In addition to toxins A and B, some strains of C. difficile are able to produce a third toxin, which is known as 
binary toxin and possessing ADP-ribosyl transferase activity. Binary toxin is encoded by cdtA and cdtB genes 
that are located on a locus called CdtLoc, which is located away from the PaLoc and presents important 
differences respect this latter (fig 27). The biological function of the binary toxin is not well understood, but 
it seems that may produce the disruption of the microtubules involved in cell rounding. 
The function of the toxins A and B have been most thoroughly characterized; in particular, toxins destroy 
the layer of mucin deposited over the intestinal epithelium and subsequently recognize specific receptors 
on gut cells, specifically the toxin A binds to the apical side, while the toxin B to the basement side of them. 
Toxins can trigger, thus, their function both altering the cytoskeleton and causing a strong inflammatory 
response based on the release of interleukins (IL-1b, IL-6, and IL-8) and mediators of the immune response 
(neutrophils and polymorphonuclear leukocytes). 
It is assumed that toxin A may have a prevalent role in the disease progression, being involved directly in 
causing both the disruption of the tight junctions of intestinal cells, leading to increased permeability on 
the lumen of the gut, than attracting the principal mediators of the immunitary response to the 
inflammation site. Once the damage in the mucosal membrane is done by action of the polymorphonuclear 
leucocytes and other immunomodulatory mediators, toxin B may diffuse to the lumen and causes further 
damages. The intestinal cells damage leads to the release of mucus and cells debris which favors the 
formation of pseudomembranes, a rare but severe disease presentation. 
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Given the imbalance of membrane permeability, resulting in electrolytic imbalance and the extended 
damage to the epithelium, typical symptoms (mainly colitis-associated diarrhea) of C. difficile infection (CDI) 
generally occurs. A synthetic scheme of CDI cycle is showed in figure 26. 
 
 
Figure 26. Representation of C. difficile infection cycle, comprising the spore-mediated contamination of the 
environment and colonization of patient mediated by their ingestion; cells maturation and production of toxins 
leading to the inflammation process and appearance of symptoms. During the diarrhea, spores are released and 
cycle starts again. Red arrows indicate events of the infectious cycle that are linked to spores or their germination. 
CA, cholate; CDCA, chenodeoxycholate [254] 
 
 
Not all variants of Clostridium species are capable of producing toxins, in fact only toxigenic isolates carried 
the pathogenicity locus (PaLoc) and are considered the cause of the infection onset. Although the majority 
of toxigenic strains are capable of producing both the A that the B toxins, however there are isolate lacking 
of genes coding for toxin A (i.e. C. difficile ribotype 017, which is A-B+ isolate). In these cases, the 
mechanisms that lead to damage of the intestinal epithelial layer are generated by the high amounts of 
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toxin B released, unlike most of the strains that release both types of toxins and where toxin A plays a key 
role in intestinal inflammation. 
Toxins A and B belong to the family of Large Clostridial Toxin (LCT) together with lethal toxin (TcsL) and 
hemorrhagic toxin (TcsH) of Clostridium sordellii  and  alpha toxin (Tcnα) of  Clostridium novyi. 
C. difficile toxins are high molecular weight glucosyltransferases (308 kDa and 270 kDa, respectively) which 
display a high degree of similarity to each other at the amino acid level (63%) and consequently are similar 
in the structural organization, which is composed by three main domains: a receptor binding domain, a 
catalytic/enzymatic domain and a translocation domain (fig 27) (231). 
At the N-terminus, the greatest similar region between the two toxins, is located the catalytic site. It acts by 
acts mono-glucosylation of the Rho-GTPase elements, thus activating pathway which lead to the alteration 
of intestinal permeability and inflammation of intestinal epithelium. 
The translocation domain allows to the toxigenic complexes to penetrate the membrane during the 
infectious process [274, 275], while the C-terminal binding domain facilitates interaction with the host 
receptors [276]. 
 
Figure 27. Schematic representation of:  a) pathogenicity locus (PaLoc), harboring genes for synthesis and regulation 
of A and B toxins. In detail, domains of toxins structure, consisting in enzymatic, translocation, and binding domain; 
b) CDT locus (CdtLoc), harboring genes for binary toxin synthesis (cdtA/cdtB) genes and the regulator cdtR gene 
[277] 
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The first step of pathogenic pathway consists in a specific interaction between toxin A and B and the 
receptors located on the intestinal host cells. Toxins are so translocated into the cytosol into an early 
endosome, by which subsequently translocate into the cytosol. Through autoproteolysis, the 
glucosyltransferase domain is released. At this point, the interaction between glucosyltransferase domains 
and the target GTPases leads to the activation of specific signaling pathways which have as consequence 
the alteration and disorganization of the actin cytoskeleton of the intestinal epithelium (fig 28). Effects of 
the toxigenic processes are: the rupture of the tight junctions of the intestinal cells and increased 
permeability of the cell membrane; increased accumulation of fluid in the intestinal lumen; and activation 
of inflammatory responses, through the stimulation of the secretion of cytokines (as interleukins IL-1, IL-6, 
and IL-8) [278] 
In particular, during active CDI, the IL-8 is involved in the recruitment and activation of neutrophils, which 
are present in high amounts in inflammation sites, causing the formation of pseudomembranes [279].  
The ability to produce a toxins-associated cytopathic effect seems to be correlated to the amount of toxins 
A and B produced. Deletions in the regulator gene (tcdC, negative feedback) are hypothesized to lead to an 
over expression of tcdA and tcdB genes (coding for toxin A and B, respectively), with subsequent release of 
a great amount of toxins and relative increase on cytopathic effect [280].  
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Figure 28. Intracellular pathway of C. difficile toxins. The first step is internalization of toxin structures via specific 
receptor-mediated endocytosis; subsequently, at low pH, toxins translocate from early endosomes to cytosol when, 
enzymatic domain is released and the toxins are able to recognize the target GTPases, leading to cytopathic effects  
[278] 
 
Pathogenicity locus (PaLoc) 
The pathogenicity locus (PaLoc) is a 19.6 kb region located in the same chromosomal integration site of all 
toxigenic strains and carried genes coding for toxin A (tcdA) and toxin B (tcdB) and three important open 
reading frames (tcdC, tcdE, tcdR) for the regulation of toxins expression (fig 27). 
It is interesting that in non-toxigenic strains the PaLoc is replaced by a 115 bp non-coding sequence [281, 
282], for what reason it is unclear how toxigenic isolates acquired this region. This evidence has long been 
debated by various scientists, suggesting that the locus had been incorporated by one or more unrelated 
strains through a process of horizontal gene transfer (HGT),  which explains why in several phylogenetic 
clades may exist together toxigenic and non-toxigenic strains [283, 284]. 
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In particular, tcdR gene encodes for a 22kD protein which acts as positive transcriptional regulator of toxin 
expression, by activation of promoter-specific transcription through binding of the RNA-polymerase [285]. 
The tcdE gene is a 501 bp open reading frame (ORF) located between tcdA and tcdB genes that encode a 
hydrophobic protein presenting homology with phage holins. It was assumed that this regulator may act as 
a lytic protein, forming membrane pores to facilitate toxins release [286]. 
Finally, tcdC gene is the most debated and characterized ORF of the PaLoc, mainly because mutations 
within this region seem to have important effects on the amount of toxins produced. In fact this gene 
encodes for a 26kD membrane-associated protein, which has no homology to any described regulatory 
protein and acts as negative regulator of tcdA and tcdB product [280]. For this reason, strains which possess 
deletions in tcdC gene are associated with toxin overproduction: for example, C. difficile NAP1/BI/CD027 
harbors a single-bp deletion in position 117nt and the 18bp deletion on tcdC gene, which are believed to be 
the cause of higher pathogenicity in this epidemic strains, although this suggestion is now questioned 
(257)[287]. 
 
Binary toxin 
In addition to toxins A and B, several subsets of C. difficile, such as epidemic strains ribotype 027 and 
ribotype 078, may express the binary toxin (CDT), whose biological role in the pathogenesis of Clostridium 
difficile infection has not yet been clarified [288]. Gene encoding for binary toxin (cdtA and cdtB genes) and 
a regulator gene (cdtR) are carried by the CdtLoc, a chromosomal region located at distance from the PaLoc 
[289]. 
The cdtA and cdtB genes encode for the enzymatic (CdtA) and binding (CdtB) components of binary toxins, 
which act similarly to toxins A and B, i.e. inducing destruction of the actin cytoskeleton and 
depolymerization of the microtubules with consequent formation of protrusions, facilitating adhesion of 
bacterial cells to host gut (fig 29) [290]. 
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In CdtLoc, also a regulator gene (cdtR gene) is present, which similarly to as already written for the PaLoc 
acts as a negative regulator and, in the case of mutations, it can cause the altered production of toxins 
[291]. 
 
 
Figure 29. Schematic representation of the binary toxin mechanism of action [289] 
 
Toxinotyping 
The genetic variability on PaLoc genes allows the existence of numerous variants of the C. difficile strains 
given by the differential expression of toxins A and B (also considering the existence of strains producing 
binary toxins, although its role in the pathogenesis it is already undefined); so that the introduction of a 
method to differentiate them it was necessary. Toxinotyping is the technique of choice to classify toxigenic 
strains on the basis of PaLoc structural variations using a molecular method (i.e. RFLP-PCR) to analyze the 
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possible changes (i.e. deletions, single nucleotidic polymorphism, insertions) occurring in the 19 kb region 
of the C. difficile pathogenicity locus [292]. These variations, conserved at protein level, confer to the 
strains differences in antibody reactivity, targeting of intracellular small GTPases proteins and consequently 
a change in the effects on cells.  
The method is based on the amplification of 10 specific regions of the PaLoc. In particular, for each toxin 
gene the fragments obtained correspond to the catalytic domain (PCR fragments A1 and B1), the putative 
domain (PCR fragments A2 and B2) and repetitive domain (PCR fragments A3 and B3). Considering that 
amplifying all the 10 PaLoc regions in very hard-working and that the most variable fragments are the B1 
covering the 5’-end of tcdB and A3 covering the 3’-end of tcdA, in the most of the cases it is possible to 
assign a toxinotype group for the tested samples only according to the patterns obtained by the B1 and A3 
analysis. In the case that new restriction patterns are observed in these regions, identifying a new 
toxinotype, the analysis of all ten regions is performed. 
So, to each strain is assigned a toxinotype based on the comparison of the profile obtained with that of a 
strain of reference, the VPI 10463: for example, profiles similar to what of the reference (A+B+CDT-) are 
denominated toxinotype 0; up to 2015, 32 different toxinotypes had been described (named from 
toxinotype 0 to toxinotype XXXII) which main features can be found at the following page  
(http://www.mf.uni-mb.si/tox/) [293, 294] [295]. 
Considering all the possible combination of the three toxins, it is possible to obtain seven principal groups: 
A+B+CDT-; A-B+CDT-; A-B+ CDT+; A+B-CDT+; A+B+CDT+; A-B-CDT+, and A-B-CDT- (no-toxigenic strains). 
The analysis of strains producing toxins A and B is obtained by genes amplification and/or detection of 
toxins production, whereas the presence of binary toxin CTD is confirmed by only the detection of the 
intact cdtA and cdtB genes located in a different locus (CdtLoc) (table 8).  
Several toxinotypes may belong to the same toxins production group, as shown in Table 8, but to the same 
toxinotype only strains with identical PaLoc pattern belong. For example, different toxinotypes belong to 
the A-B+CDT- profile (VIII, X, XVI, and XVII) but the majority in diffusion and importance is the toxinotype 
VIII, which spread worldwide and of which most than 100 different circulating strains are known. 
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In conclusion, molecular diagnostic techniques are essentially based on the detection of genes coding for 
toxins A and/or B; for this, strains with alterations in PaLoc resulting in production of toxins variants could 
not be detected or detected but not differentiated. The usefulness of toxinotype is to identify these 
variants, although with a time-consuming method that which is beyond the necessity for a clinical 
laboratory and appropriate only for reference and research settings [293]. 
 
 
Table 8. Representation of several toxinotypes expressing different toxigenic patterns [293]. 
 
 
Other virulence factors  
Fimbriae are molecules which allow bacteria to adhere to the host tissue and are mainly involved in in favor 
adhesion to the intestinal epithelial layer, during the first phase of the inflammatory process. 
In 1998, Borriello et al demonstrated, using an in vivo model, that  the adhesion to the host epithelium 
increased in strains which express pili o fimbriae [296].  Although their importance is known, scarce 
literature is published at regard. 
The outer wall of C. difficile is covered by a polysaccharidic external layer that hypothetically would favor a 
higher resistance to the bacterium; however, also in this case, it seems that there are not demonstrations 
of a correlation between the increased virulence of some strains and the presence of this coat [297]. 
At last, it seems that some C. difficile strains may release many hydrolytic enzymes involved in destruction 
of epithelial gut wall, helping the bacterial cell to adhere to the epithelium. In 1990, a study showed that 
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several highly virulent strains were able to produce enzymes (hyaluronidase, chondroitin-4-sulphatase and 
collagenase) with high hydrolytic activity, but there was not observed an association with enlarged 
virulence, although highly virulent strains were more active than less virulent strains [298].  
 
 
2.1.6 Epidemiology of C. difficile 
Clostridium difficile is part of the intestinal flora in 1-3% of healthy individuals and more than 20% of 
hospitalized adults, who acquire the bacteria through contact with contaminated surfaces. In fact, 
symptomatic patients release large amounts of spores in the environment which can then be transferred 
on different surfaces where they resist for a large time and may be transferred to other surfaces also by 
medical staff and so be ingested from patients [299]. 
The presence of Clostridium difficile was also observed in foods (meat, salad) and in several animal species, 
although in the latter case the role of the bacterium in generating the disease is not entirely clear. 
Infection due to Clostridium difficile is the most common cause of nosocomial diarrhea and has a significant 
clinical importance because of its high morbidity and mortality and because of the prolonged stay of 
patients in hospital, causing a significant increase in health care costs [300].  
 
Considering that normally the CDI occurs in already hospitalized patients, cost of patients care increase 
because of the need of a specific treatment to eradicate C. difficile from the host gut, rigorous hygiene and 
environmental decontamination. A recent review showed that estimated healthcare costs for the 
treatment and management of CDI cases in a one year period in the USA were rising by $ 433 million to $ 
797 million a year, considering that the per patient episode cost goes from an extra € 4067 to an extra € 
9276  [300]. 
 
Our understanding of C. difficile microbiology and epidemiology is changing rapidly, considering that the 
various ribotypes seem to spread differently in the world also demonstrating a changing epidemiology. 
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Greater importance was given to the molecular epidemiology of Clostridium difficile since the early 2000s, 
when an increasing rate in frequency of severe cases in Canada and USA has been reported, related to the 
dissemination of epidemic C. difficile CD027/NAP1/B1 (PCR Ribotype, CD027; North America Pulse-field 
type, NAP1; Restriction Endonuclease Analysis, REA-type B1). This variant was able to produce toxin A, toxin 
B, and also binary toxins [301, 302], initially associated to higher virulence but whose role in the 
pathogenesis remains to be clarified. Following the spread on several outbreaks in the same period, it was 
observed that the proportion of patients with CDI who died a month after diagnosis gone from 4.7% in 
1991–1992 to 13.8% in 2003 [303, 304]. 
Since that time, nosocomial outbreaks involving strains of C. difficile ribotype 027 were characterized at 
global level [305] (fig 30) but in Europe the increased incidence of CDI cases cannot be associated only with 
the emergence and spread of CD027, as other variants were already widespread.  
 
 
Figure 30. Representation of the global spread of CD027 strain. In red, the outbreaks detected; in orange, 
sporadic/imported cases; in pink, fluoroquinolones-susceptible CD027 cases; in grey, areas CD027-“free” [305] 
 
In fact, a questionnaire-based study carried out in 2008, aimed to evaluate effectiveness of CDI diagnosis 
and to detect the circulating variants of C. difficile in Europe, has showed that the incidence of CDI, varying 
between the participating hospitals, was of 4.1 cases/10000 patients-day and that the distribution of the 
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circulating ribotypes widely differed depending to the country, among which the predominant were the 
ribotypes 014/020 (16%), 001 (9%), 078 (8%) [306]. Although outbreaks due to CD027 in UK and Ireland 
were reported, this study revealed that only 5% of the cases were due to this variant, as represented in the 
figure 31. 
Another recent study, involving 468 European hospitals, showed that CDI incidence, respect the previous 
study, increase from 4.1 cases/10000 patients-day to 7.0 cases/10000 patients-day and that to date CD027 
is the prevalent ribotype in the European territory, with a greater incidence than that observed in 2008 
(18% versus 5%, respectively).  
A part of increased incidence, interestingly it must be noted that higher incidence of CD027 cases seems to 
be shifted from UK and Ireland to Germany and Eastern Europe (Hungary, Poland, and Romania), where 
only sporadic cases were reported: this phenomenon of reduction in CDI cases in country where several 
outbreaks had been already spread is likely to be associated to the improvement in surveillance and control 
methods adopted in UK and Ireland [306, 307].Furthermore, also the diversity of the other ribotypes across 
Europe changed compared with finding from the study performed in 2008:  138 ribotypes compared to the 
previous 20 ribotypes have been detected, with increase of cases due to ribotype 001 (from 9% to 11%) and 
decrease of 014 (from 16% to 7%), highlighting the importance to perform molecular epidemiology studies 
to trace the changes in the movement of these variants. 
In Spain, up to the year 2014, the incidence of CDI cases was around 3.8 cases/10000 patients-day and the 
frequency of CD027 infections, according to the last two multicenter national studies, seems to be of 3.5% 
(2013) considering that only few unrelated cases have been detected and considered as sporadic, whereas 
other ribotypes (as 014, 078/126, 001/072, and 106) are the most commonly diffused [308, 309], similarly 
to the general situation in Europe. 
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Figure 31. Representation of the most diffused C. difficile ribotypes in Europe in 2008, source [306]. It is possible to 
note the high frequency of ribotype 014/020, followed by 001 and 078 in most of the European countries. C. difficile 
ribotype 027 has been reported mainly in UK and Ireland, where caused outbreaks 
 
 
2.1.7 Laboratory diagnosis of CDI 
 
The laboratory diagnosis is of great importance in the detection of toxigenic strains of Clostridium difficile. 
For the proper execution of this, first, it is required that the sample arrives at the laboratory in adequate 
conditions, i.e. liquid stools in sterile containers without transport media or sporicidal substances (such as 
formaldehyde) to avoid the death of the pathogen and the degradation of toxins and spores. 
Considering that the majority of the tests are based on detection of toxins which are sensitive to 
temperatures, to perform a good diagnosis it is necessary that the sample is kept at 2-8°C for a maximum of 
48 hours or frozen, to avoid alteration of the toxigenic component. 
Several studies have demonstrated a widespread underdiagnosis of CDI cases, due to the combination of 
lack of clinical suspicion and the low sensitivity of the diagnostic methods used. In particular, a multicenter 
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study carried out in Spain in 2013, showed that, although the improvement compared to study performed 
in 2008, only 50% of the CDI cases is properly diagnosed, because of the insensitive diagnostic tests (15.5%) 
or lack of clinical suspicion (35 %) [308]. 
Even at European level the situation is similar: during a recent (2014) European, multicenter, prospective, 
biannual, point-prevalence study of CDI infection in hospitalized patients (EUCLID), it was showed that only 
two-fifths of the participating hospital used adequate diagnostic methods and that the underdiagnosis rate 
of CDI cases was about 23%.   
For this reason, it is suggested to analyze all samples constituted of liquid stools, independently by age of 
the patients (excluding kids <2 years), kind of clinical request and origin of the sample (nosocomial or 
community diarrhea) [308, 310]. 
 
Method Sensibility Specificity Response time Advantages Disadvantages 
Cytotoxicity 
assay 65-85 >97 2-3 days 
Low sensibility; 
high specificity 
Experience with cell cultures; 
long response time 
Culture >90 80-90 2-3 days Good sensibility 
Hard-working; long response 
time; also no toxigenic strains 
(only culture); possibility to 
ensure anaerobiosis condition 
Culture + 
toxins 
detection 
(from pure 
colonies) 
>90 >95 2-4 days High sensibility and specificity 
GDH (EIAs) 
detection 60-90 85-95 Few minutes 
Good 
sensibility; easy 
and rapid 
Lack of specificity for 
toxigenic strains (need 
complementary test) 
Toxins A and B 
detection 50-85 90-95 Few minutes 
Moderate 
sensibility; easy 
and rapid 
Only 60% cases diagnosed 
Nucleic acid 
detection >90 >97 1-3 hours 
High sensibility 
and specificity; 
rapid 
High cost; variable 
laboriousness 
Table 9. Representation of principal features of laboratory diagnosis methods for the detection of toxigenic C. 
difficile 
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Nowadays there are many diagnostic methods used in the identification of infection due to toxigenic C. 
difficile, both as “classical” (cytotoxicity assay and toxigenic culture) and rapid tests (i.e. enzyme 
immunoassays, EIAs) for the detection of the toxins as well as molecular assays PCR-based for amplification 
of toxin genes. To date, a reference methods it is not present, because of the disadvantages presented by 
all the cited above, but in the last years toxigenic culture, followed by toxicity detection, starts to be 
accepted as gold standard [235].  
 
The cytotoxicity assay was first methods used as gold standard for different years and is based on the 
detection of cytopathic activity of B toxin exerting its effect on the structure of the cytoskeleton and on the 
cells microfilaments. The test is performed by incubation of filtered fecal suspension on a mammalian 
cellular monolayer, which is constituted by cell lines of Vero (kidney epithelial cells of African green 
monkey), HeLa (human cervical cancer cells), CHO (Chinese hamster ovary cells) and MRC-5 (human fetal 
lung fibroblast cells). Cytotoxicity was confirmed after 24-48h observing the cytopathic effect as 
morphological changes and rounding of the cells, following the neutralization by an antitoxin (C. difficile or 
C. sordellii antitoxin) (fig 32). This assays presents a high specificity (>97%) but also limitations such as the 
need of expertise in maintaining the monolayer cell line and the interpretation of the cytopathic effect, 
which, in addition to being partially subjective, requires relatively long time (several readings at 24, 48 and 
72 hours) [311]. Besides, its sensibility is not so good (65-85%) and does not give additional information 
about the toxigenic strain (table 9). 
 
 
Figure 32. Cytopathic effect caused by C. difficile toxins. (a) Morphology of untreated cells; (b) C. difficile type of CPE 
is characterized by the remaining long protrusions and is caused by ordinary toxinotype 0 strains and most of the 
variant toxinotypes as well; (c) C. sordellii type of CPE is characterized by complete cell rounding [293]  
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Enzymatic Immuno Assay (EIAs) are the most used in the laboratory for the simplicity and rapidity and may 
combines in the same time the detection of glutamate dehydrogenase (GDH, expressed by most of the 
strains of C. difficile) together with toxin detection. EIA assays for the detection of A and B toxins present a 
sensibility of 50-85% but a higher specificity (90-95%), although only the 60% of cases is detected using only 
this test.  Instead, the rapid tests for the detection of only GDH have higher sensitivity (60-90%), as this 
enzyme is produced by C. difficile strains both toxigenic and not toxigenic. This feature is the principal 
disadvantage of this technique, because GDH positivity cannot be used as the unique assay to validate 
diagnosis but must be associated with confirmatory tests for the identification of toxigenic strains 
(molecular assays or EIAs that combine the GDH and Toxins A/B detection) [312, 313] (table 9). 
 
Molecular tests are the latest methods introduced in the diagnostic laboratory and present a great 
specificity (>97%), sensitivity (>90%) and rapidity (results between 45 minutes and 3 hours). Their main 
disadvantage is to be very expensive, even if the cost can be considered amply repaid by the rapid diagnosis 
of CDI cases and also from rapid isolation of patient and his decrease in hospital stays, which effects result 
in lower costs for the hospital [314]. 
The majority of the methods provide the possibility of analyzing the sample directly, while in other cases 
intervention of the staff is required for manipulating the sample at the first phases. With regard to the 
target genes, typically the presence of toxin B (tcdB gene) is detected (to not exclude the A-B + strains) and 
in some cases it is possible to detect also the genes encoding for the binary toxin (cdtA/cdtB genes), and 
tcdC deletion nt117 (tcdCΔ117) , which is a typical feature of CD027 and allow to rapidly detect this strain 
[315, 316].  
 
Toxigenic cultures are based on isolation of C. difficile isolates in pure culture followed by detection of 
toxins by any of the methods above mentioned. Stool is pretreated with absolute ethanol or with a thermal 
shock (80°C for 15 minutes), to eliminate possible accompanying flora present in the samples, considering 
that C. difficile spores can resist to this kind of external stresses.  
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Subsequently, sample is cultured in selective media as CCFA (cycloserine, cefoxitin, fructose agar) and CCEY 
(cycloserine, cefoxitin, egg yolk agar). Nowadays these are substituted by media enriched with blood and 
antibiotics or no selective media as Brucella agar, Schaedler agar or chromogenic (selective and differential 
medium) agar. The latter allows identifying C. difficile colonies by color changes.  At this point, C. difficile 
colonies are identified for the characteristic appearance and odor, and the detection of the toxins is 
performed. The main advantages of toxigenic culture are the higher sensitivity and specificity, although, as 
for cytotoxicity assay, the method requires a long response time and the possibility to perform culture in 
anaerobe conditions.   
 
None of the techniques already described can be considered alone a technique cost-effective for the CDI 
diagnosis: molecular methods are rapid but have a high cost in order to be introduced in all laboratories 
moreover, detecting the DNA of the microorganism, carries patients or no viable bacteria; EIA technique for 
the detection of GDH alone or together with toxins are quick and specific but possess a limited sensitivity; 
finally, the cytotoxicity test and the toxigenic culture techniques are laborious and present an 
inconvenience relating to the time (48-72 hours for a result). For this reason, it is suggested to use 
diagnostic algorithms consisting of a screening assay (EIA assays for the identification of the GDH/toxins) 
and at least one confirmatory test: for example, tests based on the initial detection of the GDH/toxins 
detection may give different results: in presence of GDH+/Toxins+, normally the presence of toxigenic C. 
difficile is detected; if GDH-/Toxins- , the sample is considered negative for presence of C. difficile. In cases 
of discordant results as GDH+/Toxins- or GDH-/Toxins+, it is necessary to perform a confirmatory test 
(molecular assay for detection of toxins genes or cytotoxicity assay/toxigenic culture to confirm the 
presence of toxigenic C. difficile isolates). Initially, some international guidelines indicated confirmatory 
methods as the cytotoxicity assay and toxigenic culture, but, because of late diagnosis, they have been 
replaced by molecular methods. In this case, despite having high cost, molecular techniques allow to obtain 
a rapid diagnostic response and their cost (if used in a algorithm) is lower respect than when they are used 
as the unique diagnostic method [317] (fig 33).  
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Figure 33. Schematic representation of a diagnostic algorithm used for toxigenic C. difficile identification 
 
 
2.1.8 Molecular typing  
 
In recent years, the molecular typing of bacteria has had great success due to its ability to identify spread of 
nosocomial outbreaks due to dangerous pathogens, allowing distinguishing strains involved and the 
changing epidemiology. Molecular assays also help to distinguish when a patient recurrence is due to the 
same (relapse) or different strain (reinfection).  
The current limit in the molecular characterization of C. difficile isolates is that not all the Laboratory of 
Clinical Microbiology possesses tools and appropriate staff to carry out studies of molecular epidemiology. 
For this reason, it is very useful and important the installation of centers of reference on a regional or 
national scale, such as, for example,  the national reference center of Leeds (UK), to which many samples 
are sent for typing and sub-typing by molecular assays (Clostridium difficile Ribotyping Network, CDRN, 
https://www.gov.uk/government/collections/clostridium-difficile-ribotyping-network-cdrn-service). 
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There are several methods that allow molecular analysis of Clostridium difficile strains which are changing 
over the time and possess different characteristics and principles, but are generally considered as valid the 
methods that possess  enough discriminatory power, good reproducibility to allow comparation between 
different laboratories and typeability to discriminating the majority of the strains of a population; 
moreover, it would be appropriate that presented also quick and easy execution and simplicity in 
interpreting the results. 
 
The main molecular methods can be classified into two groups, depending on whether they are based on 
analysis of bands or sequences, with specific advantages and disadvantages (table 10): band-based 
methods such as Restriction Endonuclease Analysis (REA), Pulsed-Field Gel Electrophoresis (PFGE), capillary 
or conventional PCR ribotyping and multilocus variable-number tandem repeat analysis (MLVA) or 
sequence-based methods such as multilocus sequence typing (MLST) and whole genome sequencing (WGS) 
[318].  
A molecular typing method is adequate if it presents specific requirements, such as having a good power of 
discrimination and typeability (that is the ability to characterize unequivocally the majority of the samples 
analyzed); or a good reproducibility and transportability, i.e. the ability to achieve the same results in 
different moments and different laboratories and it should also be economical, fast and simple to apply 
(table 10). 
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Method Target Discriminatory power Typeability Transportability 
Ease of 
interpretation 
Technical 
simplicity Cost/sample 
Band-based methods 
REA 
Whole 
genome; 
HindIII 
restriction 
+++ +++ + + + + 
PFGE 
Whole 
genome; 
SmaI 
restriction 
++ ++ ++ ++ + ++ 
PCR-
ribotyping 
PCR ISR of 
16S-23S +++ +++ ++ ++ ++ + 
MLVA 
Whole 
genome; 
VNTR 
++++ ++ +++ +++ + +++ 
Sequence-based methods 
MLST 
Sequencing 
of 7 
housekeeping 
genes 
+++ +++ ++++ +++ ++ +++ 
WGS 
Whole 
genome; 
SNPs 
++++ +++ +++ + + ++++ 
Table 10. Main features associated to molecular typing techniques used for C. difficile isolates characterization, 
adapted by [318]. + poor, ++ moderate, +++ good; ++++ excellent 
 
Restriction Endonuclease Analysis (REA) 
This method was first used by Devlin et al in 1987 and it is used mainly in North America, but, in recent 
years, it has been replaced by other methods with ease of interpretation [319]. 
The REA method is based on the cut in restriction sites from high frequency restriction enzymes such as 
CfoI or HindIII of the genomic DNA of the microorganism, and the consequent creation of banding patterns. 
Numerous DNA fragments of different length are produced, which are subsequently separated by agarose 
gel electrophoresis. The band profile obtained is examined in comparison to those of the reference strains, 
obtaining a REA identity. 
Although possessing good discriminatory power and typeability, it has the great disadvantage of being 
laborious and difficult to interpret, so techniques with greater transportability are preferred to use (table 
10).  
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Pulsed-Field Gel Electrophoresis (PFGE) 
Pulsed field gel electrophoresis (PFGE) was developed in 1984 [320] and was the most diffused molecular 
methods in USA, also recommended by the CDC, although in the last years it has been replaced by methods 
with higher discriminatory power and reproducibility (table 10). 
 Specifically, it s based on initial phase of digestion of C. difficile genomic DNA with an infrequent cutting 
restriction enzyme, for example SmaI, producing large size fragments. These are separated by agarose gel 
electrophoresis, characterized by alternately pulsed, perpendicularly oriented electrical fields, which 
enables, via the application of periodic changes in the direction of the electrical field, to separate and 
resolve fragments of different sizes on the gel. The pulse time of migration is linearly increased during the 
run so that progressively larger fragments are able to migrate forward through the gel, resulting into 
specific banding patterns, which are compared with those of reference strains and named with specific 
nomenclatures (for example NAP1  refers to North America Pulsotype 1 i.e. C. difficile ribotype 027)[321, 
322](fig 34).  
PFGE presents the advantage to be a already known methods, because many laboratories perform it for the 
molecular typing of other bacterial species, so with the same tools and similar protocols it is possible to 
characterize different microorganisms. 
One of the most important limitations of PFGE applied on C. difficile regards the frequent degradation of its 
DNA, which does not allow obtaining band patterns with good resolution; furthermore, PFGE is a laborious 
technique which also requires a long time to yield results, a parte that the lack of a reference methods and 
universal nomenclatures make difficult the inter-laboratory exchange of data [321]. 
PFGE was the most common technique in USA for many years, but recently, more laboratories are using the 
"European" combination based on the application of ribotype associated MLVA, which presents a higher 
discriminatory power. 
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Figure 34. Representation of PFGE bands pattern of C. difficile isolates, which are correlated with analysis 
performed by toxinotype, detection of binary toxins and deletion in tcdC gene. Source CDC Atlanta, dispatch; 
Volume 17, Number 10—October 2011 
 
PCR-ribotyping 
PCR-ribotype is a typing method used principally in Europe, particularly in the United Kingdom, where it 
was for many years the gold standard to genotyping strains of C. difficile. 
The method is based on the amplification by PCR of specific inter spacer regions (ISR) of conserved 16S-23S 
genes (coding for ribosomal RNA) and the subsequent gel-based analysis of the banding patterns obtained. 
These ISR (size ranging from 238 bp to 566 bp) are present in different positions, numbers and sizes within 
the genomes of C. difficile strains, for which their amplification and analysis allows differentiating within 
them [323].  
In 1999, Stubbs et al published one of the most important studies about the discriminatory power of PCR-
based ribotyping: 2,030 isolates from different sources were analyzed, resulting in identification of 116 
different ribotypes, which had been used to construct a library where subsequently other samples were 
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compared [324]. Currently, the procedure indicated by Stubbs et al is the most used, although different 
others have been published [324, 325]. 
The patterns obtained must be analyzed with specific software that allows building a dendrogram of 
similarity, through image recognition and phylogenetic analyzes, because to date more than 500 ribotypes 
are known (all conserved in the Leeds library; https://www.gov.uk/government/collections/clostridium-
difficile-ribotyping-network-cdrn-service), so that it is necessary to have appropriate tools for the 
comparison of investigated samples with the reference strains that not all laboratories possess.  
Ribotyping presents a higher discriminatory power and simplicity in application, respect of PFGE and REA 
analyses, but has several limitations as the reproducibility between different laboratories and the reliability 
of the patterns obtained (table 10). 
To overcoming the inter-laboratory problems to compare typing results, a variant of the PCR-based 
ribotype was performed: the capillary-electrophoresis ribotyping is based on the use of primers associated 
with fluorophores and the subsequent analysis of the amplification product by a genetic analyzer. Surely, 
this technique has greater discriminatory power and a more objective analysis of profiles, but is more 
expensive, and it is also necessary to have a sequencer available; in any case, the problem related to 
ribotypes nomenclature assignation continues to be evident [326, 327]. 
 
Multilocus Variable-number Tandem-Repeat Analysis (MLVA) 
MVLA is a highly discriminatory molecular typing method, based on PCR amplification and fragment 
analysis of repeated short sequences in tandem, and mainly used to subtype strains of the same ribotype; 
to discriminate outbreaks and identify possible routes of transmission between patients.  
It is based on variable number tandem repeat (VNTR) analysis, where VNTR are short sequence repeat (SSR) 
motifs dispersed in the genome. Considering that the number of repetitions in each locus varies in different 
strains of Clostridium difficile, the method consists in amplifying at least 7 loci of interest with primers 
labeled with fluorescent dyes and the amplified product are analyzed with a genetic analyzer (the same 
used to sequence DNA) to obtain the size of every locus. The number of repetitions of each locus is 
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calculated comparing the size of the fragment obtained with the size of the same fragment in the presence 
of only one repetition (considering also the number of base pairs of each repetition) [328]. To perform the 
analysis many softwares are available as GeneMapper® (Applied Biosystems, Carlsbad, CA, USA) or 
BioNumerics® (Applied Maths, Belgium); alternatively, it is possible to sequence the fragments for the 
different loci and count the number of repetitions, but it is a laborious and more expensive way. A code of 
seven numbers (seven loci) is assigned to each sample. 
Once the number of repetitions on each locus is obtained, for each sample the difference of the amount of 
tandem repeat loci and the number of loci variants (summed tandem repeat difference or STRD) is 
calculated and on its basis a graphic representation through a Minimum Spanning Tree is created, which 
associates MLVA patterns on the basis of the smallest STRD [329]. 
In particular, it is considered that strains with STRD ≤2 are part of a clonal complex (are identical), while 
those with 2<STRD≤10 are genetically related; finally if there is a STRD>10 know samples are to be 
considered genetically unrelated. 
One of the first scheme for MLVA application was published in 2006, by Marsh et al, which analyzed 86 
clinical isolates of C. difficile (20 of which were reference toxigenic isolated) with MLVA and REA in order to 
confirm the susceptibility of the new technique and characterize isolates representing already the most 
common REA groups identified. Interestingly, direct comparison between MLVA and REA typing showed 
that MLVA discriminates with high specificities isolates belonging to the same epidemic cluster, highlighting 
the genetic correlation between them, concluding that MLVA could be a very useful tool in C. difficile 
genotyping for investigations of nosocomial infections [329]. 
van den Berg et al, as in previous cited study, used the MLVA technique to characterize recent outbreaks 
due to C. difficile ribotype 027 and to discriminate against severe infections due to the onset of a new strain 
RT017 (toxin A negative, toxin B positive). Also in this case, the conclusion of the study was that application 
of MLVA to C. difficile isolates was easy to perform and may give further evolutional information on 
pathogens spreading during a outbreaks situation [330].  
Subsequent studies observed that two MLVA loci (F3 and H9, accordingly to van den Berg definition) were 
not discriminative, as they were invariable and that, regarding typing of RT078, another locus (A6, van den 
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Berg definition) is a null allele and for several other loci the PCR settings had to be optimized; however, the 
protocol of van den Berg is the most widespread and used to apply MLVA analysis [331].  
In the last years, alternative schemes of MLVA methods were performed: the modified-MLVA (MMLVA) and 
the extended-MLVA (eMLVA). In the first case, instead of having seven loci, the number is reduced to five 
for the elimination of F3 and H9, by adding the PCR detection of toxins (tcdA, tcdB and deletion of tcdC) 
[332]. 
In the second case, the number of loci is increased to 15, with the advantage of a greater discriminatory 
power and allowing to grouping strains by ribotypes, but this also increases the cost and manual difficulty, 
leaving it as a second choice to “classical” MLVA with 7 loci [334]. 
The biggest disadvantage of this methods is the need of a genetic analyzer to perform analysis of data 
obtained, but, despite this, MLVA presents numerous advantages, such as a high transportability and ease 
of interpretation (table 10), moreover of being a high discriminative method (in fact allows subtyping 
elements belonging to the same ribotype), defining the route of transmission between patients, adding 
data on possible phylogenetic relationship between samples and allowing to study the evolution of them in 
a defined environment (like a hospital can be). 
 
Multilocus Sequence Typing (MLST) 
The MLST method was one of the first genomic methods applied mainly in typing of Enterobacteria and 
other microorganism as Staphilococcus aureus, having the advantage to examine long term bacterial 
population genetics and epidemiology.  
The most recent application of MLST is the molecular typing of C. difficile isolates, performed by PCR-based 
amplification and sequencing of DNA fragments of seven housekeeping genes (conserved genes); for each 
sequence variants an allelic number is assigned; the combination of seven allelic numbers is called 
Sequence Type (ST). The definition of the ST of each sample is obtained, in a simple and objective way, by 
comparison with those archived in public databases available on Internet. According to the latest 
actualization (October 2015), 326 ST of C. difficile have been deposited  
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(http://pubmlst.org/perl/bigsdb/bigsdb.pl?db=pubmlst_cdifficile_seqdef). 
MLST has a power of discrimination quite similar to that of the ribotype, but with the difference that it is a 
technique more objective (analysis of sequences), simpler and with the advantage of allowing compare the 
results between different laboratories (table 10). Furthermore, many laboratories are more familiar with 
this technique, thanks to its application in respect of different bacterial species. 
The higher limit for which probably ribotype continues to be the most used respect MLST is the high cost of 
sequencing multiple targets. 
One important discovery obtained by MLST was the phylogeny reconstruction of C. difficile strains which 
revealed that C. difficile diversified into at least five well separated lineages during evolution, and possibly a 
sixth monophyletic lineage [335]. 
 
Whole Genome Sequencing (WGS) 
During the last decade, a revolution in terms of high-throughput sequencing methodology occurred with 
the spread of WGS that replaced, in part, the conventional typing techniques. 
WGS can detect precise genetic changes occurred in bacterial genomes also analyzing mutations at single 
polymorphic locus, allowing to define epidemiological lineages, chain of transmission of infection and also 
deduct profile MLST, overcoming also many of the limitations of conventional techniques, enabling to share 
the results with other laboratories, with the ability to store the entire sequence in specific databases.  
Specifically, conventional typing methods have the disadvantage of not being able to identify very similar 
high-incidence isolates, while the WGS possess a highest discriminatory power that allows analyzing 
genomic mutations caused by SNPs (Single Nucleotide Polymorphisms) and clarifying the chain of 
transmission in space and time of each strain involved in outbreaks.  
The first WGS characterization of C. difficile was performed in 2010, analyzing thirty isolates of different 
collections of US and Europe to determine both macro and microevolution of the species. This and other 
subsequently studies demonstrated that C. difficile has a highly dynamic genome, and it was possible to 
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discriminate isolates into 25 distinct genotypes based on SNP analysis, occupying distinct evolutionary 
lineages and harboring unique antibiotic resistance genes [336, 337]. 
Despite the high discrimination power, typeability and transportability of WGS, the main disadvantages of 
remain the necessity to have adequate bioinformatics tools and staff with expertise in data analysis, a part 
of the related cost, mainly due to the sequencing of the samples. However, the possibility to extrapolate 
MLST, PFGE, resistance gene, toxins gene sequences and other data from the same test could balance the 
cost-benefit analysis. 
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2.2 Shortcomings of literature and aim of the work 
 
Clostridium difficile infection (CDI) due to CD027 strains is associated with increased transmission, higher 
severity of the disease and important public health problem regarding costs and management. 
During the last decade, much has been discovered and published on CD027 dissemination, but despite the 
large number of publications, it possible to make some observations: 
 
a) In Europe, the real incidence of C. difficile infection is probably underestimated because of the low 
susceptibility of diagnostic methods used by most of the hospitals, of the lack of correct clinical suspicion, 
and of the absence of national surveillance programs for infection control [307, 308] 
 
b) Despite being described, large outbreaks spread globally, in Spain, according to data shown by the scarce 
published studies about molecular epidemiology of C. difficile, it seems that until 2014 ribotype 027 was 
very infrequent (3.5% in 2013), with a prevalence of ribotypes 014/020, 078/126 and 001/072. However, 
since 2007, in the Hospital General Universitario Gregorio Marañon, an active surveillance monitoring for 
CD027 is performed and thanks to which only some sporadic cases were identified [308, 338] 
 
c) To date, in Europe, CD027 is the main ribotype detected, although it seems that its incidence though its 
incidence has declined in countries where so far was the main ribotype (UK and Ireland) to move to Central 
and Eastern Europe (Germany, Hungary, Poland and Romania) [306, 307] 
 
d) The epidemiology of CDI is changing, but it is unclear if the increased incidence is due to a poly- or mono-
clonal factor. There are relatively few studies that describe possible changes of molecular epidemiology of 
the spread of CD027. 
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e) Higher transmission of epidemic strains (i.e. CD027) is associated with increased  sporulation [339]. 
Several studies have been interested in measuring the in vitro ability of sporulation of CD027 and the 
possible correlation with greater transmission and environmental persistence, but published data 
presented contradictory results [263]; 
 
The main objective of this study is the application of molecular typing methods for the characterization of 
strains of Clostridium difficile belonging to ribotype 027, following the observation of an increased 
frequency in infection due to this variant in the Hospital General Universitario Gregorio Marañon (Madrid, 
Spain) from 2014. 
The second aim is to investigate, with an in vitro method, whether the increased transmission of CD027 
isolates may be related with increased spore production and higher ability to germinate. 
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2.3.1 Background 
In Spain, until 2014, the incidence of Clostridium difficile 027 was much lower than in many European 
countries. During the three national studies performed between 2011 and 2013, only a few sporadic cases 
considered unrelated were detected [308, 338].  
Since 2007, in the Hospital General Universitario Gregorio Marañon (HGUGM) a system of active 
surveillance has been introduced, which has allowed to identify, in the last year, a significant increase in 
cases of CDI due to ribotype 027. 
This first part of the study has the aim to identify and characterize through the use of molecular 
methodology, all isolates of CD027, highlighting genetic relationships among them and the presence of one 
or more clones disseminated in the HGUGM. 
 
 
2.3.2 Materials and methods 
 
Study design 
All C. difficile clinical isolates recognized as presumptive CD027 from Gene Xpert® C. difficile (Cepheid, 
Sunnyvale, CA, USA) assay or as GDH+/Toxins+ through screening with rapid tests (EIAs, C. DIFF Quik Check 
Complete®, Alere, Atlanta, GA, USA) have been sent to the laboratory of molecular bacteriology to perform 
confirmatory tests. 
Multiplex PCR assays for the presence of toxin A, B, and binary genes (tcdA, tcdB, cdtA/B, respectively) are 
performed. All binary toxin-positive samples were further subjected to PCR-ribotype to confirm the 
presence of CD027 clinical isolates. 
At this point, PCR assays are performed for the detection of the mutations in the DNA gyrase genes (in 
particular, gyrA and gyrB, which are molecular marker of epidemic lineages of CD027) and the analysis of 
the sequence of tcdC gene (CD027 counts with a single 1-bp deletion at nucleotidic position 117 and a 
deletion of 18-bp). 
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After this, CD027 samples are subjected to subtyping by MLVA analysis, to detect genetic relatedness 
among them (fig 35). 
 
 
Figure 35. Schematic representation of the workflow used in this study. All presumptive-CD027 and all the C. 
difficile clinical isolates positive for A, B and binary toxins (by EIA test) are confirmed to be toxigenic strains by 
Multiplex PCR assay; subsequently, binary toxin-positive isolates are confirmed to belong to ribotype 027 by PCR-
ribotyping. All confirmed CD027 isolates were further analyzed by sequencing of tcdC gene, PCR assay for the 
detection of mutations in gyrA and gyrB genes and MLVA, aimed to characterize genetic relatedness among them. 
 
 
Bacterial isolates 
In this study, we included all CD027 isolated from unformed stools sent to the Microbiology Laboratory of 
HGUGM in a period of 20 months (January 2014-August 2015), independently from the clinical suspicion. 
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To isolate C. difficile, stool samples were cultured on an agar plate CLO (BioMérieux, Marcy l'Etoile, France) 
at 35-37°C for 48h under anaerobic conditions. Colonies growth compatible with C. difficile were 
subcultured in Brucella agar (Becton-Dickinson) in the same condition described above. The pure cultures 
obtained were tested for detection of toxins A/B and GDH (C.DIFF Quik Chek; Alere, Atlanta, GA, USA).  
All the GDH+/Toxins+ clinical isolates were sent to the laboratory for performing molecular typing. 
When an increased incidence of CD027 was noted and the beginning of a outbreak suspected, samples 
were immediately processed by the Gene Xpert® and all presumptive CD027 sent to the laboratory for 
molecular typing. 
 
Molecular assays 
a) DNA extraction 
Chromosomal bacterial DNA was extracted from pure cultures of toxigenic C. difficile in Brucella agar using 
Chelex resin according to the manufacturer’s instructions (InstaGene Matrix, BioRad Laboratories): in detail, 
1-2 pure colonies of C. difficile were resuspended in 200µL of Chelex resin. The suspension is mixed on a 
vortex and then incubated at 56°C for 30 minutes in a thermoblock to obtain the lysis of the bacteria. 
Subsequently, the samples have been incubated at 100°C for 8 minutes in a water batch and later 
centrifuged at 14000 rpm for 3 minutes, obtaining the separation of cellular fragments (pellet) from nucleic 
acid (supernatant), of which 50µL are taken to perform molecular studies. 
 
b) Multiplex-PCR for toxins detection 
Multiplex-PCR assays for the detection of the A, B and binary toxins genes (tcdA, tcdB, and cdtA/cdtB, 
respectively) were performed as previously described with modifications, using the primers showed in 
(table 11)  [340, 341]. 
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For each PCR reaction a master mix with a  final volume of 50µL has been prepared, containing 25µL of 
Multiplex Master Mix (PCR kit, Qiagen, GmbH, Germany), 20µL of a suspension of oligonucleotides (table 
12), and  5µL of the DNA of the investigated sample. To each PCR reaction, were added a negative control 
(5µL of nuclease-free H2O) and a positive control (C. difficile ribotype 027, A+ B+ Binary+). 
The amplification reaction was performed in a GeneAmp PCR 9700 thermocycler (Life Technologies, 
California, USA) and had the sequent thermal protocol: 1x(94°C 10’) + 35x(94°C 50’’+ 54°C 40’’+ 72°C 50’’) + 
1x(72°C 3’) +  (4°C ∞). 
 
The amplification products were separated by agarose gel electrophoresis. Gel has been prepared with 
standard agarose (Standard Low-mr Agarose, Bio-Rad Laboratories, USA) at a concentration of  2% in TBE 
Primers  Target Sequence Concentration Size (bp) Reference 
tcdA- F tcdA 
(deletion at 
3’) 
5’ AGA TTC CTA TAT TTA CAT GAC AAT AT 3’ 
5 μM 
365bp 
(complete) 
110 
(deleted) 
[341] 
tcdA-R 
5’ GTA TCA GGC ATA AAG TAA TAT ACT TT 
3’ 
tcdA- 
F3345 tcdA 
(conserved 
gene) 
5’ GCA TGA TAA GGC AAC TTC AGT GGT A 3’ 
10 μM 629bp 
[342] 
tcdA-
R3969 
5’ AGT TCC TCC TGC TCC ATC AAA TG 3’ 
tcdB-
F5670 
tcdB 
5’ CCA AAR TGG AGT GTT ACA AAC AGG TG 
3’ 
5 μM 410bp tcdB-
R6079A 
5’ GCA TTT CTC CAT TCT CAG CAA AGT A 3’ 
tcdB-
R6079B 
5’ GCA TTT CTC CGT TTT CAG CAA AGT A 3’ 
cdtA-
F739A 
cdtA 
5’ GGG AAG CAC TAT ATT AAA GCA GAA GC 
3’ 5 μM 262bp 
cdtA-
F739B 
5’ GGG AAA CAT TAT ATT AAA GCA GAA GC 
3’ 
cdtB- F617 
cdtB 
5’ TTG ACC CAA AGT TGA TGT CTG ATT G 3’ 
5 μM 221bp 
cdtB-R878 5’ CGG ATC TCT TGC TTC AGT CTT TAT AG 3’ 
PS13 16S rDNA 
Control 
5’ GGA GGC AGC AGT GGG GAA TA 3’ 
5 μM 1062bp 
PS14 5’ TGA CGG GCG GTG TGT ACA AG 3’ 
Table 11. Primers used in this study to perform Multiplex-PCR for toxins detection of the C. difficile clinical isolates 
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buffer 1X, using the RealSafe Nucleic Acid Staining (Real Life Science-Solution, Durviz, Valencia, Spain)  with 
a final concentration of 10µL/mL.  
Prior to gel loading, tubes containing 8uL of the amplified product and 2µL of the loading dye (Blue/Orange 
6X Loading Dye, Promega, Madison, USA) were prepared and a total of 10µL of the final mixture were 
loaded in the gel, along with negative and positive controls and with the marker of known molecular weight 
(in this case with bands spaced every 100bp; DNA Ladder 100bp, Invitrogen, CA, USA), which serves to 
compare the expected size of the bands of the sample with those of reference. Electrophoresis was 
conducted at 50V during 40 minutes, at the end of which the gel was observed with a UV transilluminator.  
 
c) PCR-ribotyping 
The toxigenic Clostridium difficile A+B+Binary+ strains and the presumptive CD027 isolates were further 
subjected to ribotyping to confirm them as CD027 strains. 
The protocol performed as previously published by Stubbs et al [324] (table 12), was based on the  use of  
primers complementary to the 3’-end of the gene coding for the 16S rRNA and the 5'-end of that of the 
23S, allowing to amplify the Internal Transcribed Spacer Regions (ISR) between these genes. 
 
 
 
 
 
The PCR Master Mix with a final volume of 25uL, consisted of: 3.5 µL of each primer, 12.5 µL of Multiplex 
Master Mix (PCR kit, Qiagen, GmbH, Germany), 0.5 µL of nuclease-free H2O (to reach the required volume), 
and 5 µL of the DNA of the investigated sample. To each PCR reaction, were added a negative control (5µL 
of nuclease-free H2O) and positive controls (C. difficile ribotype 027 and ribotype 001). 
Target Primers Sequence Concentration 
Site 1445-1466 of 16S  5’CTG GGG TGA AGT CGT AAC AAG G 3’ 0.2 μM 
Site 20-1 of 23S  5’ GCG CCC TTT GTA GCT TGA CC 3’ 0.2 μM 
Table 12. Primers used in C. difficile PCR-ribotyping method [324] 
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The amplification reaction was performed in a GeneAmp PCR 9700 thermocycler (Life Technologies, 
California, USA) and following the sequent thermal protocol: 1x(94°C 10’) + 35x(94°C 1’+ 55°C 1’+ 72°C 2’) + 
1x(72°C 10’) + (4°C ∞). 
At the end of the PCR reaction, to each sample 3µL of Loading Dye (Blue/Orange 6X Loading Dye, Promega, 
Madison, USA) were added and of the resulting mixture, 12µL are cast into the agarose gel. This is 
composed of a specific agar, the MS-8 (Agarose MS-8, Laboratorios Conda, Torrejon de Ardoz, Madrid, 
Spain), of which chemical composition was made to ensure an efficient separation of small DNA fragments 
and PCR products.  
The gels are prepared at 3% of agarose MS-8 in TBE 1X buffer, using as staining the ethidium bromide at a 
concentration of 5µL/100mL. For each gel, a genetic marker is added (DNA Ladder 100bp, Invitrogen, CA, 
USA), which is subsequently used for the normalization of the profiles obtained. The electrophoretic run 
takes place at 150V during 4h30m; when the operation is finished, the gel is visualized by a UV 
transilluminator, with which it is possible to take a digital photo, used for the sequent analysis of banding 
patterns obtained with the specific software BioNumerics v5.0 (Applied Maths, Belgium). 
Profile analysis is based on the comparison between the tested samples and the reference strains, 
specifically CD027 isolates belonging to the library of the European reference center (Leiden University 
Medical Centre, Leiden, Netherlands). 
The interpretation of the results involves the use of a similarity dendrogram using UPGMA (Unweighted 
Pair Group Methods using Arithmetic averages) criterion for band patterns comparison.  
 
d) Sequencing of tcdC gene 
Clostridium difficile ribotype 027 has alteration on tcdC gene, consisting of a single 1-bp deletion at 
nucleotidic position 117 and a deletion of 18-bp. 
All the confirmed CD027 isolates were subjected also to the analysis of the tcdC gene sequence by products 
amplification via PCR reaction, using primers flanking tcdC (showed in table 13) and sequencing, as 
described by Spigaglia and Mastrantonio [343].  
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The PCR reaction was performed preparing the master mix with a final volume of 50µL for reaction, 
consisting of: 5µL of each primer, 0.4µL of dNTPs [0.8mM], 5µL of PCR Buffer 10X without MgCl2 (Roche, 
Basel, Switzerland), 0.5µL of MgCl2 [25mM] (Roche, Basel, Switzerland), 1.5µL of Taq DNA polymerase [5 
U/µL] (Roche, Basel, Switzerland), 5µL of investigated sample DNA and 23.1µL of nuclease-free H2O (to 
reach the required volume). To each PCR reaction, were added a negative control (5µL of nuclease-free 
H2O) and a positive control (C. difficile ribotype 027). 
The amplification reaction was performed in a GeneAmp PCR 9700 thermocycler (Life Technologies, 
California, USA), following the sequent thermal protocol: 1x (94°C 5’) + 30x(94°C 1’+ 50°C 1’+ 72°C 1’) + 
1x(72°C 10’) + (4°C ∞). 
Electrophoresis in agarose gel (2% standard agar in TBE 1X, as described above) have been performed to 
verify the presence of the amplified products, were subsequently purified before sequencing reaction with 
a purification kit (High Pure PCR Product Purification Kit, Roche Diagnostics, GmbH). Sequencing was 
performed using the genetic analyzer Abi-Prism 3100 (Applied Biosystems, Carlsbad, CA, USA) located in 
the central unit of sequencing of the HGUGM. 
Sequences obtained have been aligned with BioEdit software, version 7.0.0, and compared to the sequence 
of wild-type reference strain C. difficile 001 ATCC® 9689™. 
 
e) MultiLocus Variable-number Tandem Repeat Analysis 
All strains confirmed to belong to ribotype 027 (ribotyping and presence of the specific deletions at tcdC 
gene), were further subtyped by MLVA.   
Primers Primers Sequence Concentration 
tcdC C1 5`TAA ATT AAT TTT CTC TAC AGC TAT CC 3’ 5 μM 
tcdC C2 5’ TCT AAT AAA AGG GAG ATT GTA TTA TG 3’ 5 μM 
Table 13. Primers used in tcdC analysis, source [343] 
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Protocol used was that previously described by Van Den Berg et al [330], in which primers had been  
designed to targeting seven regions with short tandem repeats spread over the genome designated A6, B7, 
C6, E7, F3, G8 and H9 (table 14).  
The forward primers were labeled with different fluorophores (FAM or 6-carboxyfluorescein; NED or 2’-
chloro-5’-fluoro-7’,8’-fusedphenyl-1,4-dichloro-6-carboxylfluorescein; VIC or 2’-chloro-7’-phenyl-1,4-
dichloro-6-carboxylfluorescein; and HEX or 6-hexachlorofluorescein), as shown in table 15, with the 
purpose of amplifying the 7 loci by 4 different multiplex PCR reactions which can be separed by multicolor 
capillary electrophoresis and identified by the genetic analyzer, in order to obtain the size of each fragment 
and allow its subsequent analysis by specific software. 
 
Locus 
Tandem 
repeat 
sequence 
Primer forward (5’  ->  3’) Primer reverse (5’  ->  3’) 
A6 AAGAGC FAM-TTAATTGAGGGAGAATGTTAAA AAATACTTTTCCCACTTTCATAA 
B7 ATCTTCT FAM-TAATACTAAACTAACTCTCTAACCAGTAA TTATATTTTATGGGCATGTTAAA 
C6 TATTGC HEX- GTTTAGAATCTACAGCATTATTTGA ATTGGAATTGAATGTAACAAAA 
E7 ATAGATT FAM- TGGAGCTATGGAAATTGATAA CAAATACATCTTGCATTAATTCTT 
F3 TTA HEX-TTTTTGAAACTGAACCAACATA ACAAAAGACTGTGCAAATATACTAA 
G8 TAAAAGAG NED- TGTATGAAGCAAGCTTTTTATT AATCCAGCAATCTAATAATCCA 
H9 TCTTCTTCC VIC- GTTTTGAGGAAACAAACCTATC GATGAGGAAATAGAAGAGTTCAA 
Table 14. Primers used to perform PCR reaction for MLVA assay; source [330] 
 
In detail, the PCR reaction has been set up, preparing a master mixes with a final volume of 50µL, 
containing a quantity of primers with final concentration of [0,4µM], 25µL of Multiplex Master Mix (PCR kit, 
Qiagen, GmbH, Germany), 5µL of DNA sample and an amount of nuclease-free H2O to reach the final 
volume. A total of one single PCR for G8 locus and three PCR duplexes for others loci (A6-H9; B7-F3; C6-E7) 
have been performed. 
The thermal protocol provides the sequent amplification cycles: 1x (95°C 15’) + 35x(94°C 30’’+ 51°C 30’’+ 
72°C 30’’) + 1x(72°C 10’) + (4°C ∞) and has been performed in GeneAmp PCR System 9700 thermocycler 
(Life Technologies, Carlsbad, CA, USA).  
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The amplification products were separated by agarose gel electrophoresis at 150V for 20 minutes. Gel and 
the samples to be loaded have been prepared as described above. 
Once verified the presence of the amplification products, the fragments were analyzed by multicolor 
capillary electrophoresis with genetic analyzer Abi-Prism 3100 (Applied Biosystems, Carlsbad, CA, USA) and 
the results were processed by the GeneMapper software v4.0 (Applied Biosystems, Carlsbad, CA, USA) 
which assigns the fragment sizes and repeats number of each locus, comparing the size of the fragment 
obtained with the size of the same fragment in the presence of only one repetition (it is necessary to create 
a library of references for each of the 7 loci to compare the samples). 
Phylogenetic relatedness among the isolates has been defined using the summed tandem repeat difference 
(STRD) or the difference of the amount of repetitions that each strain has in all of its loci. Briefly, if the STRD 
between two samples is ≤2 means that they belong to the same clonal complex, however, if 2<STRD≤10 
samples are genetically related even though presenting a little "genetic distance". Finally, if STRD>10 
isolates do not possess genetic correlation even among representative of the same ribotype.  
For graphical representation of the correlation between different MLVA-types a Minimum Spanning Tree 
(MST) has been created from the analysis of the STRD of the investigated strains. 
 
f) PCR assay for detection of mutations in DNA gyrase genes 
In addition, PCR assays and direct sequencing were performed to detect point mutations in gyrA and gyrB 
genes, as already described by [344]. In particular, mutations in gyrA gene are used as genetic marker to 
identify and follow the dissemination of two more virulent lineages of CD027, evolved spontaneously from 
a common ancestor during the years of the large epidemics occurred in Canada and USA in early 2000s 
[336].  
Primers used, amplifying part of the quinolone resistance-determining region (QRDR) are shown in table 
15: 
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Primer Sequence Concentration Size (pb) 
gyrA-F 5’-AATGAGTGTTATAGCTGGACG-3’ 5µM 390 bp 
gyrA-R 5’-TCTTTTAACGACTCATCAAAGTT-3’ 
gyrB-F 5’-AGTTGATGAACTGGGGTCTT-3’ 5µM 390 bp 
gyrB-R 5’-TCAAAATCTTCTCCAATACCA-3’ 
Table 15. Primers used in PCR assay to detect mutation in gyrase A and gyrase B genes; source [344] 
 
The PCR reaction was prepared starting from a solution with final volume of 50µL containing 5µL of each 
primers, 0,4µL of dNTPs solution at a concentration of [0,4µM], 5µL of PCR Buffer 10X without MgCl2 
(Roche, Basel, Switzerland), 4µL of MgCl2 concentrated at [25mM] (Roche, Basel, Switzerland), 1µL of Taq 
DNA polymerase with a concentration of [5 U/µL] (Roche, Basel, Switzerland), 5µL of investigated sample 
DNA and 24,6µL of nuclease-free H2O (to reach the required volume). To each PCR reaction, a negative 
control (5µL of nuclease-free H2O) and a positive control (C. difficile ribotype 027) have been added. The 
reaction has been performed in GeneAmp PCR System 9700 thermocycler (Life Technologies, Carlsbad, CA, 
USA) with the following thermal protocol: 1x (95°C 5’) + 35x(94°C 1’+ 53°C 1’+ 72°C 1’) + 1x(72°C 10’) + 
(4°C∞).  
Amplicons have been separated with gel-based electrophoresis, purified and sequenced. 
The sequences obtained have been aligned with BioEdit software 
(http://www.mbio.ncsu.edu/bioedit/page2.html ), and compared to the sequence of the drug susceptible 
strains Peptoclostrium difficile 630 (NCBI Reference Sequence: NC_009089.1) and to those of the strain C. 
difficile ATCC® 9689™ (CD001) used as wild-type sequences. 
 
 
2.3.3 Results 
From January 2007 to August 2014, 6513 clinical isolates of Clostridium difficile have been analyzed by 
molecular assays at the Hospital General Universitario Gregorio Marañon (Madrid, Spain). 
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Of these, 977 (15%) of the isolates has been identified as A+B+Binary+ where C. difficile ribotype 027 
constituted the 19.96% (195/977) of the binary toxin-positive isolates and the 2.9% of all the isolates 
analyzed.  
Considering that up to 2014, only 9 unrelated and sporadic cases have been isolated, the remaining 186 
clinical isolates have been detected between January-2014 and August 2014. The 9 sporadic cases were 
unrelated and corresponding to 5 patients, constituting only the 0.25% of all the toxigenic isolates 
analyzed. 
The 186 CD027 clinical isolates belonged to 132 patients hospitalized in different wards of the same 
hospital, with a consequent total of 132/186 first episodes and the remaining 54/186 isolates representing 
recurrences of CDI due to C. difficile ribotype 027 (fig 36). 
 
Figure 36. Representation of increased rate of CD027 episodes during the study period (January 2014-October 
2015). Only the first episode for each single patient has been considered. In black, CDI cases considered previous to 
the outbreak. In gray, the CDI cases belonging to the outbreak. 
 
Molecular analysis by means of MLVA has been performed on the first episodes for the single patient (i.e. 
132 patients-isolates), with the purpose of showing the phylogenetic relationships among them and so has 
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allowed to identify 9 different sub-types (defined MLVA-types), which were organized in different clonal 
complexes (CC). 
In particular, as showed in figure 37, the Minimum Spanning Tree (MST) resulting from the MLVA analysis 
highlighted the presence of 5 different clonal complexes (shaded colored areas) and 4 unique MLVA 
patterns. In particular, 84% of the isolates (111/132) belong to the same expanded CC (red shaded area) 
sharing the same MLVA pattern, which was considered the responsible of a large outbreak spread in the 
hospital from October 2014.  
The remaining strains belong to other clonal complexes, specifically: 2/132 isolates belong to MLVA 
patterns called type 2 and other 2/132 to the type 7; 6/132 strains fit into the MLVA-type 8; other 5/132 
strains were of the MLVA-type 3. As already mentioned, the other MLVA-types were present as unique 
patterns (fig 37). 
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Figure 37. Minimum Spanning Tree (MST) representing spreading of 132 isolates grouped for MLVA-type. Each circle 
represents either a unique isolate or more isolates that have identical MLVA pattern. Shaded areas represent clonal 
complexes. The numbers between circles represent the STRD between strains 
 
Lines between circles indicate the distance (in STRDs) between the clonal complexes and it is known that, 
by definition, two samples belong to the same clonal complex if STRD≤2; samples are genetically related if 
2<STRD≤10 and isolates do not possess genetic correlation if STRD>10 even among representative of the 
same ribotype. All the CD027 isolates analyzed in this work, as showed in fig 38, were genetically correlated 
(shaded area) presenting all STRD≤10. 
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Figure 38. Minimum Spanning Tree (MST) representing all the CD027 isolates grouped using a STRD≤10. Each circle 
represents either a unique isolate or more isolates that have identical MLVA pattern (same color). Shaded area 
represent isolates with STRD≤10, which are considered as genetically related  
 
 
With regard to the search for possible mutations in the genes coding for the DNA gyrase A and B in the 
CD027 isolates subject of the study, all samples, regardless of the pattern of MLVA, showed the same 
mutation on the gyrA gene (figures 39), but none has been detected in the gyrB gen . 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 1 
1 
2 
1 
2 
2 
2 
2 
4 
1 
3 
2 
2 
4 
1 4 
8 
8 7 2 2 4 
 MLVA-type 1 
 MLVA-type 9 
 MLVA-type 6 
 MLVA-type 7 
 MLVA-type 5 
 MLVA-type 8 
 MLVA-type 3 
 MLVA-type 2 
 MLVA-type 4 
 
132 
 
Figure 39. Alignment of the gyrA sequences of the nine CD027 MLVA-types with those of wild-type reference 
strains: Peptoclostridium 630 (ribotype 012) and ATCC 9689 (ribotype 001).  It is highlighted the presence of the 
nucleotidic substitution C245T on the gyrA gene of CD027 strains 
  
This gyrA deletion consists in the nucleotidic C245T switch, corresponding to the aminoacidic substitution 
Thr82Ile (figure 40), defined as marker for high transmitted lineages of CD027. 
 
 
Figure 40. Alignment of the gyrA aminoacidic sequences of the nine CD027 MLVA-types with those of wild-types 
Peptoclostridium 630 (ribotype 012) and the reference strain ATCC 9689 (ribotype 001).  It is highlighted the 
presence of the aminoacidic substitution Thr82Ile on the gyrA gene of the CD027 strains 
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2.3.4 Discussion 
The global spread of C. difficile strains characterized by higher transmissibility and virulence is known 
globally [305]. In Europe, several outbreaks have occurred due to CD027 strains, whose frequency is 
increasing and a higher incidence is now detected in countries (such as Germany and Eastern Europe) 
where before only sporadic cases had been described [307].  
In Spain, according to the few national epidemiological studies carried out until 2014, only a few sporadic 
and unrelated cases had been described [308, 338]. 
The HGUGM hospital, since 2007, makes an active search for CD027 isolates, thanks to which, by the 
beginning of the year 2014, has been highlighted the increased frequency of CDI caused by this pathogen. 
Recently, a shift in the dissemination of this pathogen from UK and Ireland to the Central and Eastern 
Europe (where only sporadic cases were detected) has been described; similarly this may happen in Spain, 
showing a continue changing epidemiology respect the diffusion of this pathogen.  
 
This study showed that the current frequency of binary toxin-positive C. difficile actually is around 15% over 
the number of total toxigenic C. difficile strains analyzed, but especially it must to be noted the increase in 
the incidence of CD027 strains, which in a year period have reach the 2.9% of the toxigenic isolates, 
considering the few cases reported in previous years (9 clinical isolates belonging to 5 patients) which 
constituted the 0.25% of the total number of toxigenic C. difficile. 
The analysis of the 132 CD027 isolates, has allowed us to confirm the presence of a different subtypes 
spreading in the hospital, comprising 5 different clonal complexes. Among these, the presence of a majority 
complex (111/132 isolates) explains the presence of a monoclonal outbreak that has expanded rapidly in 
the hospital from October 2014. The simultaneous presence of these highly related clones (STRD≤10) 
justifies the increased frequency of CDI cases due to CD027, but their transmission ability is different and 
this is demonstrated by the fact that, apart from the most representative, the majority of clonal complexes 
have a contained expansion and were composed by a number between 2 and 6 strains, while others MLVA-
types are present as isolated cases.  
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The results of this study suggest that the transmissibility of the strains may depend on factors such as the 
capacity to contaminating the environment. The hypothesis is that the greater ability of several strains to 
sporulate, cause a higher environmental contamination and consequently the ability to be transmitted 
from one patient to another, especially during an epidemic. 
Besides, given their genetic relatedness, it is possible to assert a probable common origin from the same 
ancestor, unlike the strains isolated in previous years that seem to have no correlation. 
The analysis of mutations in the genes encoding the DNA gyrase subunities (gyrA and gyrB genes) has a 
dual purpose: to give additional information about the presence of resistance towards fluoroquinolones 
(used in the treatment of different diseases and related to the selection of resistant C. difficile strains) 
[345], but especially to highlight the presence of high transmittable CD027 lineages. In fact, studies 
concerning phylogenomic evolution have shown that two CD027 lineages evolved from a common ancestor 
(sensitive to fluoroquinolones), acquiring spontaneously the same mutation on gyrA gene, and then 
spreading out with different intensity [346]. So, this mutation may be used as genetic marker for the study 
of transmission route of epidemic CD027 isolates and to discriminate more virulent clones from others. In 
our case, it was not possible to identify differences between strains, because all samples tested presented 
the same mutation, i.e. an already described substitution in gyrA, consists in the nucleotidic C245T switch, 
corresponding to the aminoacidic switch Thr82Ile, whereas presented a wild-type gyrB gene. Therefore, it 
was not possible to associate this genetic trait to a greater transmissibility of the clones CD027. 
In conclusion, molecular typing (i.e. MLVA typing) provides important information about phylogenetic 
relationships among strains and help distinguishing the transmission course of different clones.  
In particular, considering the large and rapid dissemination of CD027 isolates in our hospital, it is 
convenient to assume that epidemiology may change not only for the presence of different ribotypes, but 
also for the entrance of different clones belonging to the same ribotype from different sources, having 
different features and transmission ability. 
This work shows that the active monitoring combined with molecular typing of toxigenic was crucial to 
recognize and control the spread of strains with higher virulence and transmissibility, so that it is 
 
135 
recommended the introduction of national surveillance systems, molecular epidemiology issues or 
reference centers to monitor the variation of the dissemination of the circulating strains. 
These results are a first step towards more deep studies on the characterization of C. difficile, through 
technologies such as whole genome sequencing (WGS), targeted to distinguish the temporal evolution of 
the strains, their kinetic of transmission and the possible periods of CD027 entrance in Spain.
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May sporulation have a role in C. difficile ribotype 027 
virulence? 
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2.4.1 Background 
 
Clostridium difficile is the leading cause of nosocomial diarrhea, mainly associated with the use of 
antibiotic, and increasing cause of community-acquired diarrhea.  
Infection due to Clostridium difficile (CDI) has great clinical importance in several respects because its 
incidence and relapses rates are increasing with the dissemination of epidemic strains (i.e. CD027), and 
patients are forced to prolonged hospital stays. This may be translated in a high sanitary cost and a decline 
in the quality of life of the patient [230]. 
On the basis of higher transmissibility of several strains there is possibly the greater capacity to produce 
spores, contaminating the hospital environment. In fact, symptomatic patients release large amounts of 
spores in the environment which can then be transferred on different surfaces where they resist for a large 
time and may be transferred to other surfaces also by medical staff and so be ingested from patients [299]. 
Several studies have suggested that, apart from improved production of toxins, also an increased ability to 
sporulate is the basis of the intensified virulence of epidemic strains (i.e. CD027) [259], but results are often 
contradictory [262, 347], placing a limit on defining CD027 transmissibility capacity. 
Moreover, to date, despite the multiplicity of molecular and in vitro techniques, the mechanisms by which 
C. difficile implements processes for the sporulation and germination have not yet been elucidated [265, 
348]. 
In the first part of the work, the phylogenetic relationships between CD027 clinical isolates widespread in 
Hospital General Universitario Gregorio Marañon (Madrid, Spain) have been evaluated, emphasizing the 
ability of transmission of a particular clone responsible of an outbreak. The main objective of this part of 
the work was to determine, with an in vitro method, the spore production and germination rate of 
epidemic CD027 clinical isolates compared with endemic CD001 strains.  
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2.4.2 Materials and methods 
Bacterial isolates 
In this study, we selected 25 C. difficile ribotype 027 isolates and 25 C. difficile ribotype 001 (prevalent 
ribotype in the hospital) has been investigated. Among the 25 isolates of CD027, there is at least one 
representative of each MLVA-type. Bacterial isolation and molecular typing have been performed as 
described in the methods section of the first aim of teh work (section 2.3.2). 
 
 
Sporulation and germination assay 
In vitro assays had been optimized starting from existing protocols, with modifications [349]. Sporulation 
rate, expressed as the proportion of the cell population in spore form, was measured starting from pure C. 
difficile cultures isolated in Brucella agar (BD, Heilderberg, Germany)and incubated for 5 days (120hours) at 
37°C under anaerobic conditions and then for 24 hours at 4ºC, to stimulate maximum spore production 
[350].  
Three 10-fold serial dilutions of each sample were prepared, starting from a 0.5 McFarland suspension and 
cells count (spore and vegetative cells) was performed by optical microscopy using a counting chamber 
(Neubauer chamber, Celeromics, Valencia, Spain). When observed by optical microscopy, the spores appear 
as highly reflective spherical bodies if present in free form or wrapped in the end of the cell during its 
sporulation phase (sporangium). Vegetative cells, however, appear with an elongated shape and show less 
refractive capacity. 
The sporulation rate was calculated as: number of spores per mL/number of total cells per mL (x100). Total 
cells number is considered as the count of both spore and vegetative cells. 
The germination has been defined as the efficiency of the spore to complete their maturation and 
outgrowth as vegetative cells and it was determined by heating 1mL of each 10-fold dilution of C. difficile 
isolates (used for sporulation assay) at 70ºC for 10 min to kill all vegetative cells. An aliquot of 100µL from 
each dilution and from the original untreated suspension was inoculated in Brucella Agar (BD) and 
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incubated in anaerobic conditions at 35-37°C for 48 hours. After incubation, germinated spores were 
enumerated as the CFUs growth. Spores count was performed by optical microscopy using a counting 
chamber (Neubauer chamber, Celeromics, Valencia, Spain) and the germination rate was calculated as 
number of CFU per mL/ spores per mL (x100). 
Data analysis 
All analyses were carried out using GraphPad Prism 5.0 software (GraphPad Software Inc, La Jolla,CA, USA). 
Quantitative variables were expressed with the median and interquartile ranges (IQRs). Comparisons were 
performed by using non-parametric Mann-Whitney tests. A (two-tailed) p value <0.05 was considered 
significant.  
 
 
2.4.3 Results 
 
Sporulation and germination rates of epidemic isolates of C. difficile ribotype 027 were compared to those 
of isolates belonging to ribotype 001, using an in vitro method.  
When isolates were grouped by ribotype, difference in sporulation rate was significant (p=0.005): median 
value of sporulation in CD027 isolates was of 81.92% (IQRs 76.27-83.67) while those of CD001 strains was 
76.63% (IQRs 69.31-80.31) (fig 41). 
 
The statistical analysis showed non-significant strain-to-strain variability in isolates of the same ribotype: 
comparison between sporulation rate of CD027 isolates of MLVA-type 1 (median sporulation rate of 
82.70%, IQRs 74.82-83.67) with those of the others MLVA-types (median sporulation rate of 81.50%, IQRs 
78.67-95.87) does not present statistical significance (p value=0.72) (fig 42). 
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Besides, we found that CD027 isolates showed statistically significant (p=0.0008) lower germination rate 
(median value of 0.0091%, with IQRs 0.0011 to 0.0486) compared to the ribotype 001 (median value of 
0.0384% with IQRs 0.0195-0.1679) (fig 43). 
 
When the capacity of germination among CD027 isolates belonging to the different MLVA-types was 
compared, any significant difference was not found (p value=0.24), similarly to what observed for the 
sporulation rate. In detail, germination rate of CD027 MLVA-type 1 isolates was of 0.0083% (IQRs 0.0063-
0.0359) and that of the others representative MLVA-types has a median germination rate of 0.00899% 
(IQRs 0.00172-0.0348) (fig 44). 
 
 
 
Figure 41. Sporulation rate of C. difficile ribotype 027 (n=25) versus C. difficile ribotype 001 (n=25) isolates (81.92% 
vs. 76,. %, respectively). Bars indicate standard error. P value=0.005.  
(*, p <0.05; **, p<0.01; ***, p<0.001) 
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Figure 42. Comparison of sporulation rates of C. difficile ribotype 027 isolates of the MLVA-type 1 versus strains 
representing the others MLVA-types (clones 1-9). Bars indicate standard error. Analysis has not shown significant 
difference between sporulation rates of the groups (82.70% vs. 81.50%; p value=0.72) 
 
 
 
Figure 43. Germination rate of C. difficile isolates. It is highlighted the lower efficiency of germination of CD027 
respect to CD001 (0.0091% vs. 0.0384%). Bars indicate standard error. P value=0.0008. (*p <0.05; **, p<0.01; ***, 
p<0.001) 
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Figure 44. Comparison of germination rates of C. difficile ribotype 027 isolates of the MLVA-type 1 versus strains 
representing the others MLVA-types (clones 1-9). Bars indicate standard error. Analysis has not shown significant 
difference between sporulation rates of the groups (0.0083% vs. 0.00899%; p value=0.24) 
 
 
2.4.4 Discussion 
Since the identification of the multiple CDI outbreaks caused by C. difficile ribotype 027, there has been 
great interest in elucidating the mechanisms contributing to the more virulent phenotype, particularly 
those involved in transmission: spores are inactive cellular forms with great resistance to physical and 
chemical agents, contaminating the environmental surfaces for large periods and transmitted between 
patients [261]. 
In this part of the work, an in vitro sporulation assay allowed showing significant differences in between 
CD027 isolates and endemic CD001 strains, but gave contradictory results than the germination ability of 
CD027 isolates compared to those of CD001, this being much lower than expected.  
At this regard, it is necessary to say that various studies were aimed to measuring the efficiency of 
sporulation of CD027 strains and results obtained lead to the generally accepted theory that this strain, 
 
143 
considering its higher virulence, may produce higher levels of spores than other C. difficile types [259, 260]; 
it is necessary to say that because of the variability of the methods used and especially in the absence of a 
gold standard assay, the consequent results are often discordant [263].  
In this case, the rapid spread of C. difficile ribotype 027 isolates in the HGUGM, compared to that of strains 
belonging to endemic ribotype 001 (p=0.005), may be associated with increased release of spores into the 
environment, emphasizing the importance of this factor in ensuring greater transmission of the pathogen 
[351].  
Besides, it is interesting to note that, within the same ribotype, the major circulating subtype (MLVA-type 
1) does not appear to possess greater ability to sporulate respect the others clones and this does not 
explain its rapid and extensive spread in the hospital, considering that increased transmission is commonly 
associated to higher release of spores in the environment [352]. 
By one side the production of spores allows the pathogen to spread, by the other, it is necessary that the 
spore can mature in cells able to produce toxins, which allow the inflammatory process to start. This 
phenomenon is the known as germination and probably occurs in vivo under physiological stimuli [349, 
353]. 
Interestingly, germination efficiency of the analyzed CD027 isolates showed lower values than CD001 
strains (0.0091 versus 0.0384, p=0.0008, respectively) and unexpectedly did not correlate with higher 
sporulation rate, also considering the rapid spread of this so called “more virulent” variant. 
Moreover, also analysis of germination efficiency between isolates belonging to same ribotype, particularly 
comparison between the prevalent MLVA-type 1 versus the others (0.0083 versus 0.00899, respectively), 
does not produce statistical significance (p=0.24).  
This result could be due to a limit in the method, because we have not used media enriched in germinants 
(for example, taurocholate), considering that the role of these molecules in stimulating the germination of 
C. difficile has not been completely clarified [350, 354]. So, it was preferred to evaluate the samples in a 
state of "baseline germination", to have an analysis as less influenced by the variability of growth of the 
isolates under stimulation. 
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The finding suggests that multiple mechanisms may regulate germination responsiveness and adaptability 
to the environment. We propose that, to better understand complex mechanisms, it may be preferable to 
analyze the bacterial transcriptome under different conditions (i.e. reverse-transcriptional assays) [265, 
350]. 
In conclusion, the study aimed at elucidating possible relationships between the higher transmission of C. 
difficile strains presenting rapid spread in the hospital environment and the sporulation rates. Isolates of 
CD027 were shown to have an increased spore production compared to isolates of the ribotype 001; this 
may in part explain why CDI cases due to this pathogen have increased with greater intensity in our 
hospital, but, considering the absence of differences in strains belonging to the same ribotype, the reason 
why one of the clones has been more transmittable than the others remain to be clarified. 
This finding may suggest that, most likely, the synergistic effect of different factors (greater sporulation, 
fine germination control, inability to control environmental contamination, and possibly higher toxins 
production) has helped the CD027 phenotype to spread. These hypotheses give a hint to better understand 
the transmissibility of epidemic strains, and to elucidate their role in disease severity. Further studies could 
address the correlation between the ability of sporulation of specific ribotypes and the evaluation of 
environmental contamination, because, although this is an area of great debates, until today there are not 
key studies about this [352]. 
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3. Concluding remarks 
 
The spread of the higher transmissible and resistant pathogens made it necessary to devise strategies for 
their identification and prevention as accurately and as quickly as possible. Phenotypic characterization and 
clinical diagnosis of pathogens possibly involved in nosocomial outbreaks are today increasingly supported 
by typing molecular methods (i.e. PCR-ribotyping, MLVA, PFGE, and WGS). 
 
In conclusion, this work demonstrates that: 
 
1. Worldwide dissemination of carbapenem-producing K. pneumoniae (KPC-Kp) has been reported 
globally, but molecular tracing of is required also at a local scale, to understand epidemiological 
relationships among strains and to place them in a global context. 
In fact, little information is published about the molecular epidemiology of KPC-Kp in Italy, 
especially in the local level. According with the few published studies, it seems that MDR variants of 
Kp-KPC are already spread nationwide, increasing the incidence of infections.  
 
2. The increasing incidence of infection due to particular virulent pathogen it is not always associated 
only to a single clone. In fact, molecular analysis of KPC-Kp isolates spread in the Ospedale di 
Circolo e Fondazione Macchi (Varese, Italy) showed the contemporary presence of strains 
belonging to three of the four previously characterized Italian clades belonging to CG258, 
suggesting the variability in Italian epidemiology. 
 
3. The higher frequency of K. pneumoniae infections registered in the Ospedale di Circolo e 
Fondazione Macchi was due to the polyclonal dissemination of highly resistant isolates. In 
particular, a unique clone of colistin-resistant KPC-Kp belonging to ST512 was the responsible of an 
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outbreak involving 7 patients in the ICU of the hospital. The other clones, considered as sporadic 
cases, did not present the same capacity of dissemination.  
 
4. The increased transmissibility of virulent strains of K. pneumoniae is generally associated with 
increased expression of pathogenic factors (pili/fimbriae, siderophores, hypermucousviscosity) and 
the expression of resistance genes. In this work, genomic analysis does not find a correlation 
between the increased transmissions of the epidemic clone with the specific expression of 
pathogenicity factors. Besides, all strains carried the blaKPC gene conferring carbapenems 
resistance. 
 
5. Detection of specific pathogenic factors does not always correlate with a clear phenotypic 
advantage of a more virulent clone. However, in this study, identification of the yersiniabactin 
(ybtA/S) genes only in a specific monophyletic clade of KPC-Kp strains having different origin 
suggests that some genetic features may be used as phylogenetic markers to obtain additional 
information about the genetic relatedness, the evolution and the global dissemination of these 
pathogens. 
 
6. Though spread of C. difficile ribotype 027 (CD027) has been reported globally [189, 305], molecular 
tracing of is required also at a local scale, to understand epidemiological relationships among 
strains and to place them in a global context. In fact, in Spain, up to 2014, although three national 
studies were published, only few sporadic and unrelated cases of CD027 have been described.  An 
active surveillance to identify and characterize CD027 isolates is necessary, to limit the spread of 
these dangerous pathogens. 
 
7. The increasing incidence of infection due to particular virulent pathogen it is not always associated 
only to a single clone. The increasing incidence of Clostridium difficile ribotype 027 in the Hospital 
General Universitario Gregorio Marañon (HGUGM, Madrid, Spain) has been due to the concurrent 
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presence of nine different MLVA-types, which evolving from a common ancestor and spread 
independently in the hospital. Interestingly, the higher frequency of CD027 cases has been 
associated to one of these clones that represented the 84% of the clinical isolates, showing 
elevated transmission capacity and causing an outbreak involving 111 patients. 
 
8. The increased transmissibility of virulent strains of C. difficile may be associated to the higher 
capacity to produce spores, which lead to an increased environmental contamination. This work 
demonstrated that CD027 strains have greater ability to sporulate compared with endemic 
ribotype 001; this could explain the high transmissibility of this virulent C. difficile variant. No 
differences were found between the different MLVA-types belonging to the ribotype 027; so that it 
is no possible explain why the majority clone had greater ability to spread respect all the others. 
This suggests that further studies are necessary.   
 
9. Detection of mutations in the DNA gyrase A (gyrA) gene of Clostridium difficile ribotype 027 is not 
only correlated to selection of resistant strains, but mainly it can be used as phylogenetic markers 
to obtain additional information about the genetic relatedness, the evolution and the global 
dissemination of these pathogens. 
 
 
Briefly, this work demonstrates the usefulness of molecular techniques in support of diagnostic methods 
applied to identify and characterize promptly nosocomial infections due to virulent pathogens, also 
allowing to characterize the presence of clones circulating concurrently (e.g. by WGS and/or MLVA 
subtyping), the genetic relationships between them, their transmission route and their phylogenomic 
evolution. 
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